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Tuberculosis kills nearly 2 million people each year, and more than one-third of the world’s 
population is infected with the causative agent, Mycobacterium tuberculosis.  
Mycobacteriophages, or bacteriophages that infect Mycobacterium species including M. 
tuberculosis, are already being used as tools to study mycobacteria and diagnose tuberculosis.  
More than 60 mycobacteriophage genomes have been sequenced, revealing a vast genetic 
reservoir containing elements useful to the study and manipulation of mycobacteria.  
Mycobacteriophages also encode proteins capable of fast and efficient killing of the host cell. In 
most bacteriophages, lysis of the host cell to release progeny phage requires at minimum two 
proteins:  a holin that mediates the timing of lysis and permeabilizes the cell membrane, and an 
endolysin (lysin) that degrades peptidoglycan.  Accessory lysis proteins have also been 
discovered, often with functions specific to that phage’s host. 
Many lysins of phages infecting Gram-positive bacteria are proving to be potent 
antibacterials.  Further, lysis proteins can provide insight into the properties and composition of 
the host cell wall.  Given the complexity of the mycobacterial cell wall and its medical relevance 
in tuberculosis as an immunogenic barrier that complicates treatment, as well as the urgent need 
for new therapeutic options, the mycobacteriophage lysins clearly warrant further scientific 
investigation. 
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This work focuses on the mycobacteriophage lysin LysA and the accessory lysis protein 
LysB.  Bioinformatic characterizations show that LysA proteins posess a variety of domains 
arranged in modular organizations, reflecting extensive recombination within the 
mycobacteriophage population.  In addition to known peptidoglycan-hydrolytic activities, novel 
cell wall-binding domains are identified, as well as several domains of unknown function found 
only in mycobacteriophages.  LysB proteins are unique to mycobacteriophages and perform a 
singular role as mycolylarabinogalactan esterases that sever the connection between the 
mycobacterial outer membrane and the peptidoglycan cell wall complex to ensure efficient lysis 
and progeny phage release.  There is also preliminary evidence of peptidoglycan hydrolytic 
ability, inducible cell lysis, and growth inhibition of Mycobacterium smegmatis by LysA and 
LysB proteins.  These studies suggest that mycobacteriophage lysis proteins can be exploited as 
useful tools, both in the laboratory and clinical setting. 
 
 v 
TABLE OF CONTENTS 
PREFACE............................................................................................................................... XVII 
1.0  INTRODUCTION................................................................................................................ 1 
1.1  BACTERIOPHAGE LYTIC INFECTION .............................................................. 3 
1.2  THE CELL WALL...................................................................................................... 8 
1.2.1  Peptidoglycan ................................................................................................... 8 
1.2.1.1  Glycan strands .................................................................................... 12 
1.2.1.2  Peptide cross-links .............................................................................. 13 
1.2.1.3  Alterations and Cell Growth.............................................................. 15 
1.2.2  Gram-negative Cell Wall............................................................................... 16 
1.2.3  Gram-positive Cell Wall ................................................................................ 19 
1.3  MYCOBACTERIAL CELL WALL........................................................................ 21 
1.3.1  Overall Organization ..................................................................................... 21 
1.3.2  Distinguishing Characteristics ...................................................................... 25 
1.3.2.1  Peptidoglycan Modifications.............................................................. 25 
1.3.2.2  Arabinogalactan.................................................................................. 27 
1.3.2.3  Mycolic Acids ...................................................................................... 30 
1.3.2.4  Other Components.............................................................................. 32 
1.4  PEPTIDOGLYCAN HYDROLASES ..................................................................... 34 
 vi 
1.4.1  Glycosidases .................................................................................................... 36 
1.4.1.1  Lysozymes............................................................................................ 36 
1.4.1.2  Lytic Transglycosylases...................................................................... 37 
1.4.2  Amidases ......................................................................................................... 39 
1.4.3  Peptidases........................................................................................................ 39 
1.5  BACTERIOPHAGE LYSIS ..................................................................................... 41 
1.5.1  The Lysis Cassette .......................................................................................... 42 
1.5.2  Holins............................................................................................................... 45 
1.5.3  Endolysins ....................................................................................................... 49 
1.5.3.1  Modular Structure.............................................................................. 49 
1.5.3.2  Lytic Activity....................................................................................... 52 
1.5.3.3  Cell Wall Binding Domains................................................................ 55 
1.5.3.4  Lysins with additional activities ........................................................ 57 
1.5.4  Other Lysis Proteins ...................................................................................... 57 
1.5.4.1  Anti-holins ........................................................................................... 58 
1.5.4.2  Rz/Rz1 and Spanins............................................................................ 59 
1.5.4.3  Non-peptidoglycan Hydrolytic Lysis Methods................................. 60 
1.5.5  Mycobacteriophage Lysins............................................................................ 62 
1.5.6  Lysin Applications.......................................................................................... 65 
1.5.6.1  Therapeutic Potential ......................................................................... 66 
1.5.6.2  Biocontrol of Food .............................................................................. 68 
1.5.6.3  Other Applications.............................................................................. 69 
1.5.6.4  Considerations..................................................................................... 70 
 vii 
1.6  SUMMARY................................................................................................................ 75 
2.0  CHARACTERIZATION OF THE MODULAR LYSA PROTEINS ........................... 78 
2.1  INTRODUCTION ..................................................................................................... 78 
2.2  LYSAS SHOW EXTENSIVE MODULARITY ..................................................... 80 
2.2.1  Organization of LysAs ................................................................................... 80 
2.2.2  Identified Domains and Combinations ........................................................ 83 
2.2.3  Evidence of Recombination in LysAs........................................................... 86 
2.3  PEPTIDOGLYCAN HYDROLYTIC ACTIVITIES PREDICTED IN LYSAS. 91 
2.3.1  Amidases ......................................................................................................... 91 
2.3.2  Glycosidases .................................................................................................... 98 
2.3.2.1  Glycoside Hydrolase Family 19 Muramidases................................. 98 
2.3.2.2  Glycoside Hydrolase Family 25 Muramidases............................... 103 
2.3.2.3  Transglycosylase ............................................................................... 107 
2.3.3  Peptidase ....................................................................................................... 111 
2.4  THE MYSTERIOUS N-TERMINAL DOMAINS ............................................... 113 
2.5  C-TERMINAL DOMAINS AND CELL WALL BINDING MOTIFS .............. 123 
2.6  CONCLUSIONS...................................................................................................... 132 
2.6.1  The Unique Structure of Mycobacteriophage LysAs ............................... 132 
2.6.2  The Prevalence of Various Peptidoglycan Hydrolytic Domains and Their 
Predicted Sources ..................................................................................................... 135 
2.6.3  Speculations on the Possible Functions of the N-terminal Domains ....... 142 
2.6.4  The Potential for Novel Binding Motifs in LysA C-terminal Domains... 147 
2.6.5  Summary....................................................................................................... 149 
 viii 
3.0  DETERMINATION OF THE ENZYMATIC ACTIVITY AND ROLE OF 
MYCOBACTERIOPHAGE LYSB PROTEIN...................................................................... 150 
3.1  INTRODUCTION ................................................................................................... 150 
3.2  BIOINFORMATIC CHARACTERIZATION OF LYSB PROTEINS.............. 152 
3.2.1  Sequence alignments and conserved domains ........................................... 153 
3.2.2  Conserved residues ...................................................................................... 163 
3.2.3  Mycobacteriophage lysis cassettes lacking a LysB protein ...................... 164 
3.3  ENZYMATIC ACTIVITY OF LYSB PROTEINS ON ARTIFICIAL 
SUBSTRATES .................................................................................................................. 170 
3.3.1  Cloning and expression of D29B and an active site mutant ..................... 170 
3.3.2  Assay of lipolytic activity with p-nitrophenyl esters ................................. 173 
3.4  CRYSTAL STRUCTURE OF D29 LYSB (Q. SUN AND J. SACCHETTINI) . 176 
3.5  ACTIVITY OF LYSB ON PURIFIED MYCOLYL-ARABINOGALACTAN-
PEPTIDOGLYAN............................................................................................................ 179 
3.5.1  Preparation of purified mycolyl-arabinogalactan-peptidoglycan ........... 179 
3.5.2  Hydrolysis of mAGP .................................................................................... 180 
3.6  ROLE OF LYSB IN MYCOBACTERIOPHAGE LYSIS................................... 184 
3.6.1  Construction of a LysB deletion mutant phage......................................... 184 
3.7  CHARACTERIZATION OF GILES LYSB MUTANT .................................... 188 
3.7.1  Loss of lysB in Giles directly results in a small plaque phenotype .......... 188 
3.7.2  Lysis defects in the Giles lysB and lysA mutants .................................. 191 
3.7.3  Production and distribution of new phage particles in Giles lysB and 
lysA mutants ........................................................................................................... 195 
 ix 
3.8  CONCLUSIONS...................................................................................................... 198 
4.0  DISCUSSION ................................................................................................................... 203 
4.1  A COMPLEX BACTERIUM REQUIRES A COMPLEX LYSIS SYSTEM.... 205 
4.1.1  The Diversity of LysA Proteins................................................................... 207 
4.1.2  The Novelty of the LysB Proteins and Comparison to Other Host-Specific 
Lysis Proteins............................................................................................................ 213 
4.2  A FUTURE FOR MYCOBACTERIOPHAGE LYSINS IN RESEARCH AND 
THERAPY?....................................................................................................................... 216 
4.2.1  Applications of Mycobacteriophage Lysins in Research.......................... 216 
4.2.2  Mycobacteriophage Lysins as Anti-mycobacterial Agents ...................... 218 
5.0  MATERIALS AND METHODS .................................................................................... 226 
5.1  BACTERIAL STRAINS AND MEDIA................................................................. 226 
5.1.1  Mycobacterium smegmatis............................................................................ 226 
5.1.2  Escherichia coli ............................................................................................. 226 
5.2  GENERAL CLONING AND DNA MANIPULATIONS .................................... 227 
5.2.1  Plasmids ........................................................................................................ 227 
5.2.2  Primers and Oligonucleotides ..................................................................... 230 
5.2.3  General Cloning Procedures ....................................................................... 235 
5.2.3.1  Ligation and Transformation .......................................................... 235 
5.2.3.2  Sequencing......................................................................................... 236 
5.2.4  PCR ............................................................................................................... 236 
5.2.4.1  Primer Design.................................................................................... 236 
5.2.4.2  Standard and Diagnostic PCR......................................................... 237 
 x 
5.2.4.3  Colony and Plaque PCR................................................................... 237 
5.2.4.4  DADA-PCR ....................................................................................... 237 
5.2.4.5  Site-directed mutagenesis................................................................. 238 
5.3  PROTEIN EXPRESSION AND PURIFICATION.............................................. 238 
5.4  PHAGE MANIPULATIONS ................................................................................. 239 
5.4.1  Lysate production and titering ................................................................... 239 
5.4.2  Single-step infections.................................................................................... 240 
5.4.3  DNA Isolation ............................................................................................... 240 
5.5  BACTERIOPHAGE RECOMBINEERING ........................................................ 241 
5.5.1  Deletion Mutant Construction .................................................................... 241 
5.5.2  Competent cell preparation......................................................................... 241 
5.5.3  Transformation and isolation of mutant phage ........................................ 241 
5.6  IN VITRO ASSAYS ................................................................................................. 242 
5.6.1  Zymography ................................................................................................. 242 
5.6.2  p-Nitrophenol Ester Assay........................................................................... 242 
5.6.3  mAGP Hydrolysis ........................................................................................ 243 
5.6.3.1  Purification of mAGP....................................................................... 243 
5.6.3.2  Chemical and Enzymatic Hydrolysis of mAGP............................. 244 
5.6.3.3  Thin Layer Chromatography .......................................................... 244 
5.7  IN VIVO ASSAYS.................................................................................................... 245 
5.7.1  OD Assay....................................................................................................... 245 
5.7.2  ATP Release Assay....................................................................................... 245 
5.7.3  Total Phage and Distribution Assay........................................................... 246 
 xi 
5.7.4  Growth Inhibition Assay ............................................................................. 246 
5.8  BIOINFORMATIC ANALYSIS............................................................................ 247 
5.8.1  Programs....................................................................................................... 247 
5.8.1.1  Sequence Comparisons..................................................................... 247 
5.8.1.2  Protein Analysis and Pattern Recognition ..................................... 247 
5.8.1.3  Others................................................................................................. 248 
5.8.2  Databases ...................................................................................................... 248 
5.8.2.1  Annotated and Classified Protein Sequences ................................. 248 
5.8.2.2  Enzymes ............................................................................................. 248 
5.9  REAGENTS AND BUFFERS ................................................................................ 249 
5.9.1  Protein purification buffers......................................................................... 249 
5.9.2  SDS-PAGE.................................................................................................... 249 
5.9.3  Zymograms ................................................................................................... 251 
5.9.4  p-Nitrophenol Ester Assay........................................................................... 252 
5.9.5  mAGP hydrolysis and Thin Layer Chromatography............................... 253 
5.9.6  Others............................................................................................................ 253 
APPENDIX................................................................................................................................ 255 
BIBLIOGRAPHY..................................................................................................................... 296 
 xii 
 LIST OF TABLES 
 
Table 1. LysA domain structures organized by phage cluster ...................................................... 82 
Table 2. N-terminal domain characterization ............................................................................. 115 
Table 3. C-terminal domain characterization.............................................................................. 125 
Table 4. Plasmids cloned by others............................................................................................. 227 
Table 5. Plasmids cloned by KP ................................................................................................. 228 
Table 6. Cloning primers ............................................................................................................ 230 
Table 7. Sequencing and verification primers ............................................................................ 233 
Table 8. Recombineering primers............................................................................................... 234 
 xiii 
LIST OF FIGURES 
 
Figure 1. Bacteriophage lytic and lysogenic pathways................................................................... 6 
Figure 2. Peptidoglycan Structure................................................................................................. 11 
Figure 3. Gram-negative and Gram-positive bacterial cell walls ................................................. 18 
Figure 4. Models of structure of the mycobacterial cell wall ....................................................... 23 
Figure 5. Peptidoglycan modifications in mycobacteria............................................................... 26 
Figure 6. Arabinogalactan chain with branching mycolic acids................................................... 28 
Figure 7. Mycolic acid structures.................................................................................................. 31 
Figure 8. Target bonds of peptidoglycan hydrolases .................................................................... 35 
Figure 9. Lysozyme versus transglycosylase activity................................................................... 38 
Figure 10. Lambdoid phage lysis cassette .................................................................................... 44 
Figure 11. Holin and lysin mechanisms........................................................................................ 48 
Figure 12. Evidence of recombination in Streptococcus phage lysins ......................................... 51 
Figure 13. LysA modular organizations ....................................................................................... 84 
Figure 14. Domain organization in Sub-cluster A2 LysAs........................................................... 87 
Figure 15. Recombination of domains between LysAs ................................................................ 90 
Figure 16. Phylogenetic Tree of LysA amidase domains ............................................................. 93 
Figure 17. Ami1 and Ami2 domains............................................................................................. 96 
 xiv 
Figure 18. Glycoside hydrolase family 19 domains ................................................................... 101 
Figure 19. Glycoside hydrolase family 25 domains ................................................................... 105 
Figure 20. Transglycosylase domains......................................................................................... 109 
Figure 21. M23 peptidase domains............................................................................................. 112 
Figure 22. N-terminal domain motif maps ................................................................................. 119 
Figure 23. C-terminal domain motif maps.................................................................................. 128 
Figure 24. Mycobacterial peptidoglycan structure and lysin targets .......................................... 137 
Figure 25. Alignment of LysB protein using ClustalW.............................................................. 159 
Figure 26. Phylogenetic relationships of LysB proteins............................................................. 161 
Figure 27. Genetic organization of mycobacteriophage lacking lysB ........................................ 168 
Figure 28. Purification of D29 LysB .......................................................................................... 172 
Figure 29. D29 LysB is a lipolytic enzyme ................................................................................ 175 
Figure 30. Crystal structure of D29 LysB (Q. Sun and J. Sacchettini)....................................... 177 
Figure 31. D29 LysB is a mycolyl-arabinogalactan esterase...................................................... 182 
Figure 32. Construction of a Giles lysB deletion ........................................................................ 187 
Figure 33. Giles∆lysB has a small plaque phenotype that can be complemented by D29 LysB 190 
Figure 34. Giles lysA and lysB mutants show inefficient and incomplete lysis.......................... 193 
Figure 35. Phage particles are retained in unlysed cells in Giles lysA and lysB mutants ........... 196 
Figure 36. A model for mycobacteriophage lysis of mycobacteria ............................................ 199 
Figure 37. Domain organization of LysAs cloned and purified for empirical study.................. 257 
Figure 38. SDS PAGE and corresponding zymogram of three LysA proteins .......................... 260 
Figure 39. Identification of Corndog gp69 fragment with increased lytic activity .................... 262 
Figure 40. Zymography with M. luteus, B. subtilis, and M. smegmatis substrates..................... 266 
 xv 
Figure 41. Growth inhibition by D29 LysA, LysB, and LysB S82A mutant ............................. 273 
Figure 42. Lysin protein present in growth media over time...................................................... 275 
Figure 43. The effect of combinations of lysins on growth of M. smegmatis ............................ 278 
Figure 44. Addition of lysins to Propionibacterium acnes......................................................... 281 
Figure 45. Cloned LysAs for expression in M. smegmatis ......................................................... 286 
Figure 46. Expression profiles of lysins induced in M. smegmatis ............................................ 287 
Figure 47. ATP release upon induction of lysin expression ....................................................... 290 
Figure 48. Turbidity of induced and uninduced M. smegmatis cultures expressing lysin.......... 292 
Figure 49. Effect of endogenous lysin expression on M. smegmatis growth on solid media..... 293 
 xvi 
PREFACE 
To start, I wish to thank my advisor, Dr. Graham Hatfull, for the invaluable guidance he has 
provided me as I pursued my doctorate.  Graham provided a wealth of knowledge, patience, and 
insight to my aid, but it was his positive attitude and enthusiasm that truly inspired me, and I 
hope to emulate his passion for science and sharing it through education and outreach. 
I also must thank my thesis committee, to whom I attribute much of my success.  My 
bioinformatic analyses would not have been possible without the help of Dr. Jeffery Lawrence, 
who patiently taught me not only the methods but the underlying theory as well.  Always 
questioning, Dr. Jeff Brodsky pushed me to think critically and consistently offered insightful 
advice.  I greatly admire his ability to ask these penetrating questions, and I hope to someday be 
just as dangerously inquisitive.  I am inspired by Dr. Roger Hendrix’s deep passion for science 
and the myriad ways he expresses it.  I will miss his outrageous phage phacts, as well his clarinet 
leading the BSO down the hallway.  Finally, I’m grateful to Dr. “Kip” Kinchington, both for his 
advice over the years and later accepting me into his lab as a postdoc.  Early on I was impressed 
by his focus on critical thinking, and I look forward to his mentorship as my career continues.  
I was lucky to be in a lab of smart, kind, supportive, and fun people who made my time in 
grad school so enjoyable.  Several people have had a great impact on my life these last four 
years.  Dr. Laura Marinelli has mentored me in every aspect of science, and I could not have 
accomplished as much as I have without her.  Dr. Greg Broussard was a constant source of 
 xvii 
 xviii 
support and advice, on science, careers, and life, and it is because of him that I feel prepared to 
move forward.  And it was Amrita Balachandran who kept me sane and was always there for me, 
even when she “had no words”.  I greatly admire her kindness, patience, and passion for 
teaching.  I also won’t forget the plethora of undergrads and Phagehunters, especially Andrew 
Savinov, Drew Hryckowian, Tim Sampson, and Charlie Bowman.   
I am hugely grateful to the entire Department of Biological Sciences; I can’t imagine a 
more friendly, close-knit, and fun department and my interactions with everyone greatly enriched 
my graduate experience.  I want to acknowledge Crystal Petrone, Cathy Barr, and Pat Dean, who 
worked behind the scenes to keep my academic life on track, and Dr. Tom Harper for sharing 
Photoshop tricks and a lot of good conversation.  I also wish to thank those who mentored me in 
teaching, including Drs. Valerie Oke, Karen Arndt, and Melanie Popa.  Melanie, I cannot express 
how thankful I am to have you as a teaching mentor and friend.  You are one of the kindest, most 
generous people I know, and your love of teaching has been an inspiration to me.   
Thank you to all those in the Program in Integrative Molecular Biology, especially my 
own class:  Drs. Eric de Groh, Arpana Dutta, Xi Liu, and Naveena Yanamala.  As a member of 
the inaugural class, I’ve had the privilege of watching our fledgling program grow strong on the 
success of our exceptional students.  We are more than a program: we are our own community.   
Lastly, my heartfelt appreciation goes to my family.  I love my wonderful, brilliant, 
amazing husband Jonathan, who gave me unwavering support, constant love, and a really cool 
last name.  And I credit my parents, Paul and Nonette Clemens, with my success, for it was their 
belief in me that got me this far.  I especially wish to thank my father, for all of the walks in the 
woods, trips to the library, and impulsive experiments that usually involved or resulted in a fire.   
You taught me to question the world around me and to pursue my passion.  Thank you. 
1.0  INTRODUCTION 
Tuberculosis (TB) is a worldwide health concern; nearly two million people die from TB 
annually, making it the number one cause of death due to an infectious agent (WHO, 2009).  
More than one-third of the global population is infected with Mycobacterium tuberculosis, and 
treatment has become increasingly difficult.  The complex, waxy cell wall and slow growth of 
the mycobacterium complicate treatment, and antibiotic resistance is increasing (CDC, 2009; 
Karakousis et al., 2004).  There is an urgent need for new therapeutic options for TB, as well as 
for continued study to better understand this pathogen. 
One source of tools for the study and manipulation of mycobacteria are the 
mycobacteriophages, phages that infect Mycobacterium species.  Tailed bacteriophages are the 
most abundant biological entities in the biosphere and are predicted to be the largest reservoir of 
genetic information (Hendrix, 2003; Suttle, 2005; Wommack and Colwell, 2000).  More than 60 
mycobacteriophages have been fully sequenced and 6,858 putative open reading frames 
identified, the majority of which are of unknown function (Hatfull et al., 2010).  Whole phages 
have been used both as genetic tools and for diagnostic and strain-typing purposes (Lee et al., 
2004; Piuri et al., 2009; Snider et al., 1984) but specific phage proteins are beginning to be 
exploited for the manipulation of mycobacteria (van Kessel and Hatfull, 2007).  However, very 
few studies have attempted to identify cytotoxic proteins in mycobacteriophages (Rybniker et al., 
2008). 
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Bacteriophages were first characterized in the early 1900s, but research into therapeutic 
application of phages declined when antibiotics were commercialized in the 1940s (Borysowski 
et al., 2006; Hermoso et al., 2007).  With the advent of growing antibiotic resistance, 
investigation into phage therapies is increasing (Fischetti, 2006).  Several studies have focused 
on the potential of the well-known cytotoxic proteins involved in host lysis (Borysowski et al., 
2006; Hermoso et al., 2007; Loessner, 2005).  Bacteriophages lyse their hosts at the end of lytic 
infection by compromising the integrity of the cell wall to release progeny phages.  The 
mechanism of cell lysis by dsDNA-tailed phages involves at minimum a holin and an endolysin 
(lysin) (Young, 1992).  Lysins have a modular design, composed of combinations of 
peptidoglycan lytic domains and host-specific cell wall-binding domains that have evolved 
through recombination between the host and other phages (Lopez et al., 1997).  Recently, the 
lysins of phages infecting Gram-positive bacteria have shown promise as highly-specific 
antibacterial agents in animal disease models and food biocontrol applications (Fischetti, 2006).  
These lytic proteins are active on antibiotic-resistant strains and do not appear to generate 
resistance themselves (Loeffler et al., 2001), making them very appealing in the treatment of 
drug-resistant pathogens. 
In addition to the therapeutic-focused research on bacteriophage lysis, studies are being 
conducted to better understand the underlying mechanism of phage lysis.  These studies have 
identified accessory lysis proteins – in addition to the holin and endolysin – and are discovering 
their roles in phage lysis.  Unlike the holin and lysin, these accessory proteins are restricted to 
certain phages and appear to have host-specific functions; for example, the Rz/Rz1 proteins, 
found only in phages infecting Gram-negative bacteria, are responsible for fusing the inner and 
outer membranes – the latter structure being unique to Gram-negative species (Berry et al., 
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2008).  Because of this specificity, characterization of accessory lysis proteins can provide 
insight into both the mechanism of lysis by a specific phage and the nature of the host’s cell wall. 
The complex mycobacterial cell wall is of great interest to the medical community and is 
the focus of much research (Daffe and Draper, 1998; Karakousis et al., 2004; Kremer and Besra, 
2005; Mahapatra et al., 2005a).  Like all phages, mycobacteriophages must lyse their hosts to 
release progeny phages, and so they have evolved specific proteins suited to this purpose.   
Therefore, exploration of the mycobacteriophage lysis proteins serves two purposes: determining 
the mechanisms by which mycobacteriophages overcome the unique barriers present in the 
mycobacterial cell wall, as well as identifying cytotoxic proteins that may have potential as 
therapeutic agents. 
My investigations have focused on two mycobacteriophage lysis proteins, the endolysin 
LysA and the accessory lysis protein LysB.  A bioinformatic analysis revealed a great diversity 
of LysA proteins, with many different predicted lytic activities and several intriguing unknown 
domains.  In addition, I have determined that LysB functions to remove the barrier of the 
mycobacterial outer membrane as the final step of lysis. 
1.1 BACTERIOPHAGE LYTIC INFECTION 
Tailed bacteriophages are believed to be the most abundant biological entities on the planet, 
predicted to number approximately 1031 (Hendrix, 2003; Suttle, 2005; Wommack and Colwell, 
2000).  This vast population is responsible for an estimated 1024 new infections every second 
(Wilhelm et al., 2002).  Bacteriophage infection begins with the adsorption of the phage to the 
host, usually through specific interactions between tail fiber proteins and a receptor on the 
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surface of the host cell.  Once bound, the phage penetrates the cell wall to inject its genome into 
the cytoplasm (Figure 1 [1]).  At this point, for a temperate phage such as , a decision must be 
made between the lysogenic or lytic pathway (Oppenheim et al., 2005).  In lysogeny, the phage 
genome is integrated into the host chromosome, transforming the bacterium into a lysogen 
(Figure 1 [2]).  The phage genome is then maintained indefinitely as a prophage until it is 
induced and enters the lytic pathway (Figure 1 [3]). 
During lytic development, the virus uses the host machinery, energy, and macromolecular 
precursors to create new phage particles.  The lytic pathway culminates in the production of large 
numbers of progeny phages and cell lysis to release them from the host.  Viral genes are 
temporally expressed in early and late stages – these can be subdivided for more precise 
descriptions of specific phage life cycles (Little, 2006).  Upon initiation of lytic growth, genes 
that encode proteins necessary for replication of the viral genome are sequentially transcribed 
from an early promoter (Figure 1 [4]).  Other proteins are also produced that possess a variety of 
functions in different phages, from the regulation of late gene expression to the degradation of 
the host chromosome by T-even phages (Warren and Bose, 1968).  Once replication is 
underway, structural and lysis genes are transcribed from a late promoter (Figure 1 [5]).  The 
genomic DNA is packaged into proheads (Figure 1 [6]) that then expand to form rigid 
icosohedral capsids (Jardine and Anderson, 2006).  These capsids are then assembled with tail 
and tail fiber proteins to form mature virions (Figure 1 [7]). 
The final step of lytic infection is the release of the progeny phages from the host cell 
(Figure 1 [8]).  The obstacle to phage escape is the bacterial cell wall, a complex structure 
involving one or two hydrophobic lipid membranes, a rigid network of peptidoglycan (PG), and 
various cell wall-associated polymers.  Two basic components – the cell membrane and the PG – 
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are common to all bacteria, and dsDNA bacteriophages have evolved a universal system for 
tackling these obstacles: the holin and endolysin (Young, 1992).  In addition to the holin and 
endolysin, there are specialized accessory lysis proteins that address unique aspects of the host’s 
cell wall.  The major types of bacterial cell walls are discussed below, followed by a description 
of the mechanisms phages have developed to subvert these barriers to lyse the cells and free the 
progeny phages to infect new hosts. 
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 Figure 1. Bacteriophage lytic and lysogenic pathways 
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Figure 1:  Temperate bacteriophages can undergo lysogenic or lytic infections.  (1) Phage 
adsorption and injection of genome; (2) Integration of phage genome into host chromosome, 
beginning the lysogenic pathway; (3) Direct progression to lytic pathway; (4) Early expression of 
genes to replicate genome; (5) Late expression of genes to create structural and lysis proteins; (6) 
Formation of proheads and packaging of DNA; (7) Assembly and maturation of new virions; (8) 
Cell lysis to release progeny phage to initiate new infections. 
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1.2 THE CELL WALL 
The cell wall of bacteria is an extracellular structure composed of complex polymers and 
macromolecules that protects the cell in two ways.  First, it preserves cell integrity via a mesh-
like network of peptidoglycan (PG) that surrounds the cell in a structure called the sacculus 
(Schleifer and Kandler, 1972).  This PG scaffold maintains the cell’s shape and enables it to 
withstand internal osmotic pressures up to 25 atmospheres (Vollmer et al., 2008a), while 
remaining flexible enough to allow for the morphogenic changes required for cell growth and 
protein secretion (Dijkstra and Keck, 1996).  Second, in conjunction other cell wall-associated 
components, the cell wall provides a permeability barrier that prevents the free diffusion of 
molecules into the cell.  This is accomplished by one or two lipid membranes, both non-PG cell 
wall polymers and cell wall-associated molecules, and to some extent the PG network (Vollmer 
et al., 2008a).  These and other components of the cell wall that vary between bacteria will be 
discussed in the sections specific to Gram-negative and Gram-positive species.  Meanwhile, the 
PG is the only cell wall component common to both Gram-negative and Gram-positive bacteria. 
1.2.1 Peptidoglycan 
PG is a complex polymer of sugars and amino acids found in nearly all prokaryotes (Figure 2).  
The only exceptions are the Mycoplasma and Planctomyces species (Moulder, 1993; Tamura et 
al., 1995), which lack PG, and the presence of PG in the photosynthetic organelles of some 
eukaryotic algae (Aitken and Stanier, 1979).  While the main purpose of the PG network is to 
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prevent the rupture of the cell due to internal osmotic pressure, the intact structure is surprisingly 
elastic—capable of reversibly shrinking or expanding up to 30% in Escherichia coli (Koch and 
Woeste, 1992). Gram-positive bacteria have a thick (15-30 nm) PG complex while Gram-
negative have a monolayer (~2.5 nm) or at most three layers (Labischinski et al., 1991; Matias et 
al., 2003).  The PG structure is the product of more than 20 enzymes and is largely invariant 
between bacteria, especially within the Gram-negative group (Schleifer and Kandler, 1972).  
Most variation is seen in the peptide portions in Gram-positive bacteria (Cummins and Harris, 
1956; Schleifer and Kandler, 1972).  The pervasiveness of the PG throughout the bacterial 
kingdom and its absence in eukaryotes make it an attractive target for anti-bacterial therapies.  
PG is essential to the cell; any inhibition of PG biosynthesis or degradation during cell growth 
will result in lysis of the cell (Vollmer et al., 2008a).  For many decades, antibiotics such as 
penicillin that target the enzymes involved in PG synthesis have been used to great effect; 
however, with increasing antibiotic-resistance, new therapies are targeting the unvarying PG 
structure instead of the biosynthetic enzymes (Fischetti, 2008). 
PG is composed of glycan strands that are connected via a short peptide bridge (Figure 
2).  The glycan strands contain alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic 
acid (MurNAc) residues linked by (14) bonds (Ghuysen, 1968).   Substituting most of the D-
lactoyl moieties on the C3 of each MurNAc is a peptide stem of three to five amino acids.  The 
disaccharide of GlcNAc--(14)-MurNAc with a peptide moiety is considered a muropeptide 
(Vollmer et al., 2008a).  The peptide stems of one PG strand can cross-link with neighboring 
peptides to create a network of PG.  The type and amount of cross-linking varies for different 
bacteria, as well as under different growth states and environmental conditions (Fordham and 
Gilvarg, 1974; Pisabarro et al., 1985).  In addition, the C6s of many MurNAcs are substituted 
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through a phosphodiester linkage with species-specific cell polymers such as the teichoic acids 
found in the cell wall of Gram-positive bacteria (Shockman and Barrett, 1983). 
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 Figure 2. Peptidoglycan Structure 
Figure 2:  This diagram of peptidoglycan is based on type A1 (Schleifer and Kandler, 1972).  
Glycan strands are identified as GlcNAc (N-acetylglucosamine) and MurNAc (N-acetyl muramic 
acid) linked with a -(14) bond.  In the peptide cross-link, m-DAP represents meso-
diaminopimelic acid, and all other abbreviations are those standard for isomers of amino acids.  
Modifications or alternate residues are shown in blue and include de-acetylation of MurNAc and 
GlcNAc, O-acetylation and N-glycolylation of MurNAc, amidation of the D-Glu or m-DAP, and 
common substitutions in the peptide cross-links: L-Lys or L-Orn (ornithine) for m-DAP, and Gly 
or L-Ser for L-Ala.  
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1.2.1.1 Glycan strands 
The glycan strands comprise the rigid portion of the PG structure and are formed through the 
oligomerization of monomeric disaccharide peptide units by transglycosylation reactions 
(Vollmer et al., 2008a).  The length of the strands can vary greatly depending on the bacterial 
species and growth conditions, although this is not correlated with the thickness of the PG 
(Vollmer et al., 2008a).  Glycan strands average between 20 – 40 disaccharide units (Vollmer et 
al., 2008a); E. coli and Staphylococcus aureus are within this range with an average of 21 and 18 
units, respectively (Quintela et al., 1995; Ward, 1973).  At the far ends of the spectrum, 
Helicobacter pylori glycan strands average <10 units (Costa et al., 1999), while those of Bacillus 
subtilis range from 50 – 250 units (Ward, 1973).  The nature of the chain ends also varies; Gram-
negative and some Gram-positive bacteria glycan chains terminate in 1,6-anhydro-MurNAc 
residues, which are formed through cleavage by a lytic transglycosylase (Vollmer and Holtje, 
2001).  The glycan chains of other bacteria are hydrolyzed by a glucosaminidase or lysozyme, 
resulting in MurNAc or GlcNAc residues containing a free reducing end (-OH) at the C1 or C4 
(Vollmer et al., 2008a). 
Other modifications are seen on the glycan strands that can affect the stability of the cell 
wall, increase resistance to degradative enzyme, and confer pathogenic properties (Vollmer, 
2008).  Many Bacillus species have N-deacetylases that remove the acetyl group from a portion 
of their GlcNAc and MurNAc residues (Figure 2), and some Gram-positive bacteria, including 
some Micrococcus and Streptococcus, O-acetylate some of the MurNAc residues by adding an 
extra acetyl group on the C6 (Figure 2) to create 2,6-N,O-diacetyl muramic acid (Vollmer, 2008).  
N-glycolylation changes the acetyl group (-COCH3) on the C2 of MurNAc to a glycolyl group (-
COCH2OH) (Figure 2).  This modification was first described in M. smegmatis (Adam et al., 
 12 
1969) and is a hallmark of many Actinomycetales genera (Raymond et al., 2005; Vollmer, 2008).  
The prevalence of these alterations within a cell’s PG varies with growth phase and other 
environmental conditions.  All of these slight modifications of the GlcNAc and MurNAc chains 
subtly change the properties of the cell wall; many appear to increase the stability of the cell wall 
and all seem to increase the bacterium’s resistance to lysozyme (Vollmer, 2008). 
1.2.1.2 Peptide cross-links 
The peptide cross-links are formed through transpeptidation reactions between two neighboring 
peptide stems and are responsible for the flexibility of the PG sacculus (Vollmer et al., 2008a).  
All peptide subunits are formed of alternating L- and D-isomers of amino acids (Figure 2); the 
specific amino acids are largely uniform in Gram-negative bacteria but can vary among Gram-
positive species (Schleifer and Kandler, 1972).  Regardless of composition, the muropeptides 
begin with pentapeptide moieties that are cross-linked by an L,D-transpeptidase to another 
pentapeptide in a way that causes one pentapeptide to lose its terminal amino acid, becoming a 
tetrapeptide.  Further reduction of the peptide stem by D-Ala-carboxypeptidases can also create 
tripeptides that are unable to form cross-links (Navarre et al., 1999). 
The most common arrangement of amino acids in the peptide stem is (MurNAc)—L-
Ala—D-Glu—m-DAP—D-Ala—D-Ala, where m-DAP is meso-diaminopimelic acid (Figure 2).  
This configuration is found in nearly all Gram-negative bacteria, as well as in Bacillus and 
Mycobacterium species (Schleifer and Kandler, 1972).  Each of these amino acids occupies a 
particular ordinal position with respect to the MurNAc residue: L-Ala is position 1, D-Glu is 
position 2, m-DAP is position 3, and the two D-Ala are in positions 4 and 5.  The 
transpeptidation reaction creates a peptide bond between the free carboxyl of the donor in 
position 4 and the free amino group of the acceptor in position 2 or 3 (Vollmer and Holtje, 2001).  
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The energy for the reaction comes from the release of the D-Ala in position 5 of the donor’s 
pentapeptide.  However, there are various possible replacements and alterations for the amino 
acids in the peptide stem, mostly occurring in Gram-positive species.  The L-Ala in position 1 
and the two D-Alas in positions 4 and 5 are nearly universal, but other positions 2 and 3 are 
highly variable.  Interestingly, most other amino acids are excluded from the PG, likely based on 
their structure; e.g. branching amino acids (Val, Leu, Thr); aromatic (Phe, Tyr, Trp); sulfur-
containing (Met, Cys); His, and Arg (Schleifer and Kandler, 1972). 
Schleifer and Kandler (1972) designed a classification system for the peptide cross-links 
in bacteria based on three characteristics.  First are the two groups A and B, defined by the 
anchoring point of the cross-linkage.  Group A cross-linking occurs between the amino acids in 
position 3 of one peptide stem and position 4 of the other.  In the example pentapeptide above, 
this would involve a link between the m-DAP (position 3) and the first D-Ala (position 4) of 
another peptide.  Group A cross-linking is the most common throughout all bacteria.  Group B 
involves a cross-link between position 2 (D-Glu above) and position 4 (D-Ala); this group is 
rare, primarily found in coryneform bacteria, and will not be further discussed. 
The second level of classification concerns the nature of the cross-link (Schleifer and 
Kandler, 1972).  Four subgroups are identified (A1-4) based on the presence or absence of an 
interpeptide bridge.  Subgroup 1 forms direct cross-links, such as from the -carboxyl of the -
amino group of the diamino acid in position three to the carboxyl group of the D-Ala in position 
4.  Subgroup 2 forms cross-links from position 3 of one peptide stem through a polymerized 
peptide subunit to the D-Ala in position 4 of the other peptide stem.  Lastly, subgroups 3 and 4 
utilize interpeptide bridges such as penta-Gly in S. aureus or a second diamino acid. 
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The third level of classification looks at the diamino acid in position 3, which is the most 
variable component in the peptide stem (Schleifer and Kandler, 1972).  Continuing with the most 
common type of PG, there are three variations of A1 peptide cross-links; A1 has a L-Lys in 
position 3, A1 has L-Orn, and A1 has m-DAP.  The final distinctions are based on slight 
modifications to the peptide stem.  The m-DAP variation (A1), can be divided into types based 
on the possible amidation of free carboxyls.  E. coli and Bacillus megaterium have no amidation, 
while some of the peptide subunits of Bacillus licheniformis are amidated at the -carboxyl of D-
Glu and of B. subtilis are amidated on the free carboxyl group of m-DAP.  Lastly, the cell walls 
of Lactobacillus, Corynebacterium diphtheriae, and Mycobacterium can be amidated at both 
locations (Mahapatra et al., 2005c). 
1.2.1.3 Alterations and Cell Growth 
The PG is constantly being turned-over as the cell grows.  Elongation of the sacculus is 
accomplished by incorporating new material at multiple sites along the cell wall (Burman et al., 
1983).  In Gram-positive bacteria, new PG is inserted along the inner face of the cytoplasmic 
membrane, displacing older PG outwards (Koch and Doyle, 1985); this PG is recycled into the 
growth media (Vollmer et al., 2008b).  In one generation of E. coli, an estimated 40-45% of the 
PG is released by lytic transglycosylases, amidases, and endopeptidases to be recycled (Goodell, 
1985; Vollmer and Holtje, 2001; Vollmer et al., 2008b).  Cell wall growth can also be regulated 
through the action of D,D-carboxypeptidases, which slow growth by removing the D-Ala from 
peptide pentapeptides, creating a peptide stem that can act as an acceptor for a cross-link but not 
a donor (Vollmer et al., 2008b).  Further removal of the D-Ala in position 4 will leave a 
tripeptide unable to participate in any cross-linking. 
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PG-degrading enzymes, principally lytic transglycosylases and amidases, are also 
responsible for the creation of the large holes in the PG required for various structures and events 
(Scheurwater et al., 2008; Vollmer et al., 2008b).  Degradation of the cell wall PG is absolutely 
required for cell division, and this is achieved at the septum by amidases and lytic 
transglycosylases (Vollmer et al., 2008b).  Targeted PG degradation is also necessary for the 
export of large proteins and protein complexes, the assembly of flagella and conjugation pili, and 
the competency of the cell for transforming extracellular DNA (Dijkstra and Keck, 1996).  
Finally, as cells enter stationary phase, cross-linking increases (Fordham and Gilvarg, 1974; 
Pisabarro et al., 1985), creating a more rigid and protective barrier that has increased resistance 
to lysozymes (Vollmer et al., 2008a). 
1.2.2 Gram-negative Cell Wall 
The cell wall of Gram-negative bacteria contains little PG (<10% of cell wall weight) (Schleifer 
and Kandler, 1972), but is rich in lipids.  Outside of the cytoplasmic membrane are the 
periplasmic space, the PG complex, and the asymmetrical outer membrane (Figure 3 A) (Matias 
et al., 2003).  The periplasm is immediately outside of the cytoplasmic (or inner) membrane and 
extends to the PG layer, and lipoproteins anchor the PG along the outer membrane.  Lipoproteins 
are covalently attached to the m-DAP of the PG peptides through their C-terminal Lys or Arg 
residues, while the fatty acid portion is inserted into the inner leaflet of the outer membrane 
(Holtje, 1998).  Besides the lipoproteins, the inner leaflet is composed of the fluid phospholipids.  
The outer leaflet contains membrane proteins like porins, as well as the less flexible 
lipopolysaccharides, or LPS (Gronow and Brade, 2001). 
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The negatively-charged LPS cover approximately 75% of the cell’s surface, acting as a 
barrier to hydrophobic substances like detergents and some antibiotics, while the rest of the outer 
membrane prevents the diffusion of hydrophilic compounds (Gronow and Brade, 2001).  The 
LPS is composed of three parts:  lipid A, the core, and the O-antigen (Gronow and Brade, 2001; 
Raetz and Whitfield, 2002).  The O-antigen is a long polysaccharide chain that varies greatly 
among Gram-negative bacteria, even within a single species.  The core links the O-antigen to 
lipid A and is composed of a combination of several sugars and non-carbohydrate modifications 
such as phosphate and amino acid substituents.  The most conserved region is the lipid anchor 
(lipid A), a glucosamine-based phospholipid with multiple fatty acid chains that extend into the 
outer leaflet of the outer membrane.  In particular, lipid A plays a role in pathogenesis as an 
endotoxin (Raetz and Whitfield, 2002).  In humans, lipid A and other bacterial cell wall 
components are recognized by the toll-like receptors (TLRs) of the innate immune system.  Upon 
the binding of these endotoxins, the TLRs initiate the inflammatory response and recruit 
phagocytic cells (Aderem and Ulevitch, 2000). 
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 Figure 3. Gram-negative and Gram-positive bacterial cell walls 
 
 
Figure 3:  A. Gram-negative cell wall composed of a cell membrane, periplasmic space, thin 
layer of PG anchored by lipoproteins, and outer membrane with LPS.  B. Gram-positive cell wall 
comprising a cell membrane, small periplasmic space, thick layer of PG, and polysaccharides 
(e.g. teichoic acid) extending from the membrane or PG.  (1) cell membrane; (2) periplasmic 
space; (3) peptidoglycan (PG); (4) lipoproteins; (5) outer membrane; (6) lipopolysaccharides 
(LPS); (7) lipoteichoic acid, with lipid anchor in green; (8) teichoic acid. 
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1.2.3 Gram-positive Cell Wall 
The Gram-positive cell wall is defined by a thick layer of PG that constitutes 30-70% of the total 
cell wall and surrounds a single cytoplasmic membrane (Figure 3 B) (Shockman and Barrett, 
1983).  In bacteria lacking a polysaccharide capsule or proteinaceous S-layer, the PG and 
associated cell wall polymers are the first contact with the external environment.  While not a 
true permeability barrier like the outer or cytoplasmic membranes, this structure does serve to 
limit the access of larger molecules (Shockman and Barrett, 1983).  A bipartite organization of 
the Gram-positive cell wall has been observed, using cryo-transmission electron microscopy 
(Matias and Beveridge, 2005, 2006; Zuber et al., 2006), which includes an inner wall zone of 
low density and an outer wall zone of high density (Figure 3 B).  The inner wall zone averages 
between 16 – 22 nm in S. aureus and B. subtilis (Matias and Beveridge, 2005, 2006) and appears 
analogous to the periplasmic space in Gram-negative bacteria (Figure 3 A).  It is expected to 
contain many secreted proteins and new wall polymers in the process of being added to the 
current PG and polysaccharide network (Vollmer et al., 2008a).  Interestingly, several proteins 
that are found in a soluble form in the periplasm of Gram-negative bacteria have lipid-modified 
homologs in Gram-positive bacteria (Navarre et al., 1999).  The lipid moiety likely serves to 
retain the proteins near the cytoplasmic membrane, whereas the homologous proteins in Gram-
negative bacteria are bound by the inner and outer membranes.  Beyond this periplasmic space, 
the dense outer wall zone likely comprises the PG-polysaccharide polymer complex and ranges 
between 15 – 30 nm based on the Gram-positive species, growth phase, and environmental 
conditions (Vollmer et al., 2008a).   
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Non-PG cell wall polymers account for 10-60% of the cell wall mass and primarily 
include polysaccharides such as teichoic acid (Schaffer and Messner, 2005).  These anionic cell 
wall polymers are attached either via a phosphodiester bond to the C6 of some MurNAc residues 
or to a lipid moiety that tethers them to the cytoplasmic membrane (Navarre et al., 1999).  The 
best-studied polysaccharides are the teichoic acids and teichuronic acids found in Bacillus, 
Staphylococcus, and Micrococcus (Shockman and Barrett, 1983); the choline-containing 
polysaccharides in Streptococcus (Hermoso et al., 2003); and the arabinogalactan and 
lipoarabinomannan in Mycobacterium and related genera (Brennan and Besra, 1997; Crick et al., 
2001; Yagi et al., 2003).  These polymers are indispensible for growth, and many proteins that 
localize to the PG have evolved to bind them, including host PG-remodeling enzymes, like the 
Streptococcus pneumoniae Atl autolysin (Giudicelli and Tomasz, 1984), and several 
streptococcal phage lysins (Lopez et al., 1997).  In addition, many of these polymers are linked 
to pathogenesis and can illicit an immune response, similar to the LPS of E. coli and related 
Gram-negative bacteria (Aderem and Ulevitch, 2000). 
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1.3 MYCOBACTERIAL CELL WALL 
1.3.1 Overall Organization 
Mycobacteria have been traditionally categorized as Gram-positive bacteria due to their 
extensive network of PG (Brennan and Nikaido, 1995).  Mycobacteria have a chemotype IV cell 
wall defined by the presence of arabinogalactan substituted with mycolic acids (Embley et al., 
1986); altogether this is called the mycolic acid-arabinogalactan-peptidoglycan (mAGP) 
complex (Figure 4 A).  However, the mycobacterial cell wall has been likened to that of Gram-
negative bacteria, since the covalently-attached mycolic acids intercalate with various lipids to 
form an asymmetric lipid bilayer analogous to the outer membrane of Gram-negative bacteria 
(Minnikin et al., 1982).  This layer with its associated lipids that create the cell envelope can 
account for up to 60% of the cell’s dry weight (Kremer and Besra, 2005).  There is one 
significant difference between the Gram-negative and mycobacterial cell wall structures: the 
mycobacterial outer membrane is completely tethered to the PG (Figure 4).  As a result, the 
mycolic acids are essential for outer membrane integrity, as shown with the loss of the outer 
membrane in Corynebacterium glutamicum pks13, a mutant that is defective in mycolic acid 
biosynthesis (Portevin et al., 2004).  Mycolic acids are indispensible for the growth of 
mycobacterial species (Portevin et al., 2004; Portevin et al., 2005), and so experiments disrupting 
the arabinogalactan-mycolic acid structure are conducted with related Corynebacterium species. 
Recently, this mycobacterial outer membrane has been visually verified with cryo-
electron microscopy (Hoffmann et al., 2008; Zuber et al., 2008).  Interestingly, these reports 
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found that the membrane was not much larger than the plasma membrane; the mycobacterial 
outer membrane was approximately 15% thicker than the cytoplasmic membrane (8 nm and 7 
nm, respectively) (Hoffmann et al., 2008; Zuber et al., 2008).  Considering the length of mycolic 
acids, this observation has led to the proposal of several new models for the membrane (Figure 
4).  In keeping with the asymmetrical bilayer model, Zuber et al. (2008) has proposed that the 
longer chains of the mycolic acids fold to stay within the inner leaflet (Figure 4 B).  Hoffmann et 
al. (2008) instead proposed two possible models, one in which the longer meromycolate chain of 
the mycolic acids extends into the outer leaflet (Figure 4 C), and a second in which the base of 
the mycolic acids remains in the periplasm with only the ends extending into the inner leaflet 
(Figure 4 D). 
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 Figure 4. Models of structure of the mycobacterial cell wall 
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Figure 4:  A. The mycobacterial cell wall core contains peptidoglycan (green) with branching 
chains of arabinogalactan (purple) that terminate in mycolic acids (red).  B-D.  The mAGP is 
outside of the plasma membrane (yellow), and the mycolic acids intercalate with extractable 
lipids (orange) to form the mycobacterial outer membrane.  The specific organization of the 
outer membrane is still unknown, and based on the size of the membrane as seen with cryo-
electron microscopy, three arrangements have been proposed:  B. the long meromycolate chain 
of the mycolic acids folds to remain within the inner leaflet (Zuber et al., 2008); C. the 
meromycolate chain extends fully into the outer membrane; D. only the region of the 
meromycolate not interacting with the -branch interacts with the lipids in the inner leaflet 
(Hoffmann et al., 2008). 
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1.3.2 Distinguishing Characteristics 
1.3.2.1 Peptidoglycan Modifications 
Mycobacterium and other members of the Actinomycetales suborder of Corynebacteriaceae have 
several significant differences in their PG structure. Approximately 75% of the PG is cross-
linked in Mycobacterium species, compared to 20-30% in E. coli (Mahapatra et al., 2005a). 
These organisms have type A1 PG, which is characterized by the inclusion of meso-
diaminopimelic acid (m-DAP) (Schleifer and Kandler, 1972).  The m-DAP is cross-linked to the 
D-Ala of another tetra-peptide moiety, but about one-third of the cross-linking in Mycobacterium 
species occurs between two m-DAP moieties (Figure 5); this is believed to provide additional 
rigidity to the PG (Brennan and Nikaido, 1995; Mahapatra et al., 2005a).  The cross-linking 
peptides are also more often amidated on the Glu and m-DAP (Figure 5) (Petit and Lederer, 
2000).  Additionally, Mycobacterium and Nocardia have N-glycolylated muramic acids 
(MurNGly) instead of N-acetylation (Figure 5), a modification that introduces an additional 
alcohol group and may provide more opportunities for hydrogen bonding, further adding to the 
stability of the PG (Brennan and Nikaido, 1995; Raymond et al., 2005). 
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 Figure 5. Peptidoglycan modifications in mycobacteria 
Figure 5:  The peptidoglycan structure of alternating sugars and the A1-type tetrapeptide, found 
in most Gram-negative and some Gram-positive species, are shown with modifications 
highlighted in red.  Instead of N-acetylation, the muramic acids are N-glycolated, and the D-Glu 
and m-DAP of the peptide cross-link may be amidated.  Also, in addition to the standard D-Ala 
 m-DAP linkage, there are some direct cross-links between two m-DAP (red dotted line). 
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1.3.2.2 Arabinogalactan 
Branching from 10-12% of MurNGly residues (Brennan and Nikaido, 1995) are chains of 
mycolate-arabinogalactan, or AG (Figure 6 A).  The AG is entirely composed of arabinose and 
galactose in the furanose form (Araf and Galf respectively) (Brennan and Nikaido, 1995).  The 
galactan core is covalently attached to the C6 of MurNGly through a diglycosylphosphoryl 
bridge (McNeil et al 1990), and extends as a chain of approximately 30 alternating 5- or 6-linked 
-D-Galf residues (Daffe et al., 1990).  Arabinin chains branch from the C5 of some 6-linked 
Galf residues and forms 5-linked -D-Araf extensions.  A 3,5-linked -D-Araf divides the chain 
into two branches followed by three more 5-linked Araf residues and ending with the non-
reducing terminal pentaarabinofuranosyl structure (Figure 6 B).  This structure includes a 3,5-
linked -D-Araf branching into two 2-linked β-D-Araf units.  Approximately two-thirds of the 
pentaarabinofuranosyl units are esterified by mycolic acids (McNeil et al., 1991). 
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 Figure 6. Arabinogalactan chain with branching mycolic acids 
 28 
Figure 6:  A. The long chain of approximately 30 galactan sugars (black) is connected to the C6 
of some muramic acids through a linker, the diglycosylphosphoryl bridge (purple).  From the C5 
of some Galf residues are branching chains of Araf (red/blue) (adapted from Crick et al., 2001).  
B. The Araf chains terminate in pentaarabinofuranosyl structures that are esterified (red dotted-
line box) with mycolic acids (adapted from Tripathi et al., 2005).  
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1.3.2.3 Mycolic Acids 
The mycolic acids that are characteristic of the mycobacteria are α-alkyl, β-hydroxy C60-C90 fatty 
acids (Figure 7 A), larger than those in the related Corynebacterium and Nocardia genera 
(Jacobs, 2000).  The saturated α-branch averages C20-C25, while the main chain meromycolic 
acid moiety (the β-hydroxy branch) averages C60 and can contain double bonds, cyclopropane 
rings, and oxygen functions (Figure 7 B) (Kremer and Besra, 2005).  These meromycolate 
modifications define the types of mycolic acids and can be used to identify mycobacterial species 
through isolation and analysis by mass spectroscopy (Watanabe et al., 2001) and thin-layer 
chromatography (Hamid et al., 1993).  α-mycolates (those lacking any oxygenation of the 
meromycolate chain) are found in all mycobacteria, while α’-mycolates are thus far only seen in 
fast-growing strains (Jacobs, 2000). Oxygenated mycolate types include methoxy, epoxy, keto, 
and wax ester; keto-mycolates are characteristic of slow-growing mycobacteria species (Jacobs, 
2000). In addition to the  and ’ mycolates, M. smegmatis also has epoxy mycolates (Figure 7 
B) (Parish and Stoker, 1998).  M. tuberculosis contains , methoxy, and keto mycolates (Figure 
7 B) (Parish and Stoker, 1998; Watanabe et al., 2001). 
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 Figure 7. Mycolic acid structures 
 
Figure 7:  A.  A mycolic acid esterified (red dotted-line box) to a terminal arabinofuranose 
residue.  The -branch and -branch or meromycolate are indicated.  B. Several different 
mycolic acid types that contain cyclopropane rings, double bonds, and oxygen groups.  A (+) 
indicates which mycolic acids are present in M. smegmatis or M. tuberculosis. 
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1.3.2.4 Other Components 
Lipoarabinomannan 
Anchored in the cell membrane is the lipoarabinomannan (LAM), which is analogous to the 
lipoteichoic acids found in Gram-positive bacteria.  LAM consists of a mannose chain extending 
from phosphatidyl-myo-inositol, a phospholipid inserted into the plasma membrane (Briken et 
al., 2004).  The α-1,6-linked mannose backbone is substituted at C2 by a single mannose unit.  
The arabinin chain extends from the end of the mannose backbone, and consists of α-(15)-
linked Araf with a tetra-arabinofuranoside and hexa-arabinofuranoside branch (Briken et al., 
2004; Chatterjee et al., 1991).  The capping of the terminal Araf varies between mycobacterial 
species; fast-growing species like M. smegmatis terminate the arabinin with inositol phosphate 
caps (PILAM), the pathogenic mycobacteria including M. tuberculosis have one to three 
mannose as caps (ManLAM), and Mycobacterium chelonae has been found to lack any capping 
(AraLAM) (Briken et al., 2004).  The differences in capping can influence pathogenesis; 
ManLAM is shown to inhibit dendritic cell function, better enabling M. tuberculosis to evade the 
immune system (Karakousis et al., 2004). 
Extractable Lipids and Permeability 
In addition to the covalently attached components, a number of non-covalently attached or 
extractable lipids have been found associated with the cell walls of mycobacteria.  The most 
common types include lipooligosaccharides, phenolicglycolipids, glycopeptidolipids, sulfolipids, 
glycerophospholipids, and acetylated trehaloses, such as trehalose 6,6’-dimycolate (TDM), 
commonly known as cord factor (Brennan and Nikaido, 1995).  These lipids associate with the 
mycolic acids of the mAG and largely make up the outer leaflet of the bilayer, although several 
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are now believed to associate with the mycolic acids in the inner leaflet as well (Ortalo-Magne et 
al., 1996).  The less-packed lipids of this outer leaflet are more disordered than the closely 
packed inner mycolic acids, creating a gradient of decreasing fluidity (and permeability) from the 
outside to the inside of the cell wall.  The high lipid content of the cell wall makes it virtually 
impermeable to hydrophilic compounds, although porins such as MspA allow the passage of 
small molecules such as glucose (Stahl et al., 2001).  Surprisingly, the cell wall is significantly 
less permeable to hydrophobic compounds than would be predicted, due to the decreasing 
permeability towards the inner cell wall; however, hydrophobic compounds do traverse the cell 
wall considerably more easily than hydrophilic ones (Brennan and Nikaido, 1995).  The 
impermeability of the cell wall renders mycobacteria resistant to many antibiotics and 
chemotherapeutics, contributing to the difficulty of treating TB.  Additionally, mycobacteria are 
resistant to drying, alkaline conditions, and to many disinfectants, making it difficult to prevent 
transmission in densely populated areas (Brennan and Nikaido, 1995). 
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1.4 PEPTIDOGLYCAN HYDROLASES 
The PG structure of bacterial cells is constantly being remodeled, and this requires a variety of 
enzymes that break down and recycle pre-existing PG as well as synthesize new PG.  PG 
hydrolases are therefore vital to the regulation of growth of the PG sacculus, which occurs 
through the turnover and recycling of PG subunits and the elongation and separation of cells 
during division (Vollmer et al., 2008b).  PG hydrolases also participate in the production of 
signaling molecules; remodeling needed to accommodate large molecular structures such as 
flagella and secretion systems; stimulation of growth as resuscitation promoting factors; and the 
changes associated with sporulation and germination in bacteria such as B. subtilis (Vollmer et 
al., 2008b). 
The PG hydrolases are a large group of enzymes that cleave a subset of the bonds in PG.  
There are three types of PG hydrolases that target the PG (Figure 8):  glycosidases cleave the 
bonds between the sugar residues, GlcNAc and MurNAc; N-acetyl-L-alanoyl-amidases 
(amidases) hydrolyze the bond between the glycans and the peptide bridges; and peptidases of 
varying specificities target the bonds in the peptide region. 
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 Figure 8. Target bonds of peptidoglycan hydrolases 
Figure 8:  The three types of PG hydrolase – glycosidase (glucosaminidase and muramidase), 
amidase, and peptidase – are listed in red with arrows indicating their target bonds in the PG.  All 
hydrolases labeled as peptidases, excluding carboxypeptidases, are in fact endopeptidases. 
 35 
1.4.1 Glycosidases 
The glycan strand across all bacteria contains alternating -(14)-linked N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) residues.   PG glycosidases target this -(14) 
bond; -N-acetylglucosaminidases (glucosaminidases) hydrolyze the GlcNAc--(14)-MurNAc 
bond, while -N-acetylmuramidases (muramidases) cleave the MurNAc--(14)-GlcNAc bond 
(Figure 8).  Glucosaminidases are widely seen in bacteria (Vollmer et al., 2008b), but are not 
found in many phages, while muramidases have been characterized in many phage lysins 
(Loessner, 2005).  There are two types of muramidases defined by the enzymatic mechanisms 
that result in different end products (Vollmer et al., 2008b). 
1.4.1.1 Lysozymes 
The lysozymes are muramidases that hydrolyze the MurNAc-GlcNAc bond, resulting in a 
MurNAc residue with a reducing end (Figure 9).  These enzymes are seen in phages, bacteria, 
fungi, invertebrates, and vertebrates and have been extensively studied (Jolles and Jolles, 1984).  
There are four characterized classes of lysozymes, three of which (phage T4 lysozyme or T4L, 
Hen egg-white lysozyme or HEWL, and goose egg-white lysozyme or GEWL) have a common 
structural fold containing the catalytic and substrate-binding sites and so appear to have diverged 
from a common ancestor (Weaver et al., 1984).  The fourth class is based on the Chalaropsis 
lysozyme and has an entirely different tertiary structure (Rau et al., 2001).  However, all four 
groups utilize the same acid/base catalytic mechanism, involving two Glu residues for the three 
similar classes and a Glu and Asp for the Chalaropsis-type lysozymes (Hermoso et al., 2003). 
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1.4.1.2 Lytic Transglycosylases 
Lytic transglycosylases also target the MurNAc-GlcNAc bond, but instead of hydrolysis these 
enzymes cleave the bond and concomitantly form a 1,6-anhydro ring on the MurNAc residue 
(Figure 9) (Holtje et al., 1975).  (While lytic transglycosylases do not operate with a hydrolysis 
reaction mechanism, I will be referring to the PG-modifying enzymes as a whole as PG 
hydrolases throughout this writing.)  These enzymes possess a similar fold to the goose-type 
lysozymes (Thunnissen et al., 1995), but posses a single catalytic Glu in the active site, which 
results in the intramolecular ring formation instead of hydrolysis (Thunnissen et al., 1994).  
There are four different families of lytic transglycosylases, with the fourth considered to 
represent transglycosylases from bacteriophage, with the R lysin of phage  regarded as the 
prototype (Blackburn and Clarke, 2001). 
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 Figure 9. Lysozyme versus transglycosylase activity 
 
 
Figure 9:  Muramidases include two different enzyme types, both of which cleave the MurNAc-
-(14)-GlcNAc bond.  Lysozymes (top) hydrolyze the bond, resulting in a MurNAc with a 
reducing end (red).  Transglycosylases (bottom) cleave the bond and concomitantly form a 1,6-
anhydro ring on the MurNAc (red). 
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1.4.2 Amidases 
N-acetyl-muramoyl-L-Alanine amidases, or simply amidases, hydrolyze the D-lactoyl-L-Ala 
amide bond (Figure 8) (Vollmer et al., 2008b).   This severs the link between the glycan strands 
and the peptide bridges in the PG and is one of the most effective ways of degrading PG, as 
evidenced by its use in bacteria for PG remodeling during cell division (Heidrich et al., 2001) or 
cell wall recycling (Jacobs et al., 1994) and its widespread presence in the lysins of many phages 
(Vollmer et al., 2008b).  Many amidases are metallo-enzymes with Zn2+ as part of the catalytic 
mechanism, where it activates a water molecule that then acts as a nucleophile to attack the 
amide bond (Kerff et al., 2010).  The structures of the lysin of bacteriophage T7 (Cheng et al., 
1994) and AmiD of E. coli (Kerff et al., 2010), among others, have revealed two His residues to 
be involved in the Zn2+ binding.  Structural similarities have also been observed between these 
amidases and Zn2+ peptidases such as thermolysin (Cheng et al., 1994; Kerff et al., 2010). 
1.4.3 Peptidases 
There are two primary classes of peptidases that hydrolyze PG: endopeptidases that cleave amide 
bonds within the peptide bridge, and carboxypeptidases that remove C-terminal amino acids 
(Holtje, 1995).  Carboxypeptidases have not been seen in phage lysins; the removal of a terminal 
amino acid would not cause the degradation of the PG polymer (Vollmer et al., 2008b).  
However, the diversity in amino acid composition of peptide cross-links provides many targets 
for a variety of endopeptidases (Figure 8).  Some endopeptidases are named for the amino acids 
between which they cleave, but given the variability in the peptide cross-link most 
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endopeptidases are instead identified simply by the isomers between which they cleave (Holtje, 
1995; Smith et al., 2000).  For example, L,D-endopeptidases hydrolyze the bond between the L-
amino acid in position one and the D-amino acid in position 2, and D,D-endopeptidases 
hydrolyze the cross-links made between the D-Ala and m-DAP in most PG (Vollmer et al., 
2008b); these are most commonly L-Ala-D-Glu-endopeptidases because L-Ala and D-Glu are 
the amino acids most commonly found in positions 1 and 2, respectively (Figure 2) (Vollmer et 
al., 2008a). 
Peptidases from all organisms are being indexed in the MEROPS peptidase database, 
(http://merops.sanger.ac.uk), where they are grouped into families based on sequence similarity, 
and then into clans of families defined by the catalytic mechanism (Rawlings and Barrett, 1993; 
Rawlings et al., 2010).  The clans are usually identified by the catalytic amino acid residue (e.g. 
Cysteine peptidases) (Rawlings and Barrett, 1993).  There are also metallopeptidases, which use 
a metal ion such as Zn2+ as part of the catalytic mechanism.  These have two absolutely 
conserved His residues, similar to Zn2+ amidases such as the T7 phage lysin (Cheng et al., 1994). 
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1.5 BACTERIOPHAGE LYSIS 
At the end of an infection or upon the induction of a prophage that results in new virions, phage 
progeny must escape the host cell.  While filamentous phage can extrude through the cell 
envelope with minimal harm to the cell (Russel, 1995), most phage release uses a lysis 
mechanism (Young et al., 2000).  Lysis of a bacterium requires disrupting the cell wall in order 
to release the cytoplasmic contents—including progeny phage—into the environment to find 
new hosts.  There are two known strategies for phage lysis (Young et al., 2000).  For the simple 
ssDNA and ssRNA phages a single lysis gene is used (see “Other lysis systems”).  The more-
complex dsDNA phages employ a multigenic system that at minimum involves a holin and an 
endolysin. 
The holin and lysin work together in two different capacities.  Both are expressed in the 
late stages of infection and accumulate, either in the membrane (holin) or the cytoplasm (lysin). 
The holin forms lesions in the cell membrane that result in depolarization, thereby halting 
cellular respiration.   Simultaneously, these lesions allow the lysin access to its PG substrate, 
which it degrades through one or two of several enzymatic activities.  The cell wall is no longer 
able to withstand the internal osmotic pressure and the cell lyses.  The triggering time by the 
holin is very precise and reliable; a synchronized infection can lyse a culture in seconds (Young 
et al., 2000).  Prior to triggering, the lysin accumulates harmlessly in the cytoplasm. 
The need for rapid lysis at the optimal time in phage production places great evolutionary 
pressure on holins to maintain a tight schedule specified by the rate of new phage assembly and 
maturation, the physiological state of the host, and the average time required for phage to find 
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and infect a new host (Wang, 2006).  In lysing the cells too early the maximum production of 
phage progeny is not reached.  However, while delaying lysis allows an increase in the number 
of new virions it must be balanced against the opportunity to infect new host cells (Young et al., 
2000).  In an environment of low host cell concentration, it is better to postpone lysis for a linear 
increase in virions as long as the cell is capable of producing them.   In conditions of high host 
cell concentration there is a strong advantage in decreasing the latent period for faster lysis and 
new infections, which lead to an exponential increase in phage titer. 
1.5.1 The Lysis Cassette 
The region of the genome encoding the holin, lysin, and any associated lysis genes is referred to 
as the lysis cassette.  The lysis genes can be identified through mutagenesis by specifically 
looking for a lysis-defective phenotype without a reduction in the accumulation of intracellular 
virions (Young, 1992).  The majority of studies on lysis cassettes and holins have focused on 
lambdoid phages such as λ, P22, P1, and T4 (Young, 1992), while those of Gram-positive phages 
have received less attention; conversely, most research on lysins has focused on those of Gram-
positive phages, which show therapeutic potential (Borysowski et al., 2006; Fischetti, 2008; 
Loessner, 2005; O'Flaherty et al., 2009).  As illustrated with the λ lysis cassette (Figure 10), the 
holin (S) and lysin (R) genes are generally adjacent with the holin upstream and often 
overlapping the lysin, even if only by 1 bp (Young, 1992).  There are some exceptions to this 
setup, notably the phage P1 lydA and lydB holin/anti-holin genes that are separated from the 
lysin-encoding gene 17 (Schmidt et al., 1996), and the T4 phage holin t, which is significantly 
distanced from the lysin encoded by e (Wang et al., 2000).  Rz/Rz1 (discussed below) are a pair 
of accessory lysis genes with orthologs in other Gram-negative phages (Summer et al., 2007) and 
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are located downstream of the holin and lysin (Young, 1992).  This cluster of genes was 
designated as a cassette since it can be cloned and expressed to induce lysis apart from any other 
phage genes (Garrett et al., 1981).  While both the holin and lysin are needed for lysis, they 
operate independently, as can be demonstrated by exchanging various holins and lysins of 
different phages (Garcia et al., 1997; Young et al., 2000).  As a result, the lysis cassette is highly 
mosaic both between the holin and lysin genes and within the lysins themselves (Garcia et al., 
1988; Lopez et al., 1997; Young et al., 2000). 
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 Figure 10. Lambdoid phage lysis cassette 
 
Figure 10:  The lysis cassettes of phages , P22, and 21 are the best studied and representative 
of many phages that infect Gram-negative bacteria.  Four lysis ORFs are shown: S encodes the 
holin (blue), R encodes the endolysin (red), and Rz/Rz1 (green/yellow) encode accessory lysis 
proteins found in phages infecting Gram-negative bacteria (Summers et al. 2007).  Lysis genes 
overlap slightly, except for Rz1, which is completely embedded in a different reading frame 
within Rz.  Transcription begins at the late promoter PR’. 
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1.5.2 Holins 
Holins have been traditionally considered the “protein clock” of bacteriophage infections by 
regulating when to effect host lysis (Wang et al., 2000; Young et al., 2000).  These proteins 
perform two functions:  creating a lesion in the inner membrane and timing lysis for the optimal 
release of phage progeny. 
Holins accumulate in the inner membrane throughout late gene expression.  At a 
genetically-specified time the holins disrupt integrity of the membrane to quickly dissipate the 
membrane potential and activate lysin-mediated PG hydrolysis for swift lysis of the host (Figure 
11).  This is accomplished by the oligomerization of membrane-embedded holin proteins as 
shown by electron microscopy and other structural studies (Dewey et al., 2010; Pang et al., 2009; 
Savva et al., 2008).  The resulting lesion depolarizes the membrane, which eliminates the proton 
motive force required for respiration and the overall integrity of the cell membrane.  Consistent 
with the precise timing achieved by holins in order to maximize phage production, the membrane 
potential remains constant until seconds before the holins trigger lesion formation (Grundling et 
al., 2001).  In this way holins accumulate in the membrane but do not compromise the 
biosynthetic capacity of the host to continue producing virions.  The precise trigger for lysis is 
unknown, but may be tied to a critical concentration of holin in the membrane, precipitating a 
change to form homo-oligomeric lesions.  This process that may be opposed by the energy state 
of the membrane (Grundling et al., 2001).  Once one hole forms, the global membrane potential 
collapses, which would result in the formation of more lesions leading to rapid lysis.  It has long 
been observed that energy poisons (chemicals that disrupt the membrane potential, such as 
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cyanide and dinitrophenol) can trigger lysis instantaneously (Young, 1992), theoretically by 
precipitating the formation of holin lesions. 
Due to their small size of 60-185 aa (Loessner et al., 1999) and the dynamic evolutionary 
pressures, holins are a highly diverse family of functional homologs with low sequence similarity 
(Young et al., 2000).   A single mutation can significantly affect lysis timing, giving the phage 
considerable temporal plasticity to adapt to changing environments and host conditions (Raab et 
al., 1986; Raab et al., 1988; Zheng et al., 2008b).  The majority of current knowledge of holins 
comes from the study of coliphages such as  and P21, which contain an S gene encoding the 
holin.  Two broad classes of holins have been designated based primarily on predicted 
transmembrane domains and other structural analyses examining polar, charged, and 
hydrophobic regions (Wang et al., 2000).  Class I holins as represented by Sλ are 95-183 aa and 
possess three transmembrane domains, while class II holins such as S21 average 65-95 aa and 
have two transmembrane domains (Young et al., 2000).  A third unique class exists for T, the T4 
holin, which is unusually large (218 aa) and highly hydrophilic with a single N-terminal 
transmembrane domain and the majority of the protein in the periplasm (Ramanculov and 
Young, 2001). 
The canonical holin forms a channel in the cell membrane to grant the lysin access to its 
substrate (Figure 11 A).  As seen by cryo-electron microscopy (Dewey et al., 2010), the S holin 
of λ forms exceptionally large (80 nm – 1.5 m) channels that provide lysins access to the PG 
but that can allow the passage of proteins more than 450 kDa in size (Wang et al., 2003).  In 
stark contrast, the holins of P1 and P21 form smaller “pinholins” (Figure 11 B) (Park et al., 
2006).  The hole formed by oligomers of S21 is only 1.6 nm, not wide enough to allow the 
passage of any proteins, much less lysins (Pang et al., 2009; Park et al., 2006).  These pinholins 
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are paired with the SAR endolysins (signal-anchor-release, discussed below), which travel across 
the membrane prior to the triggering of lysis via the E. coli sec transport system (Xu et al., 2004).  
Since the lysin does not need the holin for access to its substrate, these holins are only 
responsible for achieving precise timing of lysis.  There is a gradual spontaneous activation of 
SAR lysins, but the rapid depolarization of the membrane potential by the pinholin activates the 
accumulated SAR lysins simultaneously for rapid lysis (Park et al., 2006).  As the pinholins are 
unable to provide a standard lysin access to the PG it is not possible to compliment a Sλ- mutant 
with S21 since there is no passage through the cell membrane for the R lysin.  However, a S21- 
mutant can be complemented with Sλ since a canonical holin can still activate the P21 SAR lysin 
by disrupting the membrane potential, even if it is not required for substrate access, thus 
demonstrating an advantage of canonical holins in their ability to function with SAR or 
cytoplasmic lysins (Park et al., 2006). 
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 Figure 11. Holin and lysin mechanisms 
 
 
Figure 11:  The holins (blue, purple) form lesions that depolarize the membrane (represented by 
the movement of [+] across the membrane) and allow the lysins (red/yellow and pink/green) 
access to the substrate.  A. Canonical holins form a large lesion (blue) in the cell membrane that 
depolarizes the proton motive force and allows the lysin (red/yellow) to access the PG.  The lytic 
activity (red domain) may be inhibited until the cell wall-binding domain (yellow) has bound its 
substrate.  B. Pinholins form tiny pores (purple) that can only depolarize the membrane.  These 
are paired with signal-anchor-release or SAR-endolysins (pink/green), which are secreted into 
the periplasm with a transmembrane anchor (cyan) in the cell membrane.  Once the pinholin 
depolarizes the membrane, the SAR endolysin is released from the membrane and can access the 
PG. 
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1.5.3 Endolysins 
The endolysin, or lysin, works in conjunction with the holin in dsDNA bacteriophage to effect 
phage release.  Lysins degrade the PG cell wall, and once this structure has been compromised 
the contents of the cell are rapidly expelled due to the high internal osmotic pressure.  
Importantly, lysins exhibit a narrow spectrum of lytic activity that is determined by the 
recognition by the lytic domain of unique PG linkages and by the cell wall binding domain 
(CBD) of exclusive components of the host cell wall (Borysowski et al., 2006). 
1.5.3.1 Modular Structure 
Lysins are modular proteins typically consisting of two domains, an N-terminal domain with 
lytic (PG-hydrolyzing) activity and a C-terminal cell wall binding domain (CBD) (Lopez et al., 
1997).  Lysins have domain-specific sequence similarities to other PG hydrolases (Loessner et 
al., 1997; Sheehan et al., 1997) and this was proposed to be the result of extensive recombination 
between phages and their hosts through processes like non-homologous recombination and 
horizontal gene transfer (Lopez et al., 1997).  The Garcia lab has conducted a comprehensive 
investigation of lysin modularity.   Their study of the cell wall hydrolases of S. pneumoniae and 
its phages demonstrates recombination on multiple levels (Figure 12).  Several lytic and cell wall 
binding domains have been identified from the host autolysin and six different phage lysins 
(Lopez and Garcia, 2004).  These include lysozyme, glucosaminidase, and amidase activities 
paired with either of two CBDs, creating four different two-domain organizations.   
Recombination events between lysins can be identified in the lysins of phages Cp-1 and Cp-7, 
which have highly similar lysozyme domains but completely unrelated CBDs (Figure 12).   
There is also recombination between phage and host; Cpl-1 and the host autolysin, LytA, have 
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strong C-terminal similarity but completely different N-terminal domains with predicted 
activities, lysozyme and amidase, respectively (Figure 12).   Finally, the N-terminal domain of 
Pal is similar to the amidases of phages SM1 and BK5-T, which infect Streptococcus mitis and 
Lactococcus lactis, respectively.  This illustrates that the Pal lysin is a chimeric enzyme of 
intergeneric origin (Sheehan et al., 1997). 
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 Figure 12. Evidence of recombination in Streptococcus phage lysins 
 
 
Figure 12:  Lopez and Garcia (2004) demonstrated the modular nature of phage lysins with 
examples of recombination between phages, between phage and host, and between phages 
infecting different genera of bacteria.  Matching colors indicate domains with significant 
similarity and similar function.  Cpl-7, Cpl-1, and Pal are lysins of phages that infect 
Streptococcus; LytA is an autolysin of S. pneumoniae; and the final lysin is from phage BK5-T, 
which infects L. lactis.  The domains include muramidase (pfam01183, yellow); amidase_2 
(pfam01510, green); amidase_5 (pfam05382, blue); Cpl-7 binding domain (cyan); choline-
binding domain (purple); and BK5-T lysin binding domain. 
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The modular structure of lysins has also been experimentally determined by X-ray 
crystallography (Hermoso et al., 2003; Korndorfer et al., 2006), which consistently reveals a 
two-domain enzyme with the N- and C-terminal domains connected by a short linker.  Further, 
deletion mutants have been used to show that many domains can function independently (Cheng 
and Fischetti, 2007; Loessner et al., 2002).  Chimeric lysins have been experimentally generated 
that possess the properties of the individual domains used to construct them (Croux et al., 1993a, 
b; Diaz et al., 1991; Sanz et al., 1996).  In one instance a chimeric lysin with two lytic domains 
of differing activities paired with a single CBD was created and the specific functions of each 
domain were retained (Sanz et al., 1996).  This bi-functional organization was later observed in 
several natural phage lysins (below), although it does not appear to be common.  It should also 
be noted that the majority of lysins studied are from Gram-positive phages; lysins from phages 
infecting Gram-negative species, such as the  R transglycosylase and the T7 lysozyme, tend not 
to be modular but have a more globular structure (Bienkowska-Szewczyk et al., 1981; Cheng et 
al., 1994).  However, two lysins have recently been identified in phages infecting Pseudomonas 
aeruginosa that display a modular structure with an N-terminal binding domain and C-terminal 
transglycosylase activity (Briers et al., 2007). 
1.5.3.2 Lytic Activity 
Phage lysins are dependent on the permeabilization of the cell membrane by a holin to degrade 
the cell wall.  If lysin is expressed in the absence of any holin, the addition of CH3Cl (which 
artificially permeabilizes the membrane) will instantly induce lysis (Young, 1992).  The most 
basic arrangement includes a canonical holin like Sλ (discussed above) forming a large lesion in 
the cell membrane that allows passage of lysins and access to their PG substrate while 
simultaneously dissipating the membrane potential of the cell (Figure 11 A).  However, a second 
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method has recently been identified in which the holin is not responsible for the lysin to access 
the PG but is still required for efficient lysis.  An N-terminal hydrophobic domain that could 
serve as an export signal sequence was first seen in the fOg44 phage infecting the Gram-positive 
Oenococcus oeni (Sao-Jose et al., 2000) and then analyzed in E. coli phage P1 (Xu et al., 2005; 
Xu et al., 2004).  With this sequence the P1 Lyz lysin could be transported into the periplasm 
using the host sec system, where it then remained tethered via a transmembrane domain to the 
cell membrane.  Once the membrane was depolarized—by a holin, CH3Cl, or an energy 
poison—the Lyz was released to degrade the PG.  This N-terminal region was termed a signal-
anchor-release (SAR) domain and has since been identified in many lysins, including coliphages 
P21, Mu, and T1 (Xu et al., 2004).  SAR lysins are often paired with pinholins (Figure 11 B), 
which are only capable of depolarizing the membrane (Pang et al., 2009), but they can be used 
with canonical holins as well.  However there are several lysins for which the associated holin is 
not identified. 
All four PG-hydrolyzing activities—amidase, muramidase, glucosaminidase, and 
peptidase—have been identified in lysins, although amidase and lysozyme activities are the most 
common (Loessner, 2005).  The amide bond connecting the MurNAc to the L-Ala of the peptide 
is the most consistently present link in bacterial PG, which can differ in the nature of the peptide 
bridges or modifications of the glycan chains (Schleifer and Kandler, 1972).  Certain peptide 
bridge-specific peptidase activities are specifically adapted to the PG of a host, introducing one 
method of ensuring specificity in addition to the CBD (discussed below).  For example, L-
alanoyl-D-glutamate peptidase activity has thus far only been found in Listeria phage (Loessner, 
2005).  Lastly, while lysozyme-type muramidases that hydrolyze the MurNAc—GlcNAc bond 
are common, transglycosylases appear to be very rare.  Transglycosylase activity is the only lytic 
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activity that is not technically hydrolysis, since the reaction forms a 1,6-anhydrobond in 
MurNAc.  The transglycosylase motifs are actually very common in phage, but they are found in 
the tail proteins and believed to assist in entry during phage infection (L. Marinelli and G. 
Hatfull, manuscript in preparation, Moak and Molineux, 2000, 2004).  The R lysin of phage  
and KZ144 and EL188 of the P. aeruginosa phages, KZ and EL are transglycosylases 
(Bienkowska-Szewczyk et al., 1981; Briers et al., 2007), but these are from phages infecting 
Gram-negative bacteria.  To my knowledge, no Gram-positive phage transglycosylase lysins 
have been characterized. 
Several bifunctional lysins have been identified that have two lytic domains, similar to 
those previously created experimentally.  Intriguingly, the N-terminal domain for these lysins is 
an endo-peptidase, usually a D-alanyl-glycyl endo-peptidase (CHAP) (Bateman and Rawlings, 
2003), and all are from phages infecting Staphylococcus aureus or Streptococcus agalactiae.  Of 
those infecting S. aureus, LysK of phage K, LysH4 of H5, and the lysin of 11 have CHAP and 
amidase activities as well as an SH3b CBD (Becker et al., 2009; Horgan et al., 2009; Navarre et 
al., 1999; O'Flaherty et al., 2005; Obeso et al., 2008).  PlyGBS of the S. agalactiae-infecting 
phage B30 possesses CHAP peptidase and lysozyme domains with an SH3b CBD (Cheng and 
Fischetti, 2007; Donovan et al., 2006a; Pritchard et al., 2004).  The strangest of the set is the 
lysin of LambdaSa2, which infects S. agalactiae.  This lysin has an N-terminal D-γ-Gln-L-Lys 
endo-peptidase and a C-terminal glucosaminidase domain but in between these domains are two 
Cpl-7 binding domains, motifs that bind choline first identified in the S. pneumococcal phage 
Cp-7 lysin (Donovan and Foster-Frey, 2008; Pritchard et al., 2007).  The separate domains of 
11 lysin, LysK, and PlyGBS have activity in vitro as determined by reaction products and site-
directed mutagenesis studies (Donovan et al., 2006a).  However, when truncation and deletion 
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mutants were made and activity was tested on live cells, for every single bifunctional lysin the 
peptidase domain was responsible for all, or nearly all, of the activity, and the isolated central 
domain held little or no activity (Becker et al., 2009; Donovan and Foster-Frey, 2008; Donovan 
et al., 2006a; Horgan et al., 2009).  The presence or absence of the CBD varied in its effect on 
the activity (discussed below). 
1.5.3.3 Cell Wall Binding Domains 
The lytic domain of a lysin is likely to be active on a variety of bacteria due to the common 
structure of PG; however, lysins are highly specific, occasionally even to the level of certain 
serovars of a host species (Loessner et al., 2002).  The CBD binds cell wall components that are 
often unique to the host, such as the teichoic acids found in some Streptococcus species.  The 
CBD may inhibit lysin activity until it binds this substrate, and in many instances the CBD 
enhances the lytic activity.  Often the lytic domain simply lacks sufficient substrate binding 
affinity even in proximity to its substrate (Loessner, 2005).   In contrast, the affinity of the 
binding domains of Ply118 and Ply500 were comparable to affinity-matured antibacterial 
antibodies (Loessner et al., 2002).  In addition to swapping CBDs to create chimeric lysins with 
changing host specificities, CBD deletion studies have also been completed.  Oddly, the effects 
on the activity of a lysin with or without the CBD vary widely.  The loss of the CBD decreases 
activity for Streptococcus phage lysins Cpl-1, Cpl-7, and LambdaSa2, Listeria phage lysins 
Ply118 and Ply500, and Bacillus phage lysin PlyG (Donovan and Foster-Frey, 2008; Garcia et 
al., 1990; Kikkawa et al., 2008; Loessner et al., 2002).  However, the lytic activity was 
unchanged or even increased when the CBD was deleted for Listeria phage lysin Ply511, 
Bacillus phage lysins PlyL and Ply21, Streptococcus phage lysin PlyGBS and B30 lysin, and 
Staphylococcus phage lysin LysK (Becker et al., 2009; Cheng and Fischetti, 2007; Donovan et 
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al., 2006a; Gaeng et al., 2000; Horgan et al., 2009; Low et al., 2005).  It is interesting to note that 
several of the lysins that lose activity contain CBD that are highly specific to their host bacteria, 
namely the choline-binding motifs for Cpl-1, teichoic acid-binding motifs for Cpl-7 and 
LambdaSa2 (Lopez and Garcia, 2004), the Listeria-specific carbohydrate for Ply118 and Ply500 
(Loessner et al., 2002), and the unknown Bacillus cereus-specific substrate for PlyG (Kikkawa et 
al., 2008).  Further, PlyGBS, B30 lysin, and LysK all share an SH3b CBD, a binding domain in 
bacteria that is homologous to eukaryotic SH3 domains (Whisstock and Lesk, 1999). 
In addition to enhancing lysin activity, the CBD restricts the range of susceptible bacteria 
by inhibiting activity in the absence of a cell wall binding substrate that is specific to the host 
(Hermoso et al., 2003; Korndorfer et al., 2006).  The inhibitory effect is largely mediated by the 
CBD allosterically binding and suppressing the lytic activity, as has been demonstrated in the 
Bacillus anthracis prophage Ply21 (Low et al., 2005).  These cell wall binding substrates are 
often molecules unique to the host.  Pneumococcal lysins such as Cpl-1 have evolved specific 
motifs to bind choline, a component of the teichoic acids of S. pneumoniae (Hermoso et al., 
2003; Lopez et al., 1997).  These lysins are dependent on choline-binding for activity, while 
other lysins with choline-independent CBDs such as CPL-7, can lyse S. pneumoniae with 
ethanolamine in place of choline.  Studies with pneumococcal lysins have also found host-
specificity to be a transferable property.  Fusing the catalytic domain of the LYC autolysin from 
Clostridium acetobutylicum to the choline-specific CBD of CPL1 created a protein capable of 
lysing S. pneumoniae but not C. acetobutylicum (Croux et al., 1993a).  These and other studies 
associate host-specificity of lytic activity primarily—but not solely—with the CBD. 
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1.5.3.4 Lysins with additional activities 
While not common, several lysins are known or suspected of possessing additional activities 
beyond the degradation of PG.  Most notorious and thus far unique is the bifunctional T7 
lysozyme (technically an amidase) that also plays a role in transcriptional regulation by binding 
to the T7 RNA polymerase (Moffatt and Studier, 1987); oddly, the T7 lysin is not modular but 
appears to be a globular protein that performs both of these functions (Cheng et al., 1994).  Two 
other lysins, namely the T4 lysozyme (During et al., 1999) and the lysin of a Bacillus 
amyloliquefaciens phage (Morita et al., 2001b), appear to have membrane-permeabilization 
abilities.  Both have C-terminal sequences that are similar to cationic antimicrobial peptides 
known to disrupt the cell membrane (Epand and Vogel, 1999).  Interestingly, the B. 
amyloliquefaciens phage lysin was able to lyse cells without a holin and showed some 
microbicidal activity against E. coli when applied externally (Morita et al., 2001a; Morita et al., 
2001b; Orito et al., 2004), lending hope to the idea of phage lysin therapy against Gram-negative 
bacteria. 
1.5.4 Other Lysis Proteins 
While the minimum lysis cassette of dsDNA phages requires a holin and a lysin (Young et al., 
2000), additional lysis proteins have been identified in many lysis cassettes (Catalao et al., 2010; 
Gil et al., 2008; Payne et al., 2009; Summer et al., 2007).  For example, nearly all Gram-negative 
phages appear to contain one or two additional lysis proteins that address the barrier of the outer 
membrane (Summer et al., 2007); these are never found in a Gram-positive phage.  Deletion of 
these and other accessory lysis proteins results in a mild lysis phenotype that can be observed as 
differences in plaque morphology or in the timing of lysis, but this does not completely prevent 
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the phages from forming plaques (Catalao et al., 2010; Payne et al., 2009; Young, 2002; Zhang 
and Young, 1999).  In addition, research on lysis has primarily focused on dsDNA phages, but 
the mechanism of lysis by a few single-stranded (ss) nucleotide phages have been characterized 
(Bernhardt et al., 2000; Bernhardt et al., 2001b).  These phages employ single-gene lysis systems 
which target PG synthesis enzymes instead of the PG structure itself. 
1.5.4.1 Anti-holins 
Many holin systems also include an inhibitor, or anti-holin, that aids in the regulation of the 
timing of lysis.  A common feature in Sλ, S21, and other holins of both classes is a dual-start 
motif that creates two nearly-identical proteins with opposing functions from a single gene by 
utilizing alternate start codons (Barenboim et al., 1999; Blasi and Young, 1996).  In Sλ, 
translation of the S gene from the first or third start codons produces Sλ107 (Met-1—Lys-2—
Met-3…) or Sλ105 (Met-3…), respectively.  Sλ105 is the effector form of the holin that creates 
the actual lesions, while Sλ107 is an anti-holin.  The production of Sλ105 or Sλ107 is determined 
by RNA secondary structure and the relative ratios influence the timing of lysis, with a greater 
proportion of Sλ105 accelerating lysis onset (Wang et al., 2000).  However, not all anti-holins are 
encoded within the holin gene.  Many are encoded by separate genes, as is the case with the 
phage P1 lydA and lydB holin/anti-holin (Schmidt et al., 1996).   Also unique is the method of 
inhibition in T4 phage.  A situation known as lysis inhibition (LIN) occurs when there is a 
secondary infection of the cell by another T4 phage (Doermann, 1948).  This event overrides the 
lysis schedule programmed into T and virions continue to be made.  Lysis can be delayed for 
hours if there continues to be secondary infections.  LIN is accomplished by the periplasmic RI 
protein, which acts as an anti-holin to directly inhibit T (Ramanculov and Young, 2001).  The 
LIN phenomenon demonstrates the evolved ability of T4 to respond to environmental signals and 
 58 
adjust its infection accordingly; secondary infections would indicate a lack of host cells, and so 
the phage chooses to postpone lysis. 
1.5.4.2 Rz/Rz1 and Spanins 
In addition to the S holin and R lysin, two additional proteins, Rz/Rz1, are present in the lysis 
cassette whose functions were only recently elucidated (Berry et al., 2008).  Rz is directly after 
the R lysin gene and codes for a 153 aa protein.  Fully embedded in the Rz gene in the +1 reading 
frame is Rz1 which encodes a smaller 60 aa protein (Figure 10) (Hanych et al., 1993).  These 
proteins appear to be nonessential for lysis as nonsense mutations in the gene confer a 
conditional lysis phenotype only in the presence of >10 mM Mg2+ (Young et al., 1979).  Rz is a 
predicted transmembrane protein (Summer et al., 2007) and Rz1 is a lipoprotein that localizes to 
the outer membrane (Kedzierska et al., 1996) and has been demonstrated to fuse liposome 
membranes (Bryl et al., 2000).   Further, there is evidence for an interaction between Rz and Rz1 
proteins; studies with homologs encoded by 18.5 and 18.7 in T7 indicated a protein interaction 
(Bartel et al., 1996), and complementations of Rz/Rz1 with λ, P22, and PRD1 require that the 
cognate pair be used (Krupovic et al., 2008; Markov et al., 2004). 
λ Rz/Rz1 and equivalents (hereafter known collectively as Rz or Rz1) have been 
predicted in over 120 phages infecting Gram-negative bacteria (Summer et al., 2007), but none 
are seen in Gram-positive bacteria.  The homologs were identified based on similarity by 
sequence or secondary structure to known Rz and Rz1 proteins such as those in λ, P2, and T7.  
Specifically, the Rz protein needed to include a single N-terminal transmembrane domain and 
the Rz1 protein was predicted to be an outer membrane lipoprotein.  From the search, three 
architectural genetic classes were determined: embedded, where the Rz1 is entirely within Rz (λ, 
T7); overlapped, where Rz1 extends past the end of Rz (P2); and separated Rz and Rz1 genes (T4) 
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(Summer et al., 2007).  Among some genomes lacking Rz/Rz1 proteins, a single protein was 
predicted following the holin and lysin that resembled a fusion of the Rz and Rz1 structures and 
is predicted to span the entire periplasmic space, earning it the name “spanin” (Summer et al., 
2007).  The spanin of T1 has been shown to complement a λ Rz-Rz1- mutant, confirming it as a 
functional analog of Rz/Rz1 (Summer et al., 2007). 
The current model for the involvement of Rz/Rz1 places it at the final step in the phage 
infection cycle (Berry et al., 2008).  Lysis begins with the permeabilization of the cell membrane 
by the holin, followed by lysin-dependent degradation of the PG layer.  For Gram-negative 
bacteria, this still leaves the outer membrane as a barrier to phage release.  The Rz/Rz1 (or 
spanin) proteins fuse the inner and outer membranes to effectively remove all barriers to phage 
release (Berry et al., 2008).  While the Rz/Rz1 proteins function as a cognate pair, they are 
mechanistically independent of the holin and lysin (Berry et al., 2008), which allows for 
recombination that leads to the mosaicism observed in phage lysis cassettes. 
1.5.4.3 Non-peptidoglycan Hydrolytic Lysis Methods 
All dsDNA bacteriophage employ the holin-endolysin system to lyse host cells at the end of 
infection.  However, phages with smaller single-stranded (ss) nucleic acid genomes including 
Microviridae, Leviviridae, and Alloleviridae only require a single protein to effect lysis 
(Bernhardt et al., 2002).  The timing of lysis in these single gene systems is dependent upon the 
level of gene expression, the activity of the protein, and the rate of cell division (Bull et al., 
2004). 
The Microvirus X174 has a ssDNA genome of only 5386 bp encoding 11 genes.  The 
lysin gene E, is fully embedded in the +1 reading frame of gene D and creates a 91 residue 
protein with an N-terminal hydrophobic domain and positively charged C-terminus (Young et 
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al., 2000).  The mechanism of action of E was recently determined through genetic, biochemical, 
and structural studies (Bernhardt et al., 2000; Bernhardt et al., 2001a; Zheng et al., 2008a; Zheng 
et al., 2009).  E blocks cell wall synthesis by inhibiting MraY (Bernhardt et al., 2001a), a 
translocase that catalyzes the formation of the first lipid-linked precursor in cell wall synthesis 
(Ikeda et al., 1991).  By targeting a host protein, resistant strains with mutations in MraY can be 
isolated (Bernhardt et al., 2001b), an event that is not observed in holin-lysin systems, which 
target the PG structure itself (Loeffler et al., 2001; Schuch et al., 2002).  Similar to cell wall 
synthesis inhibitors like the antibiotics penicillin, E is dependent on cell growth and division, and 
E-mediated lysis is most commonly observed along the septum between newly dividing cells 
where new cell wall is being incorporated (Witte et al., 1998).  Consistent with the dependence 
of the phage on active cell growth, the addition of a protein synthesis inhibitor or energy poison 
stops lysis; in contrast, in holin-based systems the depolarization of the membrane by an energy 
poison will trigger lysis (Young, 1992). 
The E protein is capable of replacing the lysis cassette of λ with minor plaque phenotypes 
(Zheng et al., 2008b).  However, the latent period is determined by the quantity of E protein, 
whereas the latent period for a holin is almost completely dependent on the specific allele.  This 
may indicate that E has lesser control over the lysis of its host in comparison to holins, which 
have increased plasticity with the ability to adjust the timing of lysis through small mutations and 
thus adapt to changing environments (Zheng et al., 2008b). 
Two ssRNA phages also have alternative mechanisms of lysis (Bernhardt et al., 2002).  
The ssRNA Allolevivirus Qβ contains only 4 genes in a 4217 nucleotide genome, none of which 
are a lysis protein (Bernhardt et al., 2001b).  Instead, the capsid maturation protein A2 also 
fulfills the role of lysis, in addition to its functions in adsorption to the host sex pilus and the 
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protection of the virion genome from ribonucleases.  Resistant host mutants could also be 
recovered from Qβ infection and were found to have mutations in the murA gene, which 
catalyzes the first committed step in PG biosynthesis (Bernhardt et al., 2001b).  The virion-
associated A2 binds directly to MurA effectively titrating it from the cell wall synthesis pathway 
leading to an induction of lysis.  However, another study found a frame-shifted protein near the 
replicase in Qβ that appears to cause rapid lysis in high sodium chloride environments (Nishihara 
et al., 2004), so the circumstances of lysis in Qβ remain unresolved.  MS2, a 3569 nucleotide 
Levivirus phage, possesses a lysis gene, L, embedded out of frame in the coat and replicase genes 
(Bernhardt et al., 2002).  L is a transmembrane protein with a hydrophilic N-terminus and 
hydrophobic C-terminus, and requires a high level of synthesis to effect a gradual lysis 
(Bernhardt et al., 2002).  Currently the mechanism of lysis by L is unknown. 
1.5.5 Mycobacteriophage Lysins 
Isolation and characterization of mycobacteriophages began in the 1940s (Froman et al., 1954; 
Gardner and Weiser, 1947; Whittaker, 1950) with a focus on typing clinical isolates of 
mycobacterial pathogens (Jones, 1975; Snider et al., 1984) and, later, as tools for genetic 
manipulation of mycobacteria (Jacobs, 2000; Jacobs et al., 1989; Snapper et al., 1990; van 
Kessel and Hatfull, 2007).  As of this writing, 60 mycobacteriophage genomes have been 
characterized (Hatfull et al., 2010); the majority of these phage sequences are the product of the 
Phagehunter educational research program conducted in the Hatfull lab (Hatfull et al., 2010; 
Pedulla et al., 2003).  To the extent that studies have identified putative lysis genes, they have 
done so based on homology to known PG hydrolases. 
 62 
Mycobacteriophage proteins are grouped into “phamilies” corresponding to specific 
levels of sequence similarity (Hatfull et al., 2008), and there are currently more than 1500 such 
phamilies (Hatfull et al., 2010).  Pham7, the phamily comprising LysAs, is one of only three 
phamilies with a representative from every phage genome.  There is, however, no single 
sequence element common to all Pham7 members; indeed, there is extensive mosaicism 
throughout Pham7 (Hatfull et al., 2010; Hatfull et al., 2006; Pedulla et al., 2003). 
One of the first observations made about the mycobacteriophage endolysins regarded the 
modularity of the proteins.  Mediavilla et al. (2000) noted that the central regions of Bxb1 gp8 
and D29 gp10 were 59% identical, while sequences within the same ORF to either side were 
unrelated.  This central region shows weak homology to chitinase family proteins, a hydrolytic 
activity never before seen in phage lysins.   Further, the C-termini of Bxb1 gp8 and D29 gp10 
did not show significant similarity, but instead a 100 aa region in the C-terminus of Bxb1 gp8 
had 39% identity with the C-terminus of TM4 gp29 (Mediavilla et al., 2000).  The interchanging 
of regions to generate variation in the phage genome – even within a single gene – is consistent 
with the mosaic nature of phage genomes and their evolution by illegitimate recombination 
(Lawrence et al., 2002). 
Focused study of mycobacteriophage lysins began with the unsequenced 
mycobacteriophage Ms6 (Garcia et al., 2002).  Garcia et al. (2002) identified a lysis cassette that 
contained a set of 5 co-transcribed ORFs in different overlapping reading frames (e.g. the TGA 
stop codon of ORF2 overlapped the ATG start codon of ORF3).  ORF2 was identified as the 
LysA based on sequence similarity to known lysins with amidase activity, and on the lysis of E. 
coli expressing the Ms6 lysA upon the addition of chloroform to permeabilize the membrane 
(Garcia et al., 2002).  ORF4 is a holin; it shares similarity with a holin of the L. lactis phage r1t, 
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was predicted to have two transmembrane domains similar to class II holins, and was able to 
complement a  S mutant (Garcia et al., 2002).  The functions of ORF1, ORF3, and ORF5 were 
less clear; all three had homologs in other mycobacteriophages but showed little similarity 
outside of these phages, leading to the theory that they had mycobacteria-specific functions in 
infection (Garcia et al., 2002).  In addition to the lytic activity shown by Ms6 ORF2 (now Ms6 
gp2), the Giles LysA was determined to be an essential gene for plaque formation (Marinelli et 
al., 2008), which is consistent with its vital role in lysis.  Very recently, the TM4 gp29 LysA has 
been cloned and shown to have PG hydrolytic activity on zymograms and by chloroform-
induced lysis of E. coli expressing TM4 gp29 (Henry et al., 2010).  However, these analyses 
have been restricted to only a few select LysA proteins, and no characterization of the diversity 
preliminarily observed in these proteins has been conducted. 
Beyond attaining its label based on its location downstream of the Ms6 lysA gene, little 
study has been conducted on LysB until very recently.  The occurrence of lysis proteins in 
addition to endolysins and holins is not unusual, but the LysB proteins did not resemble 
antiholins, Rz/Rz1 or spanins, or any other proteins previously associated with lysis.  Pham9 
comprises the LysB proteins (Hatfull et al., 2006), which are found in 56 of the 60 published 
phage genomes (Hatfull et al., 2010).  The lysB gene is always close to lysA, despite the 
difference in the location of the lysis cassette in the broader mycobacteriophage genome 
organization.  The lysis genes generally follow those involved in virion structure and assembly, 
but in Cluster A mycobacteriophages the lysis cassette preceeds the structural genes (Payne et 
al., 2009); however, regardless of location in the genome, lysB remains linked with lysA.  The 
LysB homolog in Ms6, gp3 (previously Ms6 ORF3), has been identified as a lipolytic enzyme 
based on its conserved signature motif Gly-X-Ser-X-Gly and the hydrolysis of lipase and 
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esterase substrates, including Tween-20, Tween-80, tributyrin and various p-nitrophenol fatty 
acid esters (Gil et al., 2008).  However, the natural substrate and the purpose of the LysB 
proteins in mycobacteriophage infection were not determined. 
Very recently, the role of Ms6 ORF1, now gp1, has been identified to be that of a 
chaperone for the LysA, gp2 (Catalao et al., 2010).  Portrayed as playing a role similar to the 
SAR domain of other endolysins, gp1 is required for sec-mediated export of the gp3 LysA into 
the periplasm (Catalao et al., 2010).  Gp1 shares structural characteristics with type III secretion 
system chaperones and formed a dimer to bind gp3 and translocate it across the membrane.  The 
N-terminal 60 amino acids of the gp3 LysA were necessary and sufficient for binding and export.  
Similar to the pinholins and SAR-endolysins (Pang et al., 2009), a holin was not necessary for 
access to the PG substrate, and lysis could be induced simply by disrupting the membrane 
potential (Catalao et al., 2010).  A Ms6 gp1 deletion mutant was able to form plaques with a 
lesser efficiency and appeared to have a reduced burst size, although the cause of the latter was 
not determined (Catalao et al., 2010).  Homologs of gp1 are found in 18 out of 60 phage 
genomes, primarily in Sub-cluster F1 phages (Hatfull et al., 2010).  The identification of gp1 as 
an ancillary lysis protein playing a novel role as a lysin chaperone in mycobacteriophage further 
expands the known mechanisms of phage lysis. 
1.5.6 Lysin Applications 
Phage therapy has been pursued since the late 1800’s, although Felix d’Herelle first described 
the bacteriophages and identified their viral nature in 1917 (D'Herelle, 2007), and subsequently 
attempted to use phage in the treatment of dysentery.  A review of the history of phage therapy 
can be found in the review by Summers, W.C. (2001), and O’Flaherty et al. (2009) have written 
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an excellent overview of more recent advances.   Lysins have only recently been examined as 
potential antimicrobials.  While the lytic ability of isolated lysins was recognized in 1957 
(Krause, 1957), it was not until 2001 that the therapeutic potential of lysins was first 
demonstrated (Nelson et al., 2001). 
1.5.6.1 Therapeutic Potential 
Lysins are being tested in two therapeutic capacities:  the prevention of colonization by 
pathogenic bacteria and the elimination of infection.   Both of these functions were shown in the 
first therapeutic application of a lysin from the Streptococcus phage C1, which infects groups A, 
C, and E Streptococcus species (Nelson et al., 2001).  The purified lysin was able to rapidly 
sterilize bacteria in culture, protect the oral cavity of mice from colonization with a single dose, 
and eliminate all detectable bacteria in previously colonized mice.  This amazing demonstration 
combined with more than a decade of lysin study led many groups to examine the activity of 
other phage lysins on other pathogenic bacteria.  To date, the majority of these studies have 
targeted S. pneumoniae (Entenza et al., 2005; Grandgirard et al., 2008; Jado et al., 2003; Loeffler 
et al., 2003; Loeffler and Fischetti, 2003; Loeffler et al., 2001; McCullers et al., 2007), Group B 
streptococcus (Cheng et al., 2005), S. aureus (Rashel et al., 2007), Enterococcus faecalis and 
faecium (Yoong et al., 2004), and B. anthracis (Schuch et al., 2002).  These studies are reviewed 
in depth by Borysowski et al. (2005). 
The prevention of colonization is important because it is the starting point for an infection 
and contributes to the spread of the disease in the community (Bogaert et al., 2004; von Eiff et 
al., 2001)).  The first lysin study aimed to prevent colonization of Group A streptococci in the 
upper respiratory system of mice (Nelson et al., 2001).  Nelson et al. used the C1 lysin as a 
prophylactic agent that was applied to a mucosal surface, namely the oral cavity, to great effect.   
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Another example is the lysin PlyGBS that is active against Group B streptococci (Cheng et al., 
2005), a pathogen that can colonize human genitalia.  One goal is to develop PlyGBS as a 
potential prophylactic against infection by Group B streptococci in newborns, whose mothers 
may be vaginally colonized during pregnancy.  In addition to its lytic ability, PlyGBS is highly 
specific and does not lyse commensal bacteria (Cheng et al., 2005).  The narrow spectrum lytic 
activity is one of several advantages that lysins have over broad-spectrum antibiotics. 
Treating bacterial infections with lysins poses more difficulty because of the many host 
interactions possible (see below).  Still, lysins have proven effective in treating infections of 
pneumococcal bacteria and B. anthracis, even when delivered intravenously and 
intraperitoneally (Jado et al., 2003; Loeffler et al., 2003).  However, systemically treating 
bacteremia or other internal infections with lysins presents complications with the immune 
system that are avoided or diminished by topical application, although thus far there have been 
no problematic effects observed (Borysowski et al., 2006). 
In more difficult cases of bacterial infection it can be beneficial to use multiple 
treatments.  Co-administration of Pal and Cpl-1, two lysins specific to S. pneumoniae but 
targeting different bonds in the cell wall, showed a synergistic lethal effect (Loeffler et al., 
2003).  In addition, several studies have found that lysins can work synergistically with 
antibiotics to clear infections, provided that the bacterial strain is sensitive to the antibiotic 
(Djurkovic et al., 2005; Loeffler and Fischetti, 2003).  Adding a second bactericidal agent 
reduces the opportunity for resistance to arise, and in attacking the cell wall, the lysin may make 
access easier for the antibiotic. This cooperative treatment could help keep antibiotics as a viable 
treatment option and reduce the spread of resistance. 
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1.5.6.2 Biocontrol of Food 
The specificity of lysins provides a unique opportunity for biological control of unwanted 
bacteria.  Applications of lysins in the food industry are already a reality and the efforts have 
been pioneered by the dairy industry.  Listeria monocytogenes, the causative agent of listeriosis, 
is a serious contamination concern in dairy cultures (McLauchlin et al., 2004).  Loessner’s group 
has spent considerable time investigating the properties of Listeria phage (Loessner et al., 1999; 
Loessner et al., 2002; Loessner et al., 1995) and has designed a elegant system to prevent 
contamination of Lactococcus cultures with L. monocytogenes.  Rather than simply add purified 
lysin, they engineered L. lactis cells to secrete Ply118 and Ply511 into the medium, leading to 
lysis of any Listeria monocytogenes cells while leaving L. lactis and other bacteria intact (Gaeng 
et al., 2000).  This approach is also being considered for biocontrol of C. perfringens, a pathogen 
that is problematic in the poultry industry (Zimmer et al., 2002). 
In fact, genetic engineering of lysins has progressed beyond the level of bacteria.  
Transgenic plants that express lysin genes are being created.  Notably is the T4 lysozyme potato, 
which produced the T4 lysin to protect against damage caused by the phytopathogen Erwinia 
carotovora (de Vries et al., 1999).  When damaged, the plant cells released the lysin and 
hydrolyzed the bacterial cells.  An even more ambitious undertaking was the engineering of 
cows that secreted lysostaphin (a bacterial autolysin similar to phage lysins) into the milk (Wall 
et al., 2005).  The milk was able to kill S. aureus and the cows were protected from S. aureus 
mastitis.  As concerns about the amount of antibiotics being given to livestock continue and 
pesticide-resistant crop pathogens are becoming more frequent, biocontrol of our food sources 
with phage lysins is an appealing option. 
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1.5.6.3 Other Applications 
There are a variety of applications being pursued for lysins beyond medical treatment and 
biocontrol of food.  Control of B. anthracis, the causative agent of anthrax, was of great interest 
after concerns of bioterrorism in the U.S. Postal Service in late 2001 to early 2002.  The PlyG 
lysin was isolated from the  phage infecting B. anthracis and found to have exogenous lytic 
activity both on vegetative cells and the more dangerous spores (Schuch et al., 2002).  Further, 
due to the high specificity of the lysin, it was able to detect B. anthracis in samples, first by 
adding PlyG and then measuring any ATP release from lysing cells using a luciferase assay 
(Schuch et al., 2002) and later by using the high-affinity CBD alone for rapid and precise 
detection (Fujinami et al., 2007).  High-affinity CBDs are also being used in research to label 
cells and immobilize them on a solid surface (Loessner et al., 2002). 
Lysins can also be used to lyse their own cells in a controlled manner.  One interesting 
application of this is in cheese ripening.  The lysis of the L. lactis cells in the starter culture of 
cheese releases intracellular enzymes that are involved in flavor formation.  By inducing 
autolysis through the expression of lytA and lytH, the lysin and holin of the lactococcal phage 
US3 the cheese could theoretically ripen more quickly (de Ruyter et al., 1997).  Another novel 
application of lysin-mediated autolysis is the release of a cell’s cytoplasmic contents.  This 
technique has been employed in attempts to generate vaccines and more directly induce the host 
immune response.  The single lysis protein E of X174 has been expressed within E. coli and H. 
pylori to create “ghosts,” empty cell envelopes that are vaccine candidates (Haidinger et al., 
2003; Jalava et al., 2003; Panthel et al., 2003).  Another novel approach termed “bactofection” 
uses the intracellular pathogenic L. monocytogenes as a DNA delivery system by lysin-mediated 
spontaneous autolysis once within the mammalian cells (Pilgrim et al., 2003).  A similar 
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approach was taken with Vibrio cholerae and Salmonella enterica expressing the λ S and R lysis 
genes that act as mucosal DNA delivery vectors (Jain and Mekalanos, 2000).   
It is worth noting that these prior examples have all either utilized both a holin and lysin 
or the single lysis gene E from X174 (Bernhardt et al., 2001a).  Currently most applications of 
lysins involve exogenous exposure, which is effective for the accessible PG of Gram-positive 
bacteria.  However, there are advances being made in adapting lysins for use with Gram-negative 
bacteria.  The T4 lysozyme (During et al., 1999) and the B. amyloliquefaciens phage lysin 
(Morita et al., 2001b) have C-terminal sequences that are similar to cationic antimicrobial 
peptides, and it appears they may be capable of permeabilizing the outer membrane to induce 
lysis of Gram-negative bacteria exogenously (Morita et al., 2001a; Morita et al., 2001b; Orito et 
al., 2004).  It is possible to engineer lysins with C-terminal peptides that enhance lysis, as has 
been shown with lysozyme and E. coli (Ibrahim et al., 1994), and so it may be possible to take 
advantage of these known anti-microbial regions to confer the ability to lyse Gram-negative 
bacteria on other lysins. 
1.5.6.4 Considerations 
The use of lysins in the above applications raises several questions and concerns.  Most 
important is the safety of their use in medical therapy.  Lysins target PG, a structure exclusively 
found in bacteria, so there is minimal damage to be expected from non-specific action on non-
bacterial host substrates, especially when the lytic activity is combined with the high specificity 
conferred by the CBD.  That being said, at least one endopeptidase, the S. aureus autolysin 
lysostaphin, has shown the ability to degrade elastin, a glycine-rich polymer in mammalian 
tissues (Park et al., 1995).  The larger variety of substrate bonds targeted by peptidases may 
make them less ideal for such treatments as opposed to muramidases and amidases that target 
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bonds unique to PG (Borysowski et al., 2006).  However, no topical or systemic applications of 
lysins, even lysostaphin, have shown any toxicity or irritation to date, even after multiple 
exposures (Climo et al., 1998; Dajcs et al., 2000; Loeffler et al., 2003; Loeffler et al., 2001; 
Nelson et al., 2001). 
Interactions with the immune system are a concern for lysin therapies in two ways.  
Proteins are naturally immunogenic (able to elicit an immune response); they are recognized as 
foreign and stimulate the humoral response to produce antibodies designed to inactive them 
(Fischetti, 2005).  In addition, lysins will have to survive the body’s basic defenses, such as 
mucosal barriers, secreted proteases, and inhibitory pH environments such as the stomach.  As 
studied by repeated injections in treating mice and rabbits, introducing lysins systemically into 
the body did generate antibodies but did not significantly reduce the therapeutic activity (Jado et 
al., 2003; Loeffler et al., 2003).  The antibacterial activity against some Streptococcus and 
Bacillus species by lysins was not neutralized by the antibodies, potentially due to the very high 
affinity interaction of the lysin with the cell wall (Fischetti, 2005).  Regardless, the potential 
inactivation of lysins that provoke an immune response is still a concern.  One approach to 
reduce the immunogenicity of lysins is conjugation to polyethylene glycol (PEG).  The addition 
of PEG to a protein both reduces antibody binding, inhibits proteolysis and clearance, and 
impairs uptake by dendritic cells for antigen processing (Delgado et al., 1992).  PEGylation of 
lysostaphin has already been proven to be effective at reducing antibody binding and increasing 
the half-life in the serum (Walsh et al., 2003). 
The second immune-centered concern for lysin treatment is the release of pro-
inflammatory cell wall components as a result of bacterial lysis.  The immune system is 
hypersensitive to many bacterial molecules including endotoxins like lipopolysaccharide, 
 71 
teichoic and lipoteichoic acids, and PG.  A sudden massive release of such material can result in 
septic shock that cascades into a large-scale inflammatory response that can lead to multiple 
organ failure and death (Nau and Eiffert, 2002).  Again, no evidence of any bacteriolytic side 
effects has been observed in animal model studies to date (Jado et al., 2003; Loeffler et al., 
2003). 
A major problem in current bacterial treatments is resistance to antibiotics (Di Perri and 
Bonora, 2004; Lowy, 2003; Ong et al., 2004; Razavi et al., 2007; Saenz et al., 2004).  It is in 
their inability to generate resistance that lysins trump antibiotics (Loeffler et al., 2001; Schuch et 
al., 2002).  Since lysins are essential for the lytic phage life cycle they have evolved to target 
molecules essential to their phages’ hosts (Borysowski et al., 2006).  Instead of targeting a single 
protein in a synthesis pathway, endolysins act upon the structure that is the result of dozens of 
enzymes and is largely conserved across the entire bacterial kingdom (Schleifer and Kandler, 
1972).  Further, the CBD of lysins binds to highly host-specific components of the cell wall.  For 
example, most Streptococcus phage lysins bind teichoic acids containing choline, which is 
necessary for viability (Garcia et al., 1988; Hermoso et al., 2003).  Another cell wall component 
bound by lysins is polyrhamnose, which is important for the growth of Group A Streptococcus 
species (Fischetti, 2003).  However, while there are effective antibiotics against both Gram-
postive and Gram-negatice bacteria, lysins remain ineffective as a treatment of Gram-negatice 
infections due to their inability to reach the PG. 
One factor that can affect a bacterium’s susceptibility to lysins is the bacterial growth 
phase.  Lytic activity was decreased against stationary phase bacteria (Loeffler et al., 2001; 
Pritchard et al., 2004).  This is likely because of the changes in the cell wall associated with 
entering a non-replicating state: increased cross-linking of the PG, deacetylation of the amino 
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sugars, and increases in cell wall-associated proteins and polysaccharides (Borysowski et al., 
2006).  However, this is not unique to lysins, since these cells are also less susceptible to many 
antibiotics (Tuomanen et al., 1986) and lytic phage (Levin and Bull, 2004). 
While lysins possess many qualities that would make them a good potential 
antimicrobial, there are still potential problems are disadvantages when compared to phage 
therapy and antibiotics.  A major advantage of treatment through phage therapy is the self-
replication of the therapeutic agent, which is not possible with purified antibiotics or lysins 
(O'Flaherty et al., 2009). While antibiotics may have other side effects, they are largely resistant 
to the body’s defenses; hostile environments, proteases, and the antibodies produced by the 
humoral immune system may inactivate phages and lysins (Borysowski et al., 2006).  Phages and 
antibiotics have also been identified that are active against Gram-negative bacteria, while little 
research has produced lysins that can effectively lyse these bacteria upon exogenous application 
(Briers et al., 2007).  
In summary, no single antimicrobial agent is perfect, but there is much potential in phage 
lysins in the treatment, control, and study of bacteria for numerous reasons: (i) lysins achieve 
rapid lysis both in vitro and in vivo; (ii) unlike antibiotics, lysins do not appear to generate 
resistance; (iii) lysins target a structure that is only found in bacteria; (iv) due to the evolved 
specificity of the CBD, lysins have a very narrow spectrum of activity, preventing complications 
from the destruction of indigenous microflora; (v) to date, lysins appear to be safe for topical and 
systemic administration and are not significantly impaired by the immune system; (vi) the ease 
of genetic engineering produces opportunities to create lysins with optimal lytic ability and 
potentially exogenous activity against Gram-negative bacteria; (vii) the vast number of 
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bacteriophage (~1031) (Hendrix, 2003) provides an immense reservoir for new lysins, as well as 
other antimicrobials. 
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1.6 SUMMARY 
Past studies of dsDNA bacteriophage lysis have centered on the phages of Gram-negative 
bacteria, such as  and T4 (Calendar, 2006).  However, over the past two decades this research 
has accelerated, resulting in new models of phage lysis that reflect its regulation by holins and 
execution by endolysin proteins (Young, 1992).  Concurrently, research on the endolysins of 
Gram-positive bacteria has also expanded, revealing their modular organization, the variety of 
their activities, and their potential as highly specific and effective anti-bacterial agents (Fischetti, 
2008).  In more recent years, the role of several accessory lysin proteins has been determined 
(Berry et al., 2008); indeed new ones are still being identified (Catalao et al., 2010), which 
illustrates just how complex the phage lysis system is, and how much remains to be understood. 
Little research has been conducted on mycobacteriophage lysis proteins, and in addition to the 
benefits of increased knowledge of lysis strategies, the threat posed by drug-resistant forms of 
TB warrants the investigation of these proteins as potential therapeutics or research tools.  My 
thesis research has focused on two lysis proteins that are found in mycobacteriophages: LysA 
and LysB.  
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1.6.1  Specific Aim 1: Bioinformatic characterization of the mycobacteriophage Lysin A 
proteins. 
 
Mycobacteriophage LysA proteins are expected to serve the role of the endolysin, which 
hydrolyzes the PG to induce host lysis.  More than 60 mycobacteriophage genomes have been 
sequenced, and each has a LysA homolog.  This wealth of sequence data provides an opportunity 
to bioinformatically examine these proteins, which appear to have complex architectures 
generated by recombination and composed of a variety of domains.  In addition to the expected 
PG hydrolytic domains, several domains of unknown function that are unique to 
mycobacteriophages are also present.  The results of this bioinformatic characterization are 
described in Chapter 2.  This initial survey of the LysA proteins lays the foundation for future 
research, including an examination of phage evolutionary mechanisms that generate these mosaic 
proteins, and investigation of the domains unique to mycobacteriophage endolysins and 
implications for lysis of mycobacteria.  Mycobacteriophage lysins also have potential as 
therapeutics, and preliminary data shows some anti-mycobacterial activity by some LysAs; these 
bioinformatic studies will enable directed genetically engineering of lysins for use in research 
and antimicrobial therapy. 
 
1.6.2.  Specific Aim 2:  Determination of the function of mycobacteriophage Lysin B 
proteins. 
 
Prior studies have indicated that LysB possesses lipolytic activity characteristic of a serine 
esterase (Gil et al., 2008).  However, these studies utilized artificial substrates, and so the natural 
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target in the context of mycobacterial infection is unknown.  We hypothesized that the ester bond 
covalently linking the mycolic acids to the rest of the cell wall is the target of LysB.  We tested 
this by cloning the mycobacteriophage D29 LysB protein and assaying its activity on purified 
mAGP.  The results of these studies comprise the first half of Chapter 3.  This study has revealed 
the first known protein with mycolylarabinogalactan esterase activity.  LysB may be useful in 
research methods including isolation of mycobacterial cell wall fractions, and preliminary studies 
indicate some anti-mycobacterial activity, which should be further characterized. 
 
1.6.3.  Specific Aim 3:  Identification of the role of Lysin B in mycobacteriophage 
infections. 
 
While a LysA protein is present in all mycobacteriophage genomes, only 56 out of the 60 
surveyed mycobacteriophage genomes lack a LysB homolog, suggesting that the protein is not 
essential for lytic infection.  To examine the role of LysB, we created a lysB deletion mutant in 
mycobacteriophage Giles.  We compared the mutant phage to the wildtype Giles phage in its 
ability to form plaques, efficiently lyse cells, and release progeny phages.  The second part of 
Chapter 3 documents these results, which provide further insight into the complex system 
required for the lysis of the host mycobacterial and further emphasize the importance of its cell 
wall as a barrier.  
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2.0  CHARACTERIZATION OF THE MODULAR LYSA PROTEINS 
2.1 INTRODUCTION 
Endolysin proteins, which function to degrade the host cell wall at the completion of lytic 
growth, are found in all tailed dsDNA bacteriophages.  Recent work has focused on 
characterizing these proteins from the phages of a number of Gram-positive bacteria, including 
S. aureus, S. pneumoniae, and L. monocytogenes (Borysowski et al., 2006; Loessner, 2005; 
Lopez and Garcia, 2004).  However, little study has been done on mycobacteriophage 
endolysins, the LysA proteins, which have been identified largely based on homology to known 
peptidoglycan (PG) hydrolases (Garcia et al., 2002; Hatfull et al., 2006).  The first test of lytic 
activity was done by Garcia et al. (2002), who examined the lysis cassette of Ms6 and identified 
gp2 (ORF2).  This was characterized as having lytic activity based on the observation that E. coli 
cells overexpressing ORF2 lysed upon the addition of chloroform, which permeabilizes the 
membrane and presumably allows the lysin access to its substrate.  Additional zymography 
studies of several LysAs (Bxz1 gp236, Che8 gp32, Corndog gp69, D29 gp10) have also shown 
PG hydrolytic activity on M. luteus PG (Appendix A.1) (Payne et al., 2009).  Most recently, 
TM4 gp29 has been shown by Henry et al. (2010) to have PG hydrolytic activity by promoting 
cell lysis in the chloroform assay and clearing on a zymogram of M. luteus PG.  While these 
studies demonstrate empirically that at least several of the LysAs of mycobacteriophage have PG 
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hydrolytic activity, neither the specific enzymatic mechanisms nor cell wall binding domains 
have been characterized.  There is, however, a wealth of raw sequence data available, which 
indicates a great diversity of activities within the LysA proteins themselves.  A bioinformatic 
analysis of the more than 60 LysA proteins published (as of July 2010) will provide insight into 
the structure and diversity of these proteins, allowing a more targeted approach to examinations 
of their activity and potential application in the future. 
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2.2 LYSAS SHOW EXTENSIVE MODULARITY 
Phage lysins are established to be modular with two domains: an N-terminal PG hydrolytic 
domain and a C-terminal cell wall binding domain (Lopez et al., 1997).  Very few lysins have 
been identified that have three domains, and in every instance these lysins possess two lytic 
domains of differing specificities (Cheng and Fischetti, 2007; Navarre et al., 1999; Pritchard et 
al., 2004).  In light of these precedents, the mycobacteriophage LysA proteins are exceptional in 
the predominance of the three-domain architecture, and in the prevalence of domains of 
unknown function and LysAs with no identifiable PG hydrolytic activity. 
 
2.2.1 Organization of LysAs 
In order to further characterize the mycobacteriophage LysAs, BLASTp searches were 
performed to find conserved domains with either predicted PG hydrolase activity or sequence 
similarity to regions in other known lysins.  While many LysAs did have hits to PG hydrolytic 
domains, most also had domain-sized regions with no identifiable sequence similarity outside of 
other mycobacteriophage LysAs.  In many cases, these were conveniently on the N-terminal or 
C-terminal side of a predicted PG hydrolytic domain, effectively separating the protein into three 
modules.  In order to characterize these distinct regions, a domain was defined as a region of 
significantly shared amino acid sequence identity (e-value < 1e-05, ClustalW similarity >20%) 
between two or more mycobacteriophage LysAs.  Similar to the mycobacteriophage Pham 
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concept (Pedulla et al., 2003), claim to a domain required having similarity to at least one other 
defined region in another mycobacteriophage LysA.  As a result, two LysAs may be entirely 
unrelated by the above criteria but are still categorized as LysAs based on domain-specific 
similarities to a third LysA.  Up to three iterations of PSI-BLAST analysis that only included 
other mycobacteriophage LysA hits in subsequent iterations were used to ensure that all domains 
were distinct from each other.  Care was taken with all domains to ensure that a function was not 
attributed based solely on similarity to other proteins; several N- and C-terminal domains shared 
similarity with proteins annotated as PG hydrolases, but the shared region did not include the PG 
hydrolytic activity.  This was necessary to avoid a “guilt by association” error that is an 
important consideration when bioinformatically analyzing mosaic proteins. Applying this 
definition to more than 60 LysAs, we found 13 shared domains, as well as three domain-sized 
regions that as yet have no match in other mycobacteriophage LysAs.  The identified domains 
consist of four unknown N-terminal domains (labeled N1-N4), six domains with BLAST-
predicted PG hydrolytic activity (Ami1, Ami2, GH19, GH25, M23, and TG), and three separate 
C-terminal domains (labeled C1-C3); all of which will be discussed in more detail below. These 
domains are distributed across 20 mycobacteriophage clusters and sub-clusters (groups of phage 
with a certain level of genome sequence similarity) and four singleton phages (Table 1).  
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Table 1. LysA domain structures organized by phage cluster 
 
*unpublished 
Unmatched – domain-sized regions with no similarity to other LysAs 
2-Dom. – LysA with only two domains 
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2.2.2 Identified Domains and Combinations 
These domains (and three unknown regions) combine to make 19 unique organizations  (Figure 
13).  The most common pattern, observed 9/19 times, consists of an N-terminal domain (N1 – 
N4), a central lytic domain with predicted PG hydrolytic activity, and a C-terminal domain 
(Figure 13 C, D, F, H, I, L, M, P, R); in addition, Bxz2 gp11, though possessing an unmatched 
N-terminal region, also appears to have a three-domain organization (Figure 13 E).  Four other 
organizations contain three domains; each has two predicted lytic domains in combination with a 
C1-C3 C-terminal domain.  Interestingly, the central catalytic activity in these two-lytic domain 
lysins is always an amidase, while the N-terminal lytic domain is either a GH19 muramidase in 
Che9d gp35 (Figure 13 G) and Wildcat gp49 (Figure 13 S), or an M23 peptidase in Cluster G 
and Sub-cluster B1 (Figure 13 K) and in Giles gp31 (Figure 13 J).    
Lastly, there are five organizations that appear to contain only two domains.  Three 
consist of one of the unknown N-terminal domains (N1 or N4) matched with a C-terminal 
domain or region [N1-C3 for Cluster D, Sub-cluster H1, and Che9c gp25 (Figure 13 Q); N4-C1 
for L5 gp10 (Figure 13 N); and N4 with an unmatched C-terminal region containing a PG-
binding domain for Brujita gp29 (Figure 13 B)].  Myrna gp243 (Figure 13 O) has an N-terminal 
domain followed by a lytic domain, but it lacks a recognizable C-terminal domain or region; 
however, it has a central region of considerable size (~100 aa) that has no homology to any 
known protein.  Barnyard gp39 (Figure 13 A) is the only LysA that resembles canonical 
bacteriophage lysins: it contains a predicted lytic domain at its N-terminus and predicted binding 
region at the C-terminus with identifiable binding motifs, but this C-terminal region is 
unmatched to other LysAs. 
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 Figure 13. LysA modular organizations 
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 Figure 13:  Through combinations of 13 domains and three unmatched regions, 19 different 
organizations are observed in the 70 mycobacteriophage LysAs.  Representative phage LysAs 
are shown for each organization.  N1-N4 (red and pink shades) and C1-C3 (purple shades) are N-
terminal and C-terminal regions, respectively, with no predicted function.  Predicted catalytic 
functions include Ami1 and Ami2 (amidase 1, green; and amidase 2, aquamarine), GH19 
(glycoside hydrolase family 19, yellow), GH25 (glycoside hydrolase family 25, orange), M23 
(M23 family peptidase, blue), and TG (lytic transglycosylase, cyan).  Also identified are 
predicted binding motifs, PGBD (PG binding domain, gray) and LGFP repeats (rose).  
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2.2.3 Evidence of Recombination in LysAs 
The mosaicism of mycobacteriophage genomes (Hatfull, 2010) is echoed on a smaller scale in 
the LysA proteins.  The distribution of different domains throughout the LysA proteins speaks to 
the variety in the mycobacteriophage metaproteome, but it is interesting to note that members of 
specific phage clusters do not necessarily possess the same LysA organizations; evidence of 
recombination can be found within and between clusters and sub-clusters of phage (Table 1).  
This is especially noticeable in Sub-clusters A2 and F1.  Among the six members of Sub-cluster 
A2, there are four different organizations (Figure 13 C, I, L, N) made by combining five different 
domains: N1, N4, GH19, TG, and C1 (specific domain functions are discussed below).  The 
differences arise from the swapping between the N1 or N4 domains, as well as an exchange of 
the more common GH19 domain for a transglycosylase (TG) in Hammer gp13 (Figure 13 L, 
Figure 14).  Further, in comparing the lysis cassette of L5 gp10 (Figure 13 N) with fellow 
members of Sub-cluster A2, it appears that the central lytic domain has simply been lost (Figure 
14), similar to the absence of LysB in the lysis cassette of Che12 (Chapter 3).   
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 Figure 14. Domain organization in Sub-cluster A2 LysAs 
 
 
Figure 14:  A comparison of the domains present in the LysAs of Sub-cluster A2 phages with 
the degree of sequence similarity based on a ClustalW alignment indicated in boxes between the 
regions.  The similarity between the GH19 domain of D29 gp10 and Che12 gp11 is shown in the 
red box with the dotted lines. 
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In the F1 sub-cluster (Table 1) there are three different organizations (Figure 13 F, P, R), 
resulting from combinations of five domains, including N2, N3, the two predicted amidases 
Ami1 and Ami2, and C2.  Most LysAs in this phage sub-cluster appear to only interchange the 
N-terminal domain, with the exception being Pacc40 gp30 (Figure 13 P), in which the Ami1 lytic 
domain has been replaced by Ami2.  The C-terminal domain is constant in all Sub-cluster F1 
LysAs, including Pacc40 gp30.  Portions of the F1 LysAs are similar to other LysAs, such as 
Bxz1 LysA and other LysAs of Sub-cluster C1 phages (Figure 13 D), and the singletons TM4 
(Figure 13 D) and Corndog gp69 (Figure 13 H).   
The relationships of four of these proteins both as a whole and by individual domains 
were analyzed for evidence of recombination:  Che8 gp32 (N2-A1-C2); Corndog gp69 (N3-A2-
C2); TM4 gp29 (N2-A2-C1); and Tweety gp30 (N3-A1-C2) (Figure 15).  Maximum likelihood 
phylogenies were determined for the N-terminal and amidase domains using PHYML (Guindon 
and Gascuel, 2003) (Figure 15).  Bootstrap values were calculated to test support for the 
predicted phylogeny (Felsenstein, 1985), and an SH test was performed to test the likelihood of 
alternate topologies explaining the sequence data (Shimodaira and Hasegawa, 1999).  The 
grouping of LysAs is different for each domain (Figure 15 B, C).  For example, the tree of the N-
terminal domains groups those of Che8 gp32 and TM4 gp29 together, both of which are 
identified as having N2 domains, while the LysAs with N3 domains, Tweety gp29 and Corndog 
gp69, are also distinct from the N2 LysAs and are clustered together.  However, an evaluation of 
the Ami1 and Ami2 domains shows a completely different phylogeny, grouping Che8 gp32 with 
Tweety gp30 and Corndog gp69 with TM4 gp29.  The most parsimonious phylogenies (Figure 
15 B, C) are strongly supported by bootstrap values of 100, and the SH test rejects alternate 
topologies (SH test P-values < 0.001).  These results support recombination events as an 
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explanation for the observed modularity of the LysA proteins.  Overall, given the variety of 
domain organizations and the evidence of recombination, LysAs appear to be the most varied 
and complex phage lysins yet studied. 
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Figure 15. Recombination of domains between LysAs 
 
Figure 15:  ClustalW alignments of four LysA proteins were used to construct a phylogenetic 
tree for the N-terminal and amidase domains.  A.  Proteins are identified by phage name and gp#.  
B. and C.  Tree illustrating the most parsimonious phylogeny for the (B) N-terminal and (C) 
amidase domains.  Bootstrap values are 100 for the division of recombination between the 
domains, and an SH test rejected alternate topologies (P-value <0.001).  Branch lengths do not 
represent evolutionary distance. 
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2.3 PEPTIDOGLYCAN HYDROLYTIC ACTIVITIES PREDICTED IN LYSAS 
There are multiple predicted activities associated with mycobacteriophage LysAs.  The majority 
of LysAs contain one putative catalytic domain; however, LysAs containing two or, surprisingly, 
zero have also been observed.  The predicted PG activities were initially determined based on 
amino acid sequence similarity to known conserved domain families with a specific activity, in 
addition to sequence identity with proteins in GenBank that are annotated as having or predicted 
to have a specific activity.  The domains were more closely examined by conducting multiple 
alignments and motif searches, and by identifying conservation residues important to activity.   
2.3.1 Amidases 
One of the most common types of PG hydrolase activity seen throughout phage lysins is the N-
acetylmuramoyl-L-alanine amidase (Loessner, 2005).  Amidases hydrolyze the bond between N-
acetylmuramoyl and L-amino acids to separate the glycan strands from the cross-linking peptides 
(Figure 8).  Similar to other known phage lysins, the abundance of this activity throughout 
LysAs may speak to its effectiveness (Figure 13 A, D, F, G, H, J, K, P, R, S), and these domains 
are found in combination with every other domain except N1, N4, GH25, and TG.  In 
mycobacteriophage LysAs, these common regions are recognized – with e-values ranging from 
1e-10 to 1e-05 – as having conserved domains, including the Amidase_2 (pfam01510) and the 
Peptidoglycan Recognition Protein (PGRP) superfamily (cd06583), which itself includes Zn-
dependent amidases (EC: 3.5.1.28), such as  T7 lysozyme (Cheng et al., 1994), AmiD of E. coli 
(Kerff et al., 2010), and PlyL of Bacillus anthracis phage Ba02 (Low et al., 2005). The LysA 
amidase domains average 140 aa in length and are always in the center of the LysA, with the 
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exception of Barnyard gp39, which has only two domains total, with an N-terminal amidase 
activity (Figure 13 A).   
Comparison of the amidase domains within the LysAs reveals what appear to be two 
distinct groups, here labeled as Ami1 (Figure 13 F, K, R) and Ami2 (Figure 13 A, D, G, H, J, P, 
S).  There are no common hits between Ami1 and Ami2 domains, even after three iterations of 
PSI-BLAST and no significant similarity seen in ClustalW alignments (Figure 16), making it 
appear that the introduction of these amidase domains took place in two independent events and 
came from different sources.  Indeed, members of the Ami1 group show little similarity outside 
of other mycobacteriophage LysAs; the few similar proteins revealed by PSI-BLAST are 
predicted lysins of Corynebacterium and Propionibacterium phage.  Ami2 appears less distanced 
from non-mycobacteriophage proteins and shows similarity to hypothetical Mycobacterium 
species proteins, including Mycobacterium tuberculosis H37Rv hypothetical protein Rv3594, as 
well as a variety of amidases and PG-binding domain-containing proteins in other bacteria. 
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 Figure 16. Phylogenetic Tree of LysA amidase domains 
Figure 16:  A neighbor-joining tree based on a ClustalW alignment of all amidase domains 
found in LysAs.  Numbers indicate distance between nodes. 
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Central to amidase activity is the Zn2+ binding site.  The structures of T7 lysozyme, PlyL, 
and AmiD have three Zn2+-coordinating residues: His17-His122-Cys130 for T7 lysozyme, 
His29-His129-Cys137 for PlyL, and His35-His151-Asp161 for AmiD (Cheng et al., 1994; Kerff 
et al., 2010; Low et al., 2005).  An alignment of the Ami1 and Ami2 domains (Figure 17) shows 
a conservation of these residues.  Somewhat surprisingly, however, the third Zn2+-binding 
residue for LysA amidases is an Asp similar to the bacterial AmiD as opposed to the Cys found 
in the two phage lysins.  Additional residues involved in catalysis include a Lys (Lys128 in T7 
lysozyme, Lys135 in PlyL, Lys159 in AmiD) and a Tyr or Glu (Tyr46 in T7 lysozyme, Glu90 in 
PlyL, and Glu104 in AmiD).  The Lys residue is conserved in Ami2, exactly 2 residues before 
the catalytic Asp (Figure 17 B), but there is a His in this position in Ami1 (Figure 17 A).  A 
conserved Tyr residue is seen approximately 30 aa from the first His in Ami1 (Figure 17 A), and 
there is both a conserved Glu and partially conserved Tyr about 70 and 60 aa away from the 
catalytic His (Figure 17 B).  In AmiD, Thr37 (near the catalytic His35) is involved in substrate 
binding (Kerff et al., 2010).  A conserved Thr is observed in both Ami1 and Ami2, appearing 
immediately after the predicted catalytic His in Ami1 and after the two conserved His residues in 
Ami2 (Figure 17).  Based on these alignments, it is likely that both Ami1 and Ami2 are 
catalytically active. 
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 Figure 17. Ami1 and Ami2 domains 
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Figure 17:  ClustalW alignments of the Ami1 and Ami2 domains.  A. Alignment of unique 
Ami1 domains, with asterisks highlighting the Zn2+-binding residues (His; His; Asp) and periods 
identifying other conserved residues seen in amidase family members implicated in catalysis 
(Tyr) and substrate-binding (Thr).  B. Alignment of unique Ami2 domains, with asterisks 
highlighting the Zn2+-binding residues (His; His; Asp); the first asterisk marks the two His 
residues, one of which is the first predicted Zn2+-binding His.  Periods identify other residues 
that may contribute to catalysis (Tyr or Glu, Lys) or substrate-binding (Thr).   
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2.3.2 Glycosidases 
Glycosidase activity is the next most common hydrolytic activity identified in bacteriophage 
lysins, predominantly those infecting streptococcal species (Lopez et al., 1997; Pritchard et al., 
2004).  This is somewhat curious considering the wide array of glycosidases seen in host bacteria 
(Vollmer et al., 2008b) from which phage lysins are presumed to have been acquired via 
recombination. While there are two bonds known to be targeted by glycosidases, those found in 
phage lysins are primarily endo-N-acetylmuramidases (Loessner, 2005), which hydrolyze the ß-
(14) linkages between MurNAc and GlcNAc (Figure 8).  There are two types of muramidases:  
lysozymes, which release MurNAc fragments with a reducing end, and transglycosylases, which 
cleave the MurNAc-GlcNAc bond and concomitantly form a 1,6-anhydro ring on the MurNAc, 
leaving no reducing end (Figure 9).  Several LysAs are predicted to possess lysozyme activity 
(EC 3.2.1.17), specifically those containing glycoside hydrolase family 25 (GH25) and glycoside 
hydrolase family 19 (GH19) domains, and recently a single LysA was identified as having 
transglycosylase activity. 
2.3.2.1 Glycoside Hydrolase Family 19 Muramidases 
Several LysAs possess domains that are identified as part of the lysozyme_like superfamily 
(cl00222), which broadly includes lytic transglycosylases, some lysozymes, some chitinases, and 
several glycosidases.  In the LysAs these domains average 150 aa in size, and they identify as 
belonging to COG3179 and Glycoside Hydrolases Family 19 chitinases (cd00325, pfam00182), 
with e-values ranging from 1e-26 to 1e-10.  By definition, chitinases (EC 3.2.1.14) digest polymers 
of chitin made up of repeating units of N-acetylglucosamine, which are not found in bacterial 
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PG.   However, GH19 chitinases have recently been identified in Streptomyces species and now 
in other actinobacteria (Kawase et al., 2004; Watanabe et al., 1999).  Currently, 43 phages are 
listed in the CaZy database as having a GH19 domain, the majority of which are found in 
mycobacteriophage or Pseudomonas phage.  However, only one phage chitinase – ORF187 of 
RSL1, which infects the phytopathogenic bacterium Ralstonia solanacearum – has been 
appears to have hydrolytic activity though it has not been verified as a lysozyme (Yamada et al., 
2010) and shows little sequence similarity to any LysAs.  It was also previously noted that Bxb1 
gp8 and L5 gp10 show similarity to chitinases (Kawase et al., 2004). 
Two of the best-studied GH19 chitinases are the plant chitinase from Carica papaya 
(Huet et al., 2008) and Streptomyces griseus chitinase C (Watanabe et al., 1999).  These proteins 
were aligned with the GH19 domains of mycobacteriophage LysAs (Figure 18), revealing that 
both of the catalytic Glu residues are conserved.  Several conserved motifs were previously 
identified as present across all GH19 chitinase family proteins (Huet et al., 2008; Udaya Prakash 
et al., 2010), and some of these overlap with motifs found in actinobacterial GH19 chitinases 
(Kawase et al., 2004). The first motif, containing one of the catalytic Glu residues, is partially 
conserved when compared with signature sequences, referred to as C1 (Kawase et al., 2004) and 
M2 (Udaya Prakash et al., 2010).  The second conserved region, labeled as C2 or M1, begins and 
ends with two Tyr residues and is more strongly conserved.  While the full motifs are not 
observed, the most conserved residues for the motifs C3, C4/M4, and M5 are visible (Kawase et 
al., 2004; Udaya Prakash et al., 2010); the motif M3 is not seen (Udaya Prakash et al., 2010).   
The GH19 domain is found in the center of LysAs in Cluster A and Sub-cluster B2 
(Figure 13 C, E, I), and is also in the N-terminus of Che9d gp35 (Figure 13 G) and Wildcat gp49 
(Figure 13 S).  Interestingly, only four GH19 chitinase domains have been predicted in 
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Mycobacterium species as identified in CaZy; one is a bacteriophage protein in M. abscessus, 
and the others are predicted chitinases in Mycobacterium sp. JLS, KMS, and MCS.  When the 
GenBank database was examined with BLASTp, the sequence of GH19 in LysAs shows the 
greatest similarity to the chitinases in various species of Pseudomonas, a proteobacterium, rather 
than to those from Mycobacterium or to the numerous chitinases from Streptomyces (another 
member of the order Actinomycetales) that have been more extensively studied (Kawase et al., 
2004; Watanabe et al., 1999).  This may indicate intergeneric recombination, or genetic 
exchange between organisms belonging to different genuses or other higher taxonomic 
categories, a phenomenon that has been observed in other phage lysins (Sheehan et al., 1997).  
Still, the pervasiveness of the domain throughout LysAs suggests that the activity is highly 
effective for mycobacterial lysis. 
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 Figure 18. Glycoside hydrolase family 19 domains 
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Figure 18:  A ClustalW alignment of the LysA GH19 domains and regions of Carica papaya 
chitinase and Streptomyces griseus chitinase C proteins.  The asterisks identify the two 
conserved catalytic Glu residues.  Regions of sequence with significant similarity to signature 
chitinase motifs identified by Kawase et al. (C1-4) and Udaya Prakash et al. (M1-5) are 
identified.  Periods indicate conserved residues that are found in the motifs listed above them; the 
overall sequence of these motifs is not conserved.  More conserved residues are shaded red while 
less conserved residues are shaded blue. 
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2.3.2.2 Glycoside Hydrolase Family 25 Muramidases 
GH25 enzymes are only known to possess lysozyme activity (Henrissat et al., 1995).  Many 
glycosidases found in other phages, including those infecting S. pneumoniae (Hermoso et al., 
2003) and B. anthracis (Porter et al., 2007), are classified as GH25 lysozymes.  In 
mycobacteriophage LysAs, the majority of GH25 domains are in the center of the protein, with 
the exception of Myrna gp243, where the GH25 domain appears towards the C-terminus (Figure 
13 O).  GH25 domains are the largest domains seen in LysAs, with an average size of 200 aa, 
and all GH25-containing LysAs fall into the GH25_muramidase superfamily (cl10448), with e-
values averaging 1e-04; an exception is Omega gp50, which shows significantly more similarity 
to the GH25 superfamily and specific conserved domains, with e-values ranging from 1e-22 to 1e-
11.   
The conserved domain subfamilies differ slightly; GH25 domains in Cluster E LysAs 
(Figure 13 M) are in the GH25_PlyB-like (cd06523) sub-family, a group whose prototype is the 
PlyB lysin that is active on B. anthracis (Porter et al., 2007).  The Myrna (cluster C2) LysA, 
gp243 (Figure 13 O), contains a GH25_Lyc-like conserved domain (cd06525), while other 
Cluster C1 phages have Ami2 domains.  In addition to those seen for the above GH25 LysAs, the 
conserved domains associated with Omega gp50 (Figure 13 M) include GH25_YegX-like 
(cd06524), GH25_LysA-like (cd06417), and smaller regions with similarity to GH25_LytC-like 
(cd06414), GH25_CH-type (cd06412), GH25_Cpl1-like (cd06415), and GH25_AtlA-like 
(cd06522).  These sub-families encompass many other phage endolysins and host autolysins, 
including PlyB (Porter et al., 2007), Cpl-1 (Garcia et al., 1987), AtlA (Oshida et al., 1995), and 
LytC (Smith et al., 2000).  A PSI-BLAST of the above LysA GH25 domains reveals homology 
to many hypothetical M. tuberculosis proteins and a few Rhodococcus and Nocardia proteins.  
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The GH25 domain of Omega gp50 shows high homology to diverse bacterial proteins from 
Corynebacterium and other Actinomycetales, as well as Bacillus, and Clostridium species. 
The catalytic residues of GH25 lysozymes consist of an Asp and a Glu, with the Glu 
being part of a D-X-E motif.  GH25 is proposed to function similar to other lysozymes, via a 
general acid/base catalytic mechanism using Glu as an acid proton donor and an Asp as a 
nucleophile/base (Hermoso et al., 2003).  In the crystal structures of the B.anthracis phage lysin 
PlyB and pneumococcoal lysin Cpl-1, these catalytic residues have been identified as 
Asp6/Glu92 (Porter et al., 2007) and Asp10/Glu94 (Hermoso et al., 2003), respectively.  In 
addition to the catalytic residues, two more Asps proposed to be part of the catalytic machinery 
are conserved throughout the GH25 family: Asp90 of the D-X-E motif and Asp171 in PlyB 
(Porter et al., 2007).  Additionally, Tyr59 and Tyr125 of the pneumococcal phage lysin Cpl-1 
interact with the MurNAc, and are also conserved across GH25 family members (Perez-Dorado 
et al., 2007).  An alignment of representative LysA GH25 domains and the M. tuberculosis 
H37Ra hypothetical protein MtubH3_23920 (which has 46% sequence identity with the GH25 of 
Kostya gp33) shows a conservation of all of these residues (Figure 19) in the same order and 
approximate spacing relative to PlyB and Cpl-1.  
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Figure 19. Glycoside hydrolase family 25 domains 
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Figure 19:  A Clustal alignment of the LysA GH25 domains and a region of M. tuberculosis 
H37Ra hypothetical protein MtubH3_23920.  The asterisks identify the catalytic Asp and Glu 
residues, the latter of which is in the conserved D-x-E motif.  Periods indicate other conserved 
residues that are found in throughout members of cd00599 GH25_muramidase (Marchler-Bauer 
et al., 2009).  More conserved residues are shaded red while less conserved residues are shaded 
blue. 
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2.3.2.3 Transglycosylase 
A third glycosidase activity is predicted in the central domain of a single LysA, Hammer gp13 
(Figure 13 L), which has conserved domain hits to Transglycosylase (pfam06737) and SLT 
(pfam01464), both of which are in the lysozyme_like superfamily (cl00222).  Lytic 
transglycosylases (TG) are muramidases that target the same MurNAc-B-(14)-GlcNAc bond 
as lysozymes, but instead of hydrolyzing the bond, they catalyze an intramolecular 
transglycosylation of the glycosyl bond onto the C6 hydroxyl group of the muramic residues to 
form a 1,6-anhydromuramic acid (Scheurwater et al., 2008).  While rare in lysins – aside from 
several Gram-negative lysins, including R of phage  (Bienkowska-Szewczyk et al., 1981) and 
KZ144 of Pseudomonas phage KZ – transglycosylase motifs are commonly seen in the tip of 
phage tape measure proteins, including several in mycobacteriophage (Marinelli, 2008).  The 
phages are believed to use the transglycosylase activity to pierce the bacterial cell wall during the 
injection of phage DNA into the host (Marinelli, 2008; Moak and Molineux, 2000, 2004).   
In fact, the TG domain of Hammer gp13 shows 71% sequence identity with C-terminal 
regions in the tape measure proteins of Cluster D mycobacteriophages, suggesting that 
recombination between two mycobacteriophage genes of different functions may have created a 
TG-containing LysA or vice versa.  The tape measure protein of Hammer (gp29) is similar to 
those in other Cluster A phages, and shows no significant similarity to Hammer gp13.   The TG 
domain of Hammer also has similarity to several bacterial proteins, including an unknown 
secreted protein in M. smegmatis mc2155 (37% identity, e-value = 2e-04), the resuscitation-
promoting factor RpfA of Corynebacterium glucuronolyticum ATCC 51866 (38% identity, e-
value = 8e-04), and the N-terminus of Streptomyces sp. AA4 transglycosylase domain protein 
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(44% identity, 4e-value = 4e-06).  Rpf proteins actively degrade PG to facilitate growth of 
dormant bacteria (resuscitation), and have been well-studied in M. tuberculosis, which encodes 
multiple Rpf proteins (Kana and Mizrahi, 2010), and Rpf-motifs have been identified in the tape 
measure proteins of mycobacteriophage (Marinelli, 2008; Pedulla et al., 2003). 
A ClustalW alignment  (Figure 20) of the transglycosylase regions of these three proteins 
and two mycobacteriophage tape measure proteins (PLot gp28 from Sub-cluster D and Pacc40 
gp14 from Sub-cluster F1) shows a conserved Glu, which is the single catalytic residue in 
transglycosylases, as opposed to the Glu-Glu or Glu-Asp catalytic pairs found in most other 
lysozymes (Thunnissen et al., 1995).  There are also several consensus motifs specific to the lytic 
transglycosylase families (Blackburn and Clarke, 2001).  These include the Ser adjacent to the 
catalytic Glu, which together are identified as motif I and are observed in all lytic 
transglycosylases, as well as the later Gly and Gln in a G-[G/L]-[F/G]-Q, similar to the G-[L/I]-
[M/W]-[Q/M] sequence of motif II.  Interestingly, based on these motifs and other conserved 
residues of the four families of transglycosylases, the LysA and related TG domains from Figure 
20 most closely resemble family 1 bacterial transglycosylases (Blackburn and Clarke, 2001) 
rather than family 4  phage transglycosylases.  Additional residues in Hammer gp13 match 
those present in >80% of the sequences of sub-family 1C (Figure 20).  In sum, the overall 
sequence similarity to other known transglycosylase domains and the conservation of catalytic 
Glu strongly support the classification of the central domain of Hammer gp13 as a 
transglycosylase, the first identified in any mycobacteriophage LysA. 
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Figure 20. Transglycosylase domains 
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Figure 20:  A Clustal alignment of the Transglycosylase domains from Hammer gp13 LysA, the 
tape-measure proteins PLot gp29 and Pacc40 gp14, the resuscitation-promoting factor RpfA of 
Corynebacterium glucuronolyticum ATCC 51866, the transglycosylase domain protein of 
Streptomyces sp. AA4, and a secreted protein of M. smegmatis mc2155.  The asterisk identifies 
the single catalytic Glu residue.  Motifs characteristic of family 1 transglycosylases are labeled 
(Blackburn and Clarke, 2001).  Large periods indicate conserved residues that are found in all 
members of transglycosylase family 1, specifically the E-S and G-X-X-Q regions in each motif.  
Smaller periods indicate the residues in Hammer gp13 that are conserved in >80% of the 
members of family 1C.  More conserved residues are shaded red while less conserved residues 
are shaded blue. 
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2.3.3 Peptidase 
There were relatively few peptidases found in the LysAs, compared to their prevalence in 
the few three-domain lysins from other phages (Cheng and Fischetti, 2007; Donovan and Foster-
Frey, 2008; Navarre et al., 1999).  The LysA peptidase domains average 90 aa in length and are 
all found at the N-terminus preceding an amidase domain – either Ami1 in Cluster G and Sub-
cluster B1 LysAs (Figure 13 K) or Ami2 in Giles gp31 (Figure 13 J).  These peptidases are 
predicted to belong to the peptidase family M23 (cl09532, pfam01551), a group of zinc 
metallopeptidases that include bacterial PG hydrolases such as lysostaphin and ß-lytic 
metallopeptidases (MEROPS).  The structure of LytM, a lysostaphin-like peptidase from 
Staphylococcus aureus, has been solved (Odintsov et al., 2004).  The conserved Zn2+ binding 
cleft contains four conserved residues: N117; H210; D214; and H293, which is the second His in 
the H-X-H motif commonly found in Zn2+ binding proteins.  The M23 peptidase domains in 
LysAs do contain the zinc-binding H-X-H motif (Figure 21).  Additionally there are conserved 
Arg, His, and Asp residues seen in LysA M23 domains; however, they neither follow the order 
seen in LytM nor share flanking sequence similarity, so it is questionable whether these are the 
conserved residues and whether M23 peptidases are active.  The most closely related proteins 
outside of other LysAs are various M23 family peptidases, beginning with an M23 peptidase of 
Corynebacterium jeikeium ATCC 43734, with an e-value of 7e-25.  The closest Mycobacterium 
hit is a peptidase in Mycobacterium sp. KMS with an e-value of 1e-11.  There are also some 
peptidase motifs found in the tape measure proteins of phages, such as motif 3 
mycobacteriophage TM4 (Piuri and Hatfull, 2006), but the M23 domains do not show significant 
similarity to any non-LysA mycobacteriophage proteins. 
 111 
 Figure 21. M23 peptidase domains 
 
 
Figure 21:  A ClustalW alignment of three representative M23 family peptidase domains from 
Giles gp31, Halo gp27, and Orion gp49.  More conserved residues are shaded red while less 
conserved residues are shaded blue.  The asterisks highlight the Zn2+-binding H-X-H motif.  
Periods identify conserved His, Arg, and Asp residues (Odintsov et al., 2004). 
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2.4 THE MYSTERIOUS N-TERMINAL DOMAINS 
The majority of LysA organizations (13/19; Figure 13 B, C, D, F, H, I, L, M, N, O, P, Q, R) 
possess one of four unrelated N-terminal domains, labeled N1 – N4.  The LysAs that lack one of 
these domains either have a second predicted catalytic domain at the N-terminus (discussed 
above), have an N-terminal region that is unknown and does not match another identified LysA 
in a mycobacteriophage, thus not qualifying as a domain (Bxz2 gp11, Figure 13 E), or do not 
appear to have a third N-terminal domain (Barnyard gp39, Figure 13 A).  There are no predicted 
signal peptides (predicted with SignalP Server, v. 2.0), signal-anchor-release (SAR) domains or 
transmembrane domains (predicted with TMHMM Server v. 2.0).  A search for conserved motifs 
was conducted using Multiple Em for Motif Elicitation (MEME 4.4.01, http://meme.nbcr.net) to 
find the top three significant (lowest e-value) motifs of length no greater than 50 aa across the 
domains.  The sequences included in the search were representative (e.g. the N2 domain of Bxz1 
gp236 is identical or nearly identical to all other Sub-cluster C1 phage N2 domains, and so Bxz1 
gp236 was chosen to be representative, so as not to skew the search results).  Any sequences that 
were identified only in a subset of protein domains that were nearly identical – and thus did not 
represent a signature sequence found across varied proteins in that domain – were ignored. 
N1 domains average 160 aa in size and are only paired with glycosidases or alone with a 
C-terminal domain in a two-domain LysA (Table 2).  In the N1 LysAs possessing three domains, 
N1 is followed by GH19-C1 (Cluster A and Sub-cluster B2, Figure 13 C) or by TG-C1 (Hammer 
gp13, Figure 13 L).  Otherwise N1 is paired with C3 to create the two domain lysins lacking a 
predicted catalytic domain in Clusters D and H1, as well as Che9c gp25 (Figure 13 Q).  The N1 
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domains show limited sequence similarity to hypothetical Streptomyces and Rhodococcus 
proteins.  A MEME search identified three conserved motifs found in all N1 domains in the same 
order (Figure 22 A, B).   
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Table 2. N-terminal domain characterization 
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 Figure 22. N-terminal domain motif maps 
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Figure 22:  A., C., E., G.  Sequence logos of motifs identified by MEME (http://meme.nbcr.net).  
In each column, all letters with observed frequencies greater than 0.2 are shown; less-frequent 
letters are not included in the RE (N-terminal Domain Table).  B., D., F., H.  Block diagram of 
the domain with blocks summarizing the locations of identified motifs and the combined p-value.  
The height of the block is proportional to the p-value; only blocks with a p-value > 0.0001 are 
shown, and overlapping blocks will only display the one with the lower p-value. 
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The N2 domains are the largest at around 215 aa and are only associated with amidases 
(Table 2).  N2 precedes Ami1-C2 in Sub-cluster F1 (Figure 13 F), Ami2-C1 in Sub-cluster B4 
and TM4 gp29 (Figure 13 D), and Ami2-C2 in Pacc40 gp30 (Figure 13 P).  A BLASTp of 
several N2 domains found sequence similarity to various bacterial proteins and even several 
fungal proteins.  Many were predicted peptidases, often M23/M37 family metallopeptidases 
similar to those found in the N-terminus of other LysAs; however, the region of similarity was 
always separate from the peptidase domain or any other identified regions.  Three fungal proteins 
had significant similarity to the N2 domain of Bxz1: Pc12g06060 of Penicillium chrysogenum 
Wisconsin 54-1255 (e-value = 5e-22); a conserved hypothetical protein of Aspergillus fumigatus 
Af293 (e-value = 2e-21); and a hypothetical protein of Tuber melanosporum Mel28 (e-value = 5e-
17).  An analysis of the N2 domains and the fungal sequences by MEME revealed three 
conserved motifs, all identifiable in both LysA N2 domains and fungal proteins, and always in 
the same order (Figure 22 C, D).  
N3 domains average 150 aa in size and are also only associated with amidases (Table 2).  
N3 is found with Ami1-C2 in Sub-clusters B1 and F1 (Figure 13 R) and with Ami2-C2 in 
Corndog gp69 (Figure 13 H).  There is no significant similarity to any proteins in GenBank 
outside of the LysAs.  Two significant motifs were identified by MEME (Figure 22 E, F); the 
first motif is repeated two or three times in these domains, while the second is only present once, 
but is between two of the repeated sequences.  Repeated motifs in a binding domain are not 
uncommon, as seen with the choline-binding motifs in many autolysins and phage lysins of 
Streptococcus (Lopez et al., 1997), so this may support a binding role for the N3 domain. 
N4 is similar to N1 in its association solely with glycosidases or its presence alone with a 
C-terminal domain (Table 2).  N4 domains average 150 aa and are paired with GH19-C1 in Sub-
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cluster A2 (Figure 13 I), GH25-C1 in Cluster E and Omega gp50 (Figure 13 M), and alone with 
a C1 domain in L5 gp10 (Figure 13 N).  Like N3, no significant matches to the N4 domain are 
found using BLAST against the GenBank database.  There is significant variation between the 
different N4 domains in the presence, and location, of three motifs identified by MEME (Figure 
22 G, H).   The first and second motif are found in all N4 domains, but their order is variable; the 
first motif precedes the second in Omega gp50, Kostya gp33, CJW1 gp33, and Brujita gp29, and 
the reverse is seen in D29 gp10, Che12 gp11, and L5 gp10.  The third motif is absent from 
Omega gp50, Kostya gp33, and CJW1 gp32.  Similar to the first motif in N3, the third motif in 
N4 is also repeated twice, with one copy at the beginning of the domain and a second copy at the 
end.  
Most intriguing are the two organizations of LysAs that consist of two domains, neither 
of which are predicted to be catalytic: either N1 or N4 paired with a C-terminal domain (Figure 
13 B, I, N, O, Q; Table 2).  In the absence of a predicted PG hydrolase, this could indicate a lytic 
function for N1 or N4 that is, as yet, uncharacterized.  While there are many LysAs with the N1-
C2 organization, the single two-domain N4 protein, L5 gp10, is unique in its close resemblance 
to D29 gp10.  The two have 81% sequence identity in their N4 domain and 46% identity in the 
C1 domain, and they have extensive synteny along their genomes (Figure 14).  Given the 
presence of GH19 in the LysAs of similar phage, including Che12 gp11, D29 gp10, Bxz2 gp11, 
and Pukovnik gp11, it appears that the GH19 domain was simply lost from L5 gp10.  However, 
there is experimental evidence that L5 gp10 is catalytically active within mycobacteria, although 
the substrate is not known (Appendix A.3).  
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2.5 C-TERMINAL DOMAINS AND CELL WALL BINDING MOTIFS 
All phage lysins characterized to date possess a C-terminal cell wall binding domain that is an 
important determinant of enzyme specificity (Loessner et al., 2002; Lopez et al., 1997).  The 
three C-terminal domains seen in mycobacteriophage LysAs are expected to serve the same 
function (Table 3).  The C1 domains are moderately divergent but share no similarity outside of 
LysA proteins.  Three conserved motifs were identified by MEME (Figure 23 A, B), always in 
the same order.  However, they are not evenly distributed; several C1 domains (Bxz1 gp236, 
CJW1 gp32, Cooper gp44, Porky gp31, L5 gp10, D29 gp10, and Rosebush gp46) lack the third 
motif.  Additionally, Wildcat gp49 lacks the first motif, and D29 gp10 and Pukovnik gp11 only 
contain the second and third motifs, respectively. 
The majority of C2 domains only show similarity to some predicted hydrolase and 
hypothetical Rhodococcus proteins, but the C2 of Corndog gp69 is similar, with an e-value = 1e-
09, to the hypothetical protein Rv3594 of M. tuberculosis H37Rv and to a metallopeptidase from 
Rhodococcus jostii RHA1, with an e-value of 8e-04.  The M. tuberculosis protein Rv3594 
resembles a two-domain lysin, with an N-terminal amidase that is similar to LysA Ami2 domains 
and a C-terminus that resembles C2.  The metallopeptidase of R. jostii RHA1 contains both an 
N-terminal M23 peptidase and central GH25 lysozyme domain in addition to a C-terminal region 
similar to Corndog gp69 C2.  These two bacterial protein domains were included in the MEME 
search for motifs.  Of three motifs found, none is present in all sequences (Figure 23 C, D).  The 
first, and largest, motif is present in members of Sub-cluster F1 (Boomer gp32, Che8 gp32, 
Fruitloop gp29, Ramsey gp32, and Tweety gp30) as well as in Pipefish gp48 and Phaedrus gp42, 
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although the latter two display weak similarity (2.72 e-03 and 1.68e-02, respectively), and this is 
the only motif they possess.   The second motif is in every domain except for Pipefish gp48 and 
Phaedrus gp42.  This motif is the only one present with two copies in the R jostii 
metallopeptidase.  The third motif was only found in Corndog gp69, Che9d gp35, Pacc40 gp30, 
and M. tuberculosis Rv3594.  These four domains all have the same configuration, lacking the 
first motif but possessing the second and third motifs, with the third motif preceding the second 
motif. 
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Table 3. C-terminal domain characterization 
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Figure 23. C-terminal domain motif maps 
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Figure 23:  A., C., E.  Sequence logos of motifs identified by MEME (http://meme.nbcr.net).  In 
each column, all letters with observed frequencies greater than 0.2 are shown; less-frequent 
letters are not included in the RE (C-terminal Domain Table).  B., D., F.  Block diagram of the 
C-terminal domains, with blocks summarizing the locations of identified motifs and the 
combined p-value.  The height of the block is proportional to the p-value; only blocks with a p-
value > 0.0001 are shown, and overlapping blocks will only display the one with the lower p-
value.  
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The mycobacteriophage LysA C3 domain contains PG binding motifs (PG_binding_1 
superfamily, cl03228; PG_Binding_1, Pfam01471), which supports a predicted role for these C-
terminal domains in cell wall binding.  The C3 domain is only found in LysAs with peptidase 
activity (Sub-cluster B1, Cluster G, and Giles gp31; Fig 1J, K) or in two domain LysAs with an 
N1 domain (Cluster D, Sub-cluster H1, Che9c gp25; Fig 1Q) or N4 domain (Brujita gp29; Fig 
1B).  Notably, this specific conserved domain has been described in two Gram-negative 
Pseudomonas aeruginosa phages, KZ and EL, whose lysins KZ144 and EL188 have N-
terminal PG_binding_1 domains and C-terminal lytic transglycosylase domains (Briers et al., 
2007).  A MEME analysis of the C3 domains and the N-terminus of KZ144 (Figure 23 E, F) 
reveals a single motif (motif 1) that is repeated two to three times in the majority of the domains 
(though only one copy appears in PLot gp36).  This repeated sequence is a good candidate for a 
PG binding motif, similar to the choline-binding motif repeat identified in Cpl-1 and other 
streptococcal phage lysins (Hermoso et al., 2003).  A second and third motif were also found 
between, or after, the repeats of the first motif.  Both are found in Konstantine gp39 and Predator 
gp30, while only the second motif is present in Che9c gp25, and only the third motif is present in 
PLot gp36. 
Three other LysAs contain regions in their C-terminus that do not match any other 
proteins.  Similar to the C3 domain, Brujita gp29 (Figure 13 B) also has the same predicted PG 
binding motif as C3, but otherwise its C-terminal region does not have similarity to any LysAs or 
other proteins.  Myrna gp243 does not have a predicted C-terminal domain (Figure 13 O), and 
indeed, the catalytic GH25 domain is predicted to extend to just 15 amino acids before the end of 
the protein, leaving little room for a binding domain.  However, there is a central region of about 
100 aa that shows no similarity to any other protein, yet is large enough to conceivably contain a 
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binding domain.  One example of a central cell wall binding domain has been found in the lysin 
of the LambdaSa2 prophage from Streptococcus agalactiae, which has two Cpl-7 binding 
domains between an endo-peptidase and a glucosaminidase (Pritchard et al., 2007), so it is 
possible that a binding region exists in the center of the Myrna LysA. 
Barnyard gp39 has a C-terminus with two predicted LGFP repeats (pfam08310; 
superfamily cl07065) (Figure 13 A).  These 54 aa repeats were first identified in the N-terminus 
of PS1 (Adindla et al., 2004), a mycolyltransferase in C. glutamicum that bears homology to the 
mycobacterial antigen 85, albeit in a separate region from the LGFP repeats(Puech et al., 2000).  
LGFP repeats have also been identified in some mycobacterial proteins such as M. tuberculosis 
Rv3811, a protein that also includes an Ami_2 domain.  Currently Barnyard gp39 is the only 
LGFP-containing protein listed under the virus taxonomy in InterPro IPR013207, although this 
may not consider possible prophages among the 195 bacterial entries. 
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2.6 CONCLUSIONS 
In summary, I have characterized more than 70 of the complex mycobacteriophage LysA 
proteins, breaking them into 19 organizations comprised of 13 domains and several unmatched 
regions, as well as identified five predicted PG degrading activities associated with these 
proteins.  While this has increased our understanding of the LysAs, the mysterious N-terminal 
domains are novel within the greater set of bacteriophage lysins and present an attractive object 
for further study.  Currently, I am examining the activity of various LysAs with special attention 
to the function of the N-terminal domains.  As the LysAs have evolved over great spans of time 
to efficiently and effectively lyse their target mycobacterial hosts, understanding these proteins 
on a molecular level may provide insight into the mycobacterial cell wall, the mechanism of 
mycobacteriophage lysis and evolution, and potential therapies or research tools for diseases like 
tuberculosis. 
2.6.1 The Unique Structure of Mycobacteriophage LysAs 
A modular theory for the construction of lysins was proposed some time ago (Diaz et al., 1990; 
Garcia et al., 1988; Lopez et al., 1997), and as more lysins are sequenced – including the 
mycobacteriophage LysAs – this theory is further validated.  With more than 60 sequenced 
mycobacteriophage LysAs to compare, the extensive recombination is obvious and impressive, 
with 13 unique modules and 19 different combinations identified to date.   
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One thing that makes LysAs unique is their preponderance of three-domain 
organizations; other phage lysins possess only two domains, with some rare exceptions (Cheng 
and Fischetti, 2007; Donovan and Foster-Frey, 2008; Navarre et al., 1999; Pritchard et al., 2004). 
This would indicate some sort of advantage for phage infecting mycobacteria in having three 
domains, potentially tied to the unknown function of the N-terminal domains.  PG hydrolase 
domains identified by BLASTp most commonly comprise the central domain, except in the rare 
LysAs with two identifiable lytic domains: Cluster G, Sub-cluster B1, Che9d gp35, Giles gp31, 
and Wildcat gp49.  There are four different N-terminal domains of unknown function that are 
most frequently paired with a central catalytic activity, and almost every LysA has a C-terminal 
domain predicted to bind the cell wall.  Interestingly, the majority of two-domain LysAs consist 
of one of the unknown N-terminal domains and a C-terminal domain.   Only Barnyard gp39 is 
directly analogous in structure to other phage lysins with an N-terminal Ami2 activity and C-
terminal region with LGFP motif repeats known to specifically bind structures found in 
mycobacteria or similar bacteria. 
Bacteriophage evolution is thought to occur through both homologous and illegitimate or 
non-homologous recombination (Hendrix et al., 2000).  Evidence in broad support of 
recombination leading to the variety of LysA organizations was provided above.  For the ease of 
characterization, somewhat arbitrary boundaries based on sequence similarity were used, but the 
exact locations of recombination between LysAs cannot be readily identified.  However, the 
predicted secondary structure could be analyzed in future studies, provided the predictions are 
accurate enough for a comparison and domains are neither too similar nor too distantly related.  
If recombination only occurs at domain boundaries, then the secondary structure similarities 
between two LysAs should change abruptly when there is a change in the domain.  Alternately, if 
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the location of recombination is random with selection later preserving combinations that are 
functional, then secondary structure may be conserved across some of the above identified 
domain boundaries.  The latter result would support the theory that mosaic phage genomes are in 
part the result illegitimate or non-homologous reocombination (Hendrix et al., 2000). 
The consistent presence of a third N-terminal domain is not entirely unprecedented; 
several other lysins in streptococcal and staphylococcal phages have three domains in which two 
are PG hydrolases (Cheng and Fischetti, 2007; Donovan and Foster-Frey, 2008; Navarre et al., 
1999; Obeso et al., 2008; Pritchard et al., 2004; Pritchard et al., 2007).  As most lysins only 
contain one lytic domain, it is reasonable to suspect that lysins such as PlyGBS (Cheng and 
Fischetti, 2007; Pritchard et al., 2004) are exceptions to the rule.  These bifunctional lysins are 
likely the result of the extensive recombination of lytic and binding modules seen throughout 
phage lysins, resulting in a dual-catalytic product that, at least in the circumstances where it was 
isolated, did not significantly decrease the fitness of the phage.  It is interesting to note that in all 
of these bifunctional lysins, the N-terminal lytic domain is an endo-peptidase, specifically a D-
alanyl-glycyl (CHAP) peptidase (Bateman and Rawlings, 2003) in all except Sa2.  However, 
there are no predicted CHAP domains in any LysAs so far characterized.  Additionally, all of the 
second lytic domains are amidases for lysins of Staphylococcal phages, and glycosidases for 
Streptococcus phages.  The majority of the LysAs for which a lytic activity can be identified in 
the N-terminal domain are also predicted peptidases, although they are Zn2+ metallopeptidases 
(M23 family).  Additionally the second domain in most of these LysAs is an Ami1 or Ami2.  The 
exceptions to this are Che9d gp35 and Wildcat gp49, which have N-terminal GH19 and central 
Ami2 domains.  
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Most studies with purified bifunctional lysins found that only one domain was active; in 
all cases, the active domain was the N-terminal endo-peptidase domain, which had full or 
increased activity when expressed alone or with only the cell wall binding domain (Cheng and 
Fischetti, 2007; Donovan and Foster-Frey, 2008; Donovan et al., 2006a; Navarre et al., 1999).  
The central amidase or glycosidase domains, even if active in the full protein or in vitro, were 
largely inactive with live bacteria when expressed alone or with the cell wall binding domain.  It 
would be interesting to test the separate activities in the LysAs with two identified catalytic 
domains; the N-terminal M23 peptidases have the conserved zinc-binding motifs required for 
activity, and the N-terminal GH19 domains of Wildcat gp49 and Che9d gp35 have the conserved 
Glu residues as well, suggesting that both domains may be catalytically active.  It is less certain 
if the Ami1 and Ami2 domains are active based solely on sequence alignments; however, several 
LysAs containing these domains have demonstrated PG hydrolytic activity on zymograms 
(Appendix A.1). 
2.6.2 The Prevalence of Various Peptidoglycan Hydrolytic Domains and Their Predicted 
Sources 
The array of PG hydrolytic activities seen in LysAs is comparable to that seen in most phage 
lysins, and the bonds targeted are also those most commonly hydrolyzed by other phage lysins 
(Figure 24).  The overall conservation of catalytic and other important residues suggests that 
these domains are capable of hydrolyzing PG, and several preliminary empirical studies support 
this (Appendix A.1).  However, the origins and evolutions of the different domains are most 
intriguing.  One curiosity is why the LysA proteins (and other non-mycobateriophage lysins) 
have such a variety of PG hydrolytic activities when all have the same goal with minor 
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differences in targets.  Given the apparent inability for the host to develop resistance to the 
catalytic activity of a lysin, it is unlikely that the variety is an evolutionary insurance against the 
generation of a mutant host population that is resistant to a particular lysin.  Alternatively, it is 
possible that the different activities address the minor variations in PG between different hosts or 
during different stages of host growth.  For example, the degree of cross-linking increases as a 
bacterium enters stationary phase, and thus lysins with peptidase activity may have an advantage 
in lysins such a host. 
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 Figure 24. Mycobacterial peptidoglycan structure and lysin targets 
Figure 24:  Diagram of mycobacterial PG and enzyme targets.  A diagram of chemotype A1 
PG including modifications seen in mycobacteria (glycolation of muramic acids and amidation 
of D-Glu and m-DAP).  In addition to the cross-linking bond between m-DAP and D-Ala, 
mycobacteria also have direct m-DAP – m-DAP links (dotted line).  Possible hydrolases are 
listed with an arrow to their target bond.  Those with activities identified in LysAs are in red, and 
the corresponding activity listed in parentheses below.  
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The predicted amidase domains (Ami1 and Ami2) appear to be unrelated (Figure 16), 
showing no similarity even after three iterations of PSI-BLAST, despite both being identified as 
belonging to the Amidase_2 superfamily.  These domains appear to have different origins, 
suggesting two independent acquisition events in the past; Ami2 shows similarity to 
mycobacterial proteins, but Ami1 only weakly resembles proteins from Corynebacterium and 
Propionibacterium.  Alignments of Ami1 and Ami2 domains revealed several conserved 
residues, including the essential Zn2+-binding residues: His, His, and Asp or Cys (Cheng et al., 
1994; Kerff et al., 2010; Low et al., 2005).  Additionally, other important residues implicated in 
catalysis and substrate-binding (Kerff et al., 2010) are nearly all conserved in both Ami1 and 
Ami2.  The retention of these important residues—despite their divergent sequences—suggests 
that both Ami1 and Ami2 are capable of hydrolyzing the N-acetylmuramoyl-L-alanine amide 
bond (Figure 24).  Further, there is also empirical support for the activity of Ami-containing 
LysAs, although it has not been determined if the activity is specifically amidase.  Purified 
Ami1-LysA Che8 gp32 and Ami2-LysAs Bxz1 gp236 and Corndog gp69 show PG hydrolytic 
activity on zymograms (Appendix A.1). 
The presence of Glycoside Hydrolase family 19 chitinase domains in LysAs is 
interesting, considering both the primary activity of GH19 hydrolases and their seeming rarity in 
the mycobacterial genome and in known phage lysins.  Chitinases generally hydrolyze the ß-1, 4-
linkages in the polymers of N-acetylglucosamine that make up chitin, a component of fungal cell 
walls that is not present in bacteria.  GH19 chitinases have been found in Streptomyces 
(Watanabe et al., 1999) and subsequently other actinobacteria (Kawase et al., 2004), and due to 
their similarity to the class IV chitinases found in higher plants, it is proposed that the presence 
of GH19 is the result of horizontal gene transfer between Actinobacteria and higher plants, rather 
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than from another bacterial source (Udaya Prakash et al., 2010).  While bacteria can use chitin as 
an energy and carbon source (Cohen-Kupiec and Chet, 1998), some chitinases have shown 
activity characteristic of muramidases like GH25 (Flach et al., 1992; Jolles and Jolles, 1984), and 
they share structural similarity with lysozymes (Holm and Sander, 1994).  As phages are not 
likely to encounter chitin in any situation where their lysin would also be needed, we expect that 
the GH19-like domains in LysAs have lysozyme-like activity.  The conservation of predicted 
catalytic Glu residues, as well as sequence similarity with several GH19 chitinase-specific motifs 
(Kawase et al., 2004; Udaya Prakash et al., 2010), strongly suggests that these domains are 
catalytically active.  The GH19-containing LysA D29 gp10 has also shown activity on 
zymograms (Appendix A.1). 
GH25 lysozymes are common both in bacterial cell wall remodeling enzymes (Holtje and 
Fastrez, 1996) and in many phage lysins (Hermoso et al., 2003; Porter et al., 2007), and so their 
presence in LysAs is not surprising.  Of the four families of lysozymes with known PG hydrolase 
activity, GH25 belongs to the Chalaropsis lysozyme family (Ch-type), which is distinct from the 
other three families prototyped by hen egg-white (HEWL, c-type), goose egg-white (GEWL, g-
type) and T4 lysozyme (T4L, t-type).  All of these have a Glu-Asp acid/base catalytic 
mechanism, but only HEWL, GEWL, and T4L appear to have diverged from a common ancestor 
(Weaver et al., 1984).  While these latter three families share a common core of two α-helices 
and a three-stranded β-sheet (Monzingo et al., 1996), the Ch-type lysozymes show a completely 
different tertiary structure with a β/α barrel fold as seen with Streptomyces coelicolor cellosyl 
(Rau et al., 2001).  Thus while the target and catalytic mechanism might be the same, the 
structure distinguishes GH25 lysozymes from the GH19 chitinases.  Again, the notable aspect of 
this domain in LysAs is the seeming evolutionary divergence from a common amidase ancestor.   
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The GH25 of Omega gp50 appears much more closely related to known GH25-containing 
proteins, while other LysA GH25 domains in Cluster E and Myrna gp243 domains are 
significantly different from that in Omega gp50, implying a separation far in the past, if not two 
separate instances of acquisition. 
The transglycosylases share a lysozyme-like fold and target the same bond as 
muramidases (Figure 9), with the only difference in activity being the enzymatic mechanism – 
cleavage results in formation of 1,6-anhydromuramyl residues rather than muramic acid residues 
with reducing ends (Scheurwater et al., 2008).  The reason for this difference is attributed to the 
presence of a single catalytic Glu instead of a Glu-Asp or Glu-Glu pair found in other lysozymes.  
Transglycosylase domains have been identified in phages for some time, but most are present as 
part of the tape measure protein and may be involved in phage entry (Lehnherr et al., 1998; 
Marinelli, 2008).  The precise function of these tape measure protein-associated hydrolases has 
not been definitely shown.  However, they may facilitate penetration of the cell wall during 
phage DNA injection, and possibly stimulate bacterial growth, similar to the Rpf proteins 
(Marinelli et al., 2008; Moak and Molineux, 2000, 2004; Pedulla et al., 2003; Piuri and Hatfull, 
2006).  Hammer gp13 is also the first transglycosylase identified in any mycobacteriophage 
LysA, and the strong similarity between the TG of Hammer gp13 and the portions of tape 
measure proteins of Cluster D phage argue for a recombination event within mycobacteriophage 
genomes.  It is curious that more transglycosylases are not seen in phage endolysins but rather 
are restricted to the tape measure proteins.  Most transglycosylase lysins are found in phages that 
infect Gram-negative hosts, including the  R endolysin (Bienkowska-Szewczyk et al., 1981), 
and the Pseudomonas phage PHIKZ144 lysin (Briers et al., 2007); there are a few putative 
transglycosylase lysins in some Staphylococcal and Lactococcal phage as well (InterPro 
 140 
IPR008258).  Based on the general distribution of transglycosylases in phages infecting Gram-
positive and Gram-negative bacteria, and the novelty of finding a transglycosylase domain in any 
mycobacteriophage LysA, transglycosylase activity may be ill-suited – but still viable – for 
mycobacteriophage lysis. 
The presence of an M23 family peptidase in mycobacteriophage lysins is initially 
confusing.  The best-studied M23 peptidases, lysostaphin (Heinrich et al., 1987), ALE-1 (Lu et 
al., 2006), and LytM (Odintsov et al., 2004), prefer Gly5 peptide bridges and hydrolyze Gly-Gly 
bonds, which are not seen in Mycobacterium PG.  However, neither are Gly5 peptide links seen 
in Bacillus subtilis, but this bacterium also has lysostaphin homologs (Smith et al., 2000) and 
type A1 PG, the same type as mycobacteria (Schleifer and Kandler, 1972).  Based on 
alignments (Spencer et al., 2010), structural similarity to other peptidases (Odintsov et al., 2004), 
and activity in B. subtilis (Horsburgh et al., 2003), it is now thought that M23 family peptidases 
can act as L-Ala-D-Glu endopeptidases.  If the M23 peptidase domains are catalytically active in 
LysAs, we expect that they have this specific endopeptidase activity (Figure 24).  Indeed, many 
recent structural studies of metallopeptidases have discovered similar folds in peptidases based 
around a Zn2+ binding site that, nonetheless, have distinctly different targets (Bochtler et al., 
2004; Hooper, 1994).  Further, metallopeptidase motifs have been found in the tape measure 
proteins of several mycobacteriophages, and PG hydrolytic activity was demonstrated on 
zymograms (Piuri and Hatfull, 2006); however, there is no significant similarity seen to the M23 
domains in LysAs.  
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2.6.3 Speculations on the Possible Functions of the N-terminal Domains 
The vast majority of LysAs, both two- and three-domain, contain N-terminal domains of 
unknown function.  There are several possible functions for these four different domains, none of 
which need be mutually exclusive.  The existence of LysAs with two catalytic domains suggests 
that these N-terminal domains may have a lytic function, potentially with activity that is specific 
to mycobacteria, similar to what has been observed for LysB (see Chapter 3).  N2 and N3 are 
always present in front of a PG hydrolase, so a lytic role may be more likely with the N1 and N4 
domains, which are seen in LysAs without any other predicted PG hydrolytic activity (Figure 13 
B, N, Q).  Indeed, lytic activity has been observed with D29 gp10, Kostya gp33, and L5 gp10 
upon endogenous expression in M. smegmatis (Appendix A.3).  All of these proteins share an N4 
domain, and L5 gp10 is a two-domain LysA lacking any other predicted activity.  
No transmembrane domains have been observed in these domains, making it unlikely that 
they function as SAR domains or holins.  However, in the case of N3 a potential role has already 
been identified (Catalao et al., 2010).  Very recently, Catalao et al. identified a role for gp1 of 
Ms6, a 77 aa protein immediately upstream of the gp2 LysA in an overlapping alternate reading 
frame.  Gp1 acts as a LysA chaperone that uses the sec transport system to translocate Ms6 gp2 
across the membrane into the periplasm.  Here, Ms6 gp2 appears to be inactive until the 
membrane is depolarized, a function theoretically carried out by the Ms6 holin, gp4, similar to 
the manner in which pinholins like S21 activate SAR-endolysins (Xu et al., 2004).  The first 60 
amino acids of Ms6 gp2 are necessary and sufficient for gp1 binding and export; this may 
represent a role for the N3 domain.  According to a BLASTp search, Ms6 gp1 homologs are also 
found upstream of the LysA proteins of several mycobacteriophages in Sub-cluster F1 
(Fruitloop, Tweety, Llij, Che8, Pacc40, Ramsey, and Boomer) with e-values < 1e-15.  The LysAs 
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of these phages have N2 and N3 domains (Table 2), and so this may be the role of the N2 and N3 
domains; however, this does not account for the full size of the domains, which average 215 and 
150 residues, respectively (Table 2).  Experimental evidence may indicate a greater similarity to 
SAR domain lysins than expected; in Corndog gp69 (N3-Ami2-C2), zymogram assays found 
highly active degradation products that were discovered to have lost most of the N3 domain 
(Appendix A.1).  Similar fragments were found in zymograms with Bxz1 gp236 (N2-Ami2-C1) 
(Appendix A.1), but the loss of the N2 domain has not been verified.  Export by a chaperone is 
not needed for in vitro hydrolytic studies of purified LysA, and so this domain may have been 
unnecessary or even inhibitory.  It is even possible that, in mycobacteriophage infections, 
activation of the LysA after membrane depolarization results in the cleavage of this region or 
some other conformational change that allows for increased lytic activity. 
There are still a number of other possible functions for the N-terminal domains that 
should be kept in mind.  It has been suggested that, in addition to the host specificity conferred 
by the cell wall binding domain, endopeptidases may also confer specificity, since they target the 
peptide cross-links, a structure that is more specific to a bacterial species (Lu et al., 2006).  Such 
peptidases are found in the N-terminus of several bifunctional lysins and a few LysAs.  The N-
terminal domain may require binding to specific substrates to better position the protein in 
relation to the substrate and could even sterically inhibit hydrolytic activity until it has bound, 
similar to the role observed for several other phage lysin cell wall binding domains (Low et al., 
2005).  The zymogram studies that have so far been performed on several LysAs have used 
Micrococcus luteus PG as a substrate (see Appendix A.1, Payne et al., 2009).  In addition to 
lacking unique molecules like arabinogalactan and mycolic acids, M. luteus belongs to PG group 
A2, which has an interpeptide bridge in its PG cross-links.  The A1 group, containing 
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Mycobacterium and Bacillus species and many Gram-negative bacteria, has directly cross-linked 
meso-diaminopimelyl-containing PG.  If the activity is specific to the peptide cross-link, or if 
hydrolytic activity is inhibited until the N-terminal domain is allowed to bind its mycobacteria-
specific target, then the absence of this binding substrate could be limiting the activity seen in the 
zymograms. In assays with other lysins, a loss of the C-terminal domain could result in an 
increase in increased or broader hydrolytic activity (Becker et al., 2009; Cheng and Fischetti, 
2007; Donovan et al., 2006a; Gaeng et al., 2000; Horgan et al., 2009; Low et al., 2005).  This 
role may be supported for the N2 and N3 domains by zymography studies (Appendix A.1), 
although there is already evidence that these domains may serve a function in export (Catalao et 
al., 2010).  
Another possibility is that the LysA is proteolytically processed to produce two proteins, 
one being the N-terminal domain and the other now resembling the canonical two-domain PG 
hydrolytic lysins.  This has been observed for the Staphylococcus aureus autolysin Atl, which is 
processed into two functional proteins, an amidase and a glucosaminidase (Oshida et al., 1995).  
Alternatively, this second protein could also act as a chaperone for the catalytically active lysin, 
as was recently described for the Ms6 gp1 protein (Catalao et al., 2010), except that the 
chaperone is encoded as a part of the LysA.  However, while there are homologs of this protein 
in several LysAs of phages in Sub-cluster F1, there is no similarity between Ms6 gp1 and any N-
terminal domains.  
Another alternative is that these N-terminal domains act to promote lysis in some way 
other than direct PG hydrolysis.  It is possible that these domains act on another substrate, such 
as the arabinogalactan, but unless this is combined with another PG hydrolytic activity, it is not 
likely to result in efficient lysis.  Hydrolyzing the arabinogalactan from the MurNAc residues of 
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the PG should have a similar effect to the release of the mycolic acids from arabinogalactan by 
LysB (Chapter 3), which, when lacking the PG hydrolase activity associated with the LysA 
protein, is insufficient to promote lysis (Marinelli et al., 2008; Payne et al., 2009).  Since N1 and 
N4 are found in LysA proteins lacking any other predicted hydrolytic activity, it is less likely 
that they would have this activity, at least on PG incorporated into the cell wall.   
It is still possible that these domains interact with other host proteins to indirectly cause 
PG hydrolysis.  It has recently been observed in S. pneumoniae that the host autolysin, LytA, can 
contribute to, and even replace, the function of the lysin in SV1 phage infection (Frias et al., 
2009).  It is believed that the depolarization of the cell membrane by the holin protein results in 
the activation of LytA, which is present, but held inactive within the PG.  However, while an 
SV1 lysin deletion mutant was able to propagate with the aid of LytA, mycobacteriophage 
GileslysA was unable to form plaques without complementation (Marinelli et al., 2008), 
suggesting that there may not be a convenient mycobacterial autolysin available for 
mycobacteriophage.   
The N-terminal domains may also target the PG and other cell wall precursor components 
before they are assembled into the cell wall structure, or they may target the cell wall synthesis 
proteins themselves, as seen with the lysins of X174 and phage Q (Bernhardt et al., 2001a; 
Bernhardt et al., 2001b).   Interfering in cell wall synthesis at many steps can be lethal, and the 
target need not be the PG or the enzymes that synthesize it; mycolic acids and arabinogalactan 
are also essential for mycobacterial survival.  For example, the common anti-tuberculosis drug 
isoniazid binds InhA to halt mycolic acid synthesis, quickly leading to cell lysis (Quemard et al., 
1995).  However, the host is able to mutate its proteins to prevent such binding, an adaptation 
that is creating isoniazid-resistant M. tuberculosis.  Further, being intracellular, this system 
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would not require a holin, and so theoretically the timing of phage lysis would not be determined 
by the holin.  These are both counter to the design of lysins, which, at the optimal time in phage 
production, as dictated by the holin, target and degrade an essential and complex structure that is 
the product of dozens of enzymes and largely invariable throughout prokaryotes.  In fact, the 
inability of bacteria to develop resistance to lysins is one reason that lysins are being investigated 
as a new class of antimicrobials (Borysowski et al., 2006; Fischetti, 2006). 
Lastly, the LysA N-terminal domains may also have functions that more indirectly, or 
even completely unrelated, to lysis.  The classic example of this is the T7 phage lysozyme.  In 
addition to being an amidase that degrades the PG, the T7 lysozyme binds the T7 RNA 
polymerase to inhibit transcription late in infection (Moffatt and Studier, 1987).  However, there 
are not many lysins known to have extra functions like this, and T7 lysozyme, like many Gram-
negative phage lysins, does not have a modular configuration, but rather is more globular in 
structure (Cheng et al., 1994).  Another secondary function characterized in a few phage 
endolysins is an ability to permeabilize the membrane via a short sequence similar to cationic 
antimicrobial peptides (Epand and Vogel, 1999).  Such activities have been identified in the C-
terminus of T4 lysozyme (During et al., 1999) and in the lysin of a Bacillus amyloliquefaciens 
phage (Morita et al., 2001a; Morita et al., 2001b).  These sequences make it possible to 
permeabilize a Gram-negative membrane through exogenous application of the lysins (Orito et 
al., 2004).  There is little reason to suspect that a mycobacteriophage would encode a lysin that 
could kill the host exogenously; however, it is still possible that such a region exists that would 
contribute in other ways to the disruption of the cell envelope. 
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2.6.4 The Potential for Novel Binding Motifs in LysA C-terminal Domains 
The C-terminal domains of the mycobacteriophage LysA proteins may present new binding 
motifs unique to mycobacteria or closely related genera.  Lysin cell wall binding domains often 
target molecules that are unique to the host bacteria (Hermoso et al., 2003; Loessner et al., 2002; 
Lu et al., 2006).  For example, phage lysins Cpl-1 and Pal bind the teichoic acids of S. 
pneumoniae and possess within their C-terminus, the same repeated choline-binding motifs that 
target teichoic acids as are seen in the host autolysin, LytA (Lopez et al., 1997).  The only LysA 
with a binding motif homologous to a known binding region in a related bacterium is in 
Barnyard gp39, which has the LGFP motif.  This 54 aa repeat is found in several hypothetical M. 
tuberculosis proteins, as well as in the Corynebacterium PS1 cell surface protein, which 
resembles the mycolyltransferase M. tuberculosis antigen 85 complex proteins (Adindla et al., 
2004).  The long arabinogalactan chain covalently attached to the mycobacterial or 
corynebacterial PG would seem a reasonable binding substrate for LGFP motifs.  While there is 
no indication as to the binding nature of the C1 domain, the similarity between several C2 
domains and M. tuberculosis H37Rv R3594 and the metallopeptidase of R. jostii RHA1 may 
represent a novel binding motif for Mycobacterium and related bacteria.  However, an interesting 
correlation was observed when the exogenous lytic ability of several purified LysAs was tested 
on Propionibacterium acnes, a Gram-positive bacterium in the order Actinomycetales (Appendix 
A.2).  P. acnes does not have A1-type PG and lacks mycolylarabinogalactan (Kamisango et al., 
1982), and yet it was quickly lysed by Bxz1 gp236 (N2-Ami2-C1) and D29 gp10 (N4-GH19-
C1).  These two LysAs share no domains except for C1; the other LysAs tested included Che8 
gp32 (N2-Ami1-C2) and Corndog gp69 (N3-Ami2-C2), neither of which showed strong lytic 
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activity.  Therefore it is possible that the C1 cell wall binding domain is less specific, allowing 
Bxz1 gp236 and D29 gp10 a broader range of targets.  
The PG binding domain of C3, specifically PG_binding_1 (Pfam01471), is not present in 
many other phage lysins, but has been characterized in KZ and EL.  These phages infect the 
Gram-negative Pseudomonas aeruginosa, and the lysins KZ144 and EL188 were able to lyse a 
broad range of outer membrane-permeabilized Gram-negative bacteria, including other 
Pseudomonas, E. coli, and Salmonella typhimurium (Briers et al., 2007).  In addition, large 
amounts of KZ144 were able to lyse the Gram-positive B. subtilis, but not other Gram-positives 
such as Micrococcus lysodeikticus or Staphylococcus aureus.  The common feature of Gram-
negative bacteria and B. subtilis is their PG chemotype (Schleifer and Kandler, 1972).  All Gram-
negative bacteria are chemotype A1 (Schleifer and Kandler, 1972), and KZ144 specifically 
bound the directly cross-linked N-acetylated chemotype A1γ (Briers et al., 2007), which is 
present in P. aeruginosa, E. coli, and B. subtilis (Schleifer and Kandler, 1972).  Thus, the 
PG_binding_1 domain is implicated in the specific binding of chemotype A1γ PG.  Notably, 
Mycobacterium species also have chemotype A1γ PG.  However there are two primary 
differences between Mycobacterium and B. subtilis or Gram-negative A1γ PG:  the cross-links of 
mycobacterial PG are more fully amidated, and the muramic acid residues are N-glycolated 
instead of N-acetylated (Figure 5).  It is also interesting to note that the C3 domain is found in all 
LysAs that contain M23 peptidase domains; it may be ideally situated to position the peptidase 
close to its substrate. 
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2.6.5 Summary 
This characterization of the mycobacteriophage LysA proteins has revealed these to be 
extensively modular proteins constructed from a variety of domains, both with predictable and 
unknown function, in an architecture rarely seen in the lysins of other bacteriophages.  Of those 
domains with a predicted activity, alignments show that most, or all, of the catalytic residues are 
conserved, indicating that these domains are likely to be enzymatically active, and there is 
already some experimental evidence supporting the PG hydrolytic ability of several LysAs 
(Appendix A.1) (Garcia et al., 2002; Henry et al., 2010; Payne et al., 2009).  The N-terminal 
domains seen in most of these proteins are completely uncharacterized, and several are unique to 
mycobacteriophage LysAs.  The existence of LysAs possessing one of these N-terminal domains 
in the absence of any predicted catalytic activity is intriguing, and these domains may have new 
PG hydrolytic activities or other novel functions.  The C-terminal domains, which are likely 
involved in binding, may provide information about important molecules in the mycobacterial 
cell wall and the protein motifs that are able to specifically bind them.  Further, once more fully 
characterized, these domains may prove useful in research involving labeling, discriminating, 
and/or binding of mycobacteria, as is currently done with the binding domains of lysins targeting 
B. anthracis and L. monocytogenes (Kretzer et al., 2007; Schuch et al., 2002).  Ideally this 
bioinformatic analysis of LysAs will be a starting point for many future studies to harness the 
unique properties of these proteins for research and therapeutic use, perhaps in conjunction with 
the other mycobacteriophage lysin, LysB. 
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3.0  DETERMINATION OF THE ENZYMATIC ACTIVITY AND ROLE OF 
MYCOBACTERIOPHAGE LYSB PROTEIN 
3.1 INTRODUCTION 
 LysB was originally identified as a potential lysis protein by virtue of its association with the 
predicted endolysin, LysA (Garcia et al., 2002); however, there has been little study of the LysB 
protein until recently.  The presence of lysB within the mycobacteriophage lysis cassettes 
suggested a role in phage lysis and escape from the cell, as all known proteins involved in lysis 
to date address the barrier of the cell wall in some form, but its specific function was unknown.  
The mycobacteriophages each encode a LysA protein, and in some cases a putative holin has 
also been identified, and these provide a means with which to traverse the peptidoglycan and cell 
membrane, respectively.  However, the mycobacterial outer membrane presents a final barrier to 
phage release, similar to the outer phospholipid bilayer membrane of Gram-negative bacteria.  
Just as Gram-negative phages have additional lysis proteins (e.g. the Rz/Rz1 proteins and 
spanins) to address the outer lipid bilayer (Berry et al., 2008; Summer et al., 2007), it follows 
that mycobacteriophages may need additional proteins to specifically overcome the 
mycobacterial outer membrane.  However, unlike the unattached outer lipid bilayer of Gram-
negative bacteria, the mycobacterial outer membrane is covalently connected to the 
peptidoglycan.  The outermost layer consists of mycolic acids that are integrated into the outer 
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membrane through weak interactions with the other hydrophobic molecules present, and these 
mycolic acids are in turn esterified to the arabinogalactan chains that are attached to the 
peptidoglycan (Brennan and Nikaido, 1995; McNeil et al., 1991).  
While not originally identified as LysB, ORF3 (gp3) in mycobacteriophage Ms6 was also 
recognized to be a part of the Ms6 lysis cassette in addition to a LysA (gp2) and holin (gp4), 
although its function was unknown (Garcia et al., 2002).  A limited sequence alignment with 
seven other mycobacteriophage LysBs (Gil et al., 2008) found a motif (G-X-S-X-G) that is 
characteristic of lipolytic enzymes, such as carboxyesterases (EC 3.1.1.1) and lipases (EC 
3.1.1.3), and biochemical characterization of the Ms6 LysB showed it to be a lipolytic enzyme 
(Gil et al., 2008).  This class of enzymes hydrolyzes ester bonds to create two products, one with 
an alcohol group and the other with a carboxylic acid.  Lipolytic enzymes have a catalytic triad 
containing the serine found in the G-X-S-X-G motif in addition to an Asp and His (Carvalho et 
al., 1999; Gupta et al., 2004; Longhi and Cambillau, 1999).  The specific motif seen in LysB 
proteins is Gly-Tyr-Ser-Gln-Gly, which most closely resembles that of cutinases (EC 3.1.1.74), 
although the surrounding sequence shows no significant similarity (Garcia, 2002).  Cutinases and 
other serine esterases belong to the superfamily of / hydrolases, which contain the catalytic 
serine in a sharp turn between an -helix and a -sheet (Arpigny and Jaeger, 1999; Carvalho et 
al., 1999; Ollis et al., 1992). 
Straddling the categories of serine esterases and lipases, which hydrolyze short (C10) 
and long (C10) acylglycerol chains, respectively (Arpigny and Jaeger, 1999), cutinases 
generally prefer more intermediate chain lengths but have a broader range of activity (Carvalho 
et al., 1999; Longhi and Cambillau, 1999).  Similar to many lipases and esterases, cutinases can 
hydrolyze a variety of artificial substrates that contain ester bonds (Gilham and Lehner, 2005).  
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Indeed, studies with Ms6 LysB demonstrated lipolytic activity on several artificial substrates, 
including Tween-20, Tween-80, tributyrin, triolein, and various p-nitrophenyl esters (Gil et al., 
2008).  Cutinases are normally produced by pathogenic fungi to degrade the protective plant 
polymer, cutin (Carvalho et al., 1999), which is a complex fatty acid polymer containing many 
ester bonds.  However, cutin is not expected to be encountered by mycobacteriophages. 
The only ester bond that has been identified in the covalently attached mycobacterial cell 
wall is the mycolyl-arabinogalactan bond.  Thus, we predict that this is the target of the 
mycobacteriophage LysB protein (Figure 6).  Further, it is likely that hydrolysis of this bond 
could remove, or at least compromise, the barrier of the mycobacterial outer membrane and thus 
aid in the release of new phage progeny.  In order to test this hypothesis, we conducted a multi-
approach characterization of LysB proteins by performing a bioinformatic analysis of 56 LysB 
proteins, determining the enzymatic activity on both artificial and host substrates, and identifying 
the role in mycobacteriophage lysis using lysB-deletion mutant phage. 
3.2 BIOINFORMATIC CHARACTERIZATION OF LYSB PROTEINS  
Putative LysB proteins have been detected in 56 out of the 60 fully sequenced 
mycobacteriophages.  Each of these is located within the lysis cassette adjacent to the lysA gene 
with no more than four intervening genes, some of which are putative holins.  We performed 
BLAST analyses, ClustalW alignments, and conserved domain searches for each of the 56 LysB 
proteins.  In addition, we examined the four phage that lack a recognizable LysB protein.  
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3.2.1 Sequence alignments and conserved domains 
The LysB proteins range from 254 (D29 gp12) to 451 (PG1 gp50) residues, and while they do 
not appear modular like LysAs (Hatfull et al., 2006), they are still highly diverse.  A ClustalW 
sequence alignment (Figure 25) reveals numerous gaps, and by plotting the phylogenetic 
relationships (Figure 26), one can see that the LysB proteins are highly divergent, with many of 
these displaying <20% sequence identity to other members of the phamily.  Several LysB 
proteins (D29 gp12, L5 gp12, CJW1 gp35, Porky gp35, 244 gp35, Kostya gp36, Omega gp53, 
and MAV_0786) have large gaps of 60-120 residues at their N-termini (Figure 25).  There is also 
a Gly-rich region of ~30 residues towards the C-terminus in four LysBs (PG1 gp50, Orion gp50, 
Chah gp51, and TM4 gp30 [sequence does not fully align in this ClustalX alignment]), with 
smaller regions of ~10 residues also visible in members of clusters D and G and Giles gp32.  The 
function of this region is unknown.  In the search for conserved domains using BLAST against 
the GenBank database, 14 LysB proteins, including D29 gp12, were predicted to contain a 
cutinase domain (Pfam01083), and Wildcat gp52 is predicted to have an esterase/lipase domain 
(Pfam c109107) (Figure 26).  These are all predicted lipolytic functions, which is consistent with 
the activity reported for Ms6 LysB (Gil et al., 2008).  In addition, eight LysB proteins have a 
predicted peptidoglycan-binding domain (pfam01471) at their N-terminus (Figure 26).  The 
LysB proteins listed above, whose N-terminal regions are truncated compared to other LysBs, 
may be missing this binding region.  
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 Figure 25. Alignment of LysB protein using ClustalW 
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Figure 25: The 56 LysB proteins from 60 sequenced mycobacteriophage genomes, 
mycobacteriophage Ms6, and a putative prophage of M. avium were aligned using ClustalW.  
The catalytic Ser, Asp, and His are identified with asterisks.  Also identified are the G-X-S-X-G 
motif with the catalytic Ser, the G-X-P motif, and the Gly-rich region.  Phage clusters and sub-
clusters are listed on the left.  More conserved residues are shaded red while less conserved 
residues are shaded blue. 
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 Figure 26. Phylogenetic relationships of LysB proteins 
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Figure 26: The 56 LysB proteins of sixty completely sequenced mycobacteriophage, 
mycobacteriophage Ms6, and of a putative M. avium prophage (MAV-0786) were aligned in 
ClustalW and displayed using Njplot.  Conserved domains identifiable in each LysB protein, are 
shown to the right: pfam01083, Cutinase superfamily; pfam01471, putative peptidoglycan 
binding domain; cl09107, Esterase_lipase superfamily.  The Genbank protein ID numbers are 
shown on the right, and the three LysB proteins that have been examined experimentally are 
shown in bold. 
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3.2.2 Conserved residues 
Mycobacteriophage LysB proteins contain three absolutely conserved residues (Figure 26), 
which include the predicted active site serine (position 82 in D29 LysB) plus a GXP motif 
approximately 40 residues C-terminal to it (residues 117-119 in D29 LysB).  The GXP motif is 
not absolutely conserved in all serine esterases, and its function is unknown.  The lipase- and 
cutinase-like conserved domains suggest that LysB is a serine esterase, which typically have a G-
X-S-X-G motif containing the catalytic Ser.  This motif is observed, and almost completely 
conserved, in the LysB proteins (Figure 26). 
By conducting a ClustalW alignment with a greater number of sequences the remaining 
catalytic residues are more easily identified.  Through a limited alignment, three conserved 
aspartic acids were previously proposed to be involved in catalysis (Gil et al., 2008); however, in 
this larger alignment of 58 proteins, only the aspartic acid corresponding to position 166 in D29 
LysB is highly conserved, with the single departure being the substitution of a glutamic acid in 
the LysB protein encoded by a putative Mycobacterium avium prophage (Figure 25).  This 
difference could indicate an evolutionary divergence that has inactivated the protein within a 
quiescent prophage, but since Asp  Glu is a largely conserved substitution that retains the 
important negative charge, the protein may still be active.  A conserved His residue is found 
towards the end of the LysBs, significantly further from the Asp as compared to cutinases due to 
the presence of a large insertion (Figure 25).  However, the crystal structure of the D29 LysB 
(see Section 3.4), suggests that this His residue (at position 240) is indeed part of the catalytic 
triad.  Interestingly, there is a largely conserved Tyr two or three residues C-terminal to the Asp 
and His, respectively, corresponding to positions 168 and 243 in D29 LysB, as well as several 
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highly conserved Gly residues.  These may be involved in structural stability of the protein or aid 
in correctly positioning active site residues, as is seen for Ser in the G-Y-S-Q-G motif in most 
LysBs. 
3.2.3 Mycobacteriophage lysis cassettes lacking a LysB protein 
Unlike the LysA proteins, there is not an identifiable LysB homolog in every mycobacteriophage 
genome.  Mycobacteriophages Che12, Rosebush, Qyrzula and Myrna lack lysB in or near their 
lysis cassettes (Figure 27), and it is unclear whether these phages encode alternative enzymes 
performing analogous functions.  Aside from Rosebush and Qyrzula, which are highly similar 
and constitute the only members of the subcluster B2, these phages are not closely related to 
each other on a genomic level; however, they can be compared to more similar relatives.  For 
example, the genes surrounding the lysis cassette of Che12 are syntenic with other phages in the 
subcluster A2, including L5, D29, Pukovnik and Bxz2 (Figure 27 A); it appears that Che12 has 
simply lost its lysB.  Rosebush and Qyrzula depart from their close relatives of the cluster B 
phages in the inclusion of a gene immediately downstream of lysA that is lacking in other Cluster 
B phages, all of which do encode LysB (Figure 27 B).  This predicted protein is smaller than any 
LysB proteins (178 aa) and may be a holin; it possesses two transmembrane domains like class II 
holins (Wang et al., 2000) and shows distant similarity to the D29 putative holin (gp11), while 
the location of any putative holins in the other Cluster B phages is unknown.  In Myrna, neither 
of the two ORFs (244, 245) immediately downstream of lysA is related to any other 
mycobacteriophage proteins (Figure 27 C).  However, Myrna gp244 has similarity to the N-
terminal region of the large (823 aa) Rhodococcus protein RHA1_ro08121 that contains both 
M23 family peptidase (Pfam01551) and glycoside hydrolase family 25 muramidase (cd00599) 
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motifs in its C-terminus.  These same peptidoglycan-hydrolyzing activities are predicted in 
several LysAs, suggesting that Myrna gp244 may have a role in lysis and peptidoglycan 
hydrolysis. 
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Figure 27. Genetic organization of mycobacteriophage lacking lysB 
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Figure 27:  
The lysis cassettes and surrounding genes of the mycobacteriophages lacking a LysA are 
compared to those of related mycobacteriophages.  ORFs are represented as boxes, with differing 
colors corresponding to membership in a specific Pham.  
A. The lysis cassettes and surrounding genes of the five cluster A2 genomes are shown.  All 
contain a lysA gene, but Che12 lacks lysB, seemingly through simple loss of the genes.  Note that 
the putative holin is also apparently missing in Bxz2.  The pham number with the number of 
phamily members in parentheses is shown above each gene. 
B. The lysis cassettes of five cluster B genomes are shown; Qyrzula and Rosebush belong to 
cluster B2, PG1 to cluster B1, Phaedrus to cluster B3 and Cooper to cluster B4.  Each genome 
contains a lysA gene, but both Qyrzula and Rosebush lack lysB.  While both these genomes 
contain a different gene in the same location (Qyrzula gene 45 and Rosebush gene 47), these 
genes constitute Pham1989, which PSI-Blast analysis suggests is distantly related to Pham 10, a 
group of predicted holins.  The location of putative holin genes in PG1, Phaedrus and Cooper is 
not known. 
C. The lysis cassettes of four phages of cluster C are shown; Rizal, ScottMcG and Spud all 
belong to subcluster C1, while Myrna belongs to subcluster C2.  Each genome contains a lysA 
gene, but Myrna lacks lysB.  The adjacent gene (244) is a candidate for involvement in lysis, but 
it is not related to the large family of cutinase-like proteins or other esterases.  Myrna gene 245 is 
of unknown function.  
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3.3 ENZYMATIC ACTIVITY OF LYSB PROTEINS ON ARTIFICIAL 
SUBSTRATES 
The bioinformatic analyses suggest that mycobacteriophage LysB proteins comprise a novel 
family of lipolytic proteins that are most closely related to bacterial and fungal cutinases.  
Lipolytic activity has been shown with the LysB homolog of mycobacteriophage Ms6 using 
various artificial esterase and lipase substrates (Gil et al., 2008).  Prior to studies with native 
mycobacterial substrates, we wanted to confirm this esterase activity in our cloned LysB, as well 
as engineer active site mutants to verify the classification of LysB proteins as serine esterases. 
3.3.1 Cloning and expression of D29B and an active site mutant 
The LysB (gp12) of mycobacteriophage D29 was chosen for in vitro assays to determine the 
structure and function of LysB proteins.  This is the smallest LysB protein sequenced to date 
(254 aa) and shares only 40% amino acid sequence identity with the previously characterized 
Ms6 LysB protein (Gil et al., 2008), lacking 90 N-terminal residues that are present in Ms6 LysB 
(Figure 25).  However, D29 is one of the best-studied mycobacteriophages (David et al., 1984; 
David et al., 1992; Ford et al., 1998; Rybniker et al., 2006; Schafer et al., 1977; Sellers et al., 
1962), and the genes of the lysis cassette of D29 (gene 10, lysA; gene 11, putative holin; and 
gene 12, lysB; cloned as pLAM1, pLAM2, and pLAM3, respectively) had previously been 
cloned by L. Marinelli (unpublished data) into a pET21a vector for expression with a C-terminal 
His-tag for purification.  While other phage endolysins have the cell wall binding domain at the 
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C-terminal end, most serine esterases and lipases contain secondary structure elements 
positioned above the active site that are involved in substrate binding (Gilham and Lehner, 
2005).  Since LysB does not appear to have a modular organization like other phage lysins it 
seemed reasonable to expect little or no interference on activity from a C-terminally-placed His 
tag.  D29 LysB was induced with 1 mM IPTG and expressed in high amounts, the majority of 
which was present in the soluble fraction (Figure 28).  The protein was purified to near 
homogeneity and readily concentrated to greater than 10 mg/ml (Figure 28).  In addition, based 
on the prediction of Ser82, Asp166, and H240 as the active residues, two D29 LysB active site 
mutants were created.  Using site-directed mutagenesis with the pLAM3 plasmid, the Ser82 
codon (TCG) was mutated to an Ala (GCG) and the His240 codon (CAC) was mutated to Ala 
(GCC) to create the D29 LysB S82A (pKC20) and H240A (pKC23) mutants, respectively. 
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 Figure 28. Purification of D29 LysB 
 
 
 
Figure 28:  
D29 LysB was expressed from plasmid pLAM3, a derivative of vector pET21a, in E. coli 
BL21(DE3) and purified to near-homogeneity.  SDS-PAGE of un-induced cells (U), whole cell 
lysates of induced strains (W) separated into insoluble (I) and soluble (S) fractions, and a 
clarified soluble lysate (L) are shown.  The 30 kDa His-tagged D29 LysB was bound to a cobalt-
affinity matrix, and flow-through (F), a 20 mM imidazole wash (W20) sample, and fractions 
collected at 120 mM imidazole elutions (E120) are shown. 
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3.3.2 Assay of lipolytic activity with p-nitrophenyl esters  
The activities of purified D29 LysB and the putative active site mutants were measured using a 
chromogenic assay involving hydrolysis of various p-nitrophenyl esters with acyl chains, which 
are composed of a carbon chain esterified to a p-nitrophenol group (Gilham and Lehner, 2005).  
Hydrolysis of the ester bond releases the p-nitrophenol, which can be detected as a yellow color 
that absorbs at 420 nm (Figure 29 A).  The carbon chains assayed here varied in length from a 
single carbon (p-nitrophenyl acetate) to the 16-carbon hexadecanoic acid palmitate (p-
nitrophenyl palmitate).  In general, shorter chain length substrates are used to assay esterase 
activity, while longer chain lengths assay for lipase activity (Gilham and Lehner, 2005).  Most 
studies, including those conducted on Ms6 LysB (Gil et al., 2008), utilize p-nitrophenyl butyrate 
(pNPB), which has a four-carbon fatty acid and is easily solubilized.  Therefore, the assay 
conditions were optimized using pNPB as the substrate.  During optimization, it was found that 
trace amounts of imidazole remaining after purification of the recombinant LysB proteins caused 
non-specific substrate hydrolysis, and therefore, <1 ml amounts of the purified proteins were 
dialyzed against 2 L of storage buffer instead of the standard 1 L.  Additionally, when alternate 
substrates were tested, it was found that as the carbon chain length increased, the pNP esters 
became more insoluble, as was observed in similar assays (Gilham and Lehner, 2005).  In order 
to increase solubility, an emulsifier was added to the reactions, which would allow pNP esters of 
up to 16 carbons to solubilize without greatly inhibiting activity (as measured with shorter 
substrates like pNPB).  Several concentrations of Tween-20, Tween-80, and Triton X-100 were 
tested, and optimal results were obtained with 0.1% Triton X-100. 
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Using the assays described above, we obtained a specific activity for wild-type D29 LysB 
of 0.72 U/mg (Figure 29 B).  This is somewhat higher than the 0.12 U/mg observed for Ms6 
LysB (Gil et al., 2008) or the activity of the seven cutinase-like proteins found in M. tuberculosis 
(West et al., 2008), although slightly different assay conditions may have influence the resulting 
activities.  The S82A and H240A LysB mutants were tested and found to be inactive (Figure  29 
B and data not shown), consistent with these residues being part of the catalytic triad.  As a 
positive control, a purified lipase from Pseudomonas fluorescens showed minimal activity on 
pNPB, but activity increased dramatically as the carbon chain length increased (Figure 29 B), 
which follows the known preferences of lipase enzymes (Gilham and Lehner, 2005).  The D29 
LysB, however, decreased in activity with longer substrates (Figure 29 B).  This was also 
observed with Ms6 LysB (Gil et al., 2008), supporting a shared activity between the two 
mycobacteriophage LysB proteins, despite only 40% sequence identity.  It was curious to see this 
decrease, considering that the predicted substrate of the LysBs is the exceptionally long (C40-C90) 
mycolic acids, but this could be explained by other differences in the substrate binding region 
that are specific to the structures found on the host.  Indeed, the N-terminal region is positioned 
over the active site in many serine esterases, forming the lid structure that determines substrate 
specificity (Longhi and Cambillau, 1999).  With the absence of a large portion of N-terminal 
residues of D29 LysB compared to the LysBs of Ms6 and other mycobacteriophages, it is 
possible that this may contribute to the increased specific activity observed for D29 LysB 
compared to Ms6 LysB, while substrate specificity remains similar to Ms6 LysB. 
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 Figure 29. D29 LysB is a lipolytic enzyme 
Figure 29:  
A.  Hydrolysis of the ester bond of p-nitrophenyl esters releases a fatty acid and p-nitrophenol, 
which absorbs light at 420 nm.  
B. Lipolytic activity of D29 LysB (filled bars; left axis scale) is shown using p-nitrophenyl 
substrates containing different lipid chain lengths (C4, C8, C12 and C16); lipase activities on the 
same substrate are also shown (open bars; right axis scale).  Specific activities are shown as 
Units/mg protein, with 1 Unit corresponding to the release of 1 µmol p-nitrophenol min-1.  An 
active site mutant (S82A), boiled sample, and a mock-purified sample show little or no activity. 
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3.4 CRYSTAL STRUCTURE OF D29 LYSB (Q. SUN AND J. SACCHETTINI) 
In collaboration with Qingan Sun and Dr. James Sacchettini (Payne et al., 2009), a crystal 
structure of D29 LysB was obtained (Figure 30 A) and has been deposited in the Protein Data 
Bank (PDB) with accession code 3HC7.  A structural alignment (not shown) found similarity to 
members of the α/β hydrolase family, which includes cutinases and lipases (Holm et al., 2008; 
Masaki et al., 2005).  The closest structural relative is a Cryptococcus sp. cutinase-like protein 
(PDB 2czq, superimposed in cyan over D29 LysB), although the sequence identity is only 21% 
(Table 4).  However, D29 gp12 and other LysBs are larger than most cutinases (~225 residues), 
and this extra length occurs between the catalytic Asp and His residues, which are normally <20 
residues apart (Carvalho et al., 1999; Longhi and Cambillau, 1999).  The remainder of D29 LysB 
(Ala162-Asn243) forms an 81-residue linker region of four -helices with the catalytic His240 at 
the end.  This linker region is positioned over the active site and may be involved in substrate 
binding and positioning (Figure 30 A).  Notably, the Gly-rich region seen in some LysBs (above) 
is located in this -helix linker region.  Further supporting the identification of LysB as a serine 
esterase, D29 LysB possesses the catalytic triad of Ser-Asp-His in the same place structurally as 
the cutinase-like protein, with Ser82, Asp166, and His240 (Figure 30 B).  The conserved GXP 
motif is also located near the active site, suggesting a possible role in structural stability or 
substrate specificity. 
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 Figure 30. Crystal structure of D29 LysB (Q. Sun and J. Sacchettini) 
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Figure 30:  
A.  The D29 LysB structure is shown in alignment with the Cryptococcus sp cutinase-like 
protein (PDB: 2czq).  D29 LysB is colored according to secondary structure (red: α-helix, 
yellow: β-strand, green: loops); 2czq is shown in cyan.  
B.  The catalytic triad of D29 LysB catalytic triad is composed of Ser82, Asp166 and His420 
(ball-and-stick representations).  Electron density map (2Fo-Fc) around the triad is shown in blue 
mesh at 1σ level.  The triad of 2czq is in stick. 
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3.5 ACTIVITY OF LYSB ON PURIFIED MYCOLYL-ARABINOGALACTAN-
PEPTIDOGLYAN 
The D29 LysB structure, along with the observed lipolytic activity on artificial substrates, 
confirms its identification as a serine esterase.  While D29 LysB is most similar to a 
Cryptococcus cutinase-like protein, there is little reason to believe that mycobacteriophages 
would encounter cutin in their natural life cycles, much less to such an extent as to exert a 
positive selective pressure to retain a cutinase in their genome.  Indeed, while the structure is 
largely retained, the low sequence identity between the Cryptococcus cutinase and D29 LysB 
suggests a divergence far in the past.  Given the broad nature of serine esterase substrates, it 
would follow that LysB targets a substrate that is different from cutin.  Upon examining the 
mycobacterial cell wall structure, the only fatty acid ester bond seen is that connecting the 
mycolic acids to the arabinogalactan (Figure 6).  Thus, we reasoned that this is the likely target 
of the third member of the mycobacteriophage lysis system, the LysB protein. 
3.5.1 Preparation of purified mycolyl-arabinogalactan-peptidoglycan 
To determine if the mycolyl-arabinogalactan bond is indeed the target of LysB, the entire 
mycolyl-arabinogalactan peptidoglycan (mAGP) complex was purified from M. smegmatis and 
incubated with purified LysB protein.  As with the pNP assays, the hydrophilic AGP combined 
with the hydrophobic mycolic acids was highly insoluble and required a buffer containing an 
emulsifier (0.1% Triton X-100) to solubilize the substrate.  Despite this, we were unable to 
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completely resuspend the powdered mAGP in the reaction buffer, as evidenced by visible clumps 
of substrate in all buffer mixtures.  Therefore, it was not possible to precisely determine the rate 
of hydrolysis or the specific activity, as these calculations require knowing the exact amount of 
substrate accessible to enzyme. 
3.5.2 Hydrolysis of mAGP 
Purified D29 LysB was incubated with mAGP at varying concentrations and for different lengths 
of time (Figure 31 A, B).  As a positive control, mycolic acids were released from mAGP by 
alkaline hydrolysis using tetrabutylammonium (TBAH) (Besra, 1998; Hamid et al., 1993; 
Watanabe et al., 2001).  The reaction products were phase-separated and developed by thin-layer 
chromatography (TLC) on silica plates using chloroform/methanol (97:3) and visualized by 
spraying with 5% molybdophosphoric acid in ethanol and charring for 15 minutes (Parish and 
Stoker, 1998).  These analyses showed a time- and concentration-dependent release of mycolic 
acids by D29 LysB (Figure 31 A, B).   
To further verify that the lipid products were mycolic acids, they were methyl-esterified 
with iodomethane during phase-separation, which yielded methyl esters of , ’ and epoxy 
mycolic acids similar to those from TBAH treatment and specific to M. smegmatis (Figure 31 C) 
(Watanabe et al., 2001).  Preliminary analysis of the released lipids by mass spectrometry and 
NMR was consistent with identification as free mycolic acids (L. Kremer, X. Trivelli, and Y. 
Guerardel, data not shown).   
Finally, we examined the ability of other proteins to release mycolic acids from mAGP.  
As expected, mycolic acid release was abolished when the catalytic serine or histidine was 
mutated to an alanine in the D29 LysB S82A mutant (Figure 31 D).  Further, no activity was 
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seen on mAGP by the P. fluorescens lipase (Figure 31 D), implying a substrate specificity, 
although reaction conditions could have influenced this result.   
Additionally, a second spot that traveled less distance than any free mycolates was 
observed for all reactions developed with chloroform/methanol except the TBAH alkaline 
hydrolysis control.  While its exact nature is unknown, based on the consistent presence and 
constant density of this spot in both positive and negative reactions (Figure 31 A, B, and D) it 
may be a by-product of the purification of mAGP, the hydrolysis conditions, or the phase-
separation process.  The harsh alkaline hydrolysis treatment by TBAH may have prevented the 
survival of this compound in the control samples.  
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 Figure 31. D29 LysB is a mycolyl-arabinogalactan esterase 
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Figure 31:  
A and B. Time- and enzyme-concentration-dependence of D29 LysB-mediated hydrolysis of 
mycolyl-arabinogalactan-peptidoglycan (mAGP).  mAGP was purified from M. smegmatis, 
incubated with D29 LysB, and the lipid products separated by thin layer chromatography.  The 
reaction was monitored as a function of time (panel A; incubation times as shown, in minutes) or 
amount of protein (panel B; 0.1, 0.25, 0.5, 1, 5, 10 g D29 LysB).  D29 LysB catalyzes 
production of a species migrating in the same position as the free mycolic acids released by 
tetrabutylammonium (TBAH) treatment.   
C. Methylesterification of the products generated by D29 LysB cleavage of mAGP generates 
epoxy,  and ’ mycolates.  
D. Neither a D29 LysB catalytic mutant (S82A), lipase purified from P. fluorescens, a mock 
purified sample, nor buffer release free mycolic acids from mAGP. 
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3.6 ROLE OF LYSB IN MYCOBACTERIOPHAGE LYSIS 
Based on its prevalence in mycobacteriophages (56/60 published genomes), LysB appears to 
confer some selective benefit or advantage, and its association with the lysis cassette implies that 
this role is in phage lysis.  The ability of LysB to hydrolyze mAGP, and conceivably to separate 
the mycobacterial outer membrane from the host bacterium, could arguably be a function that is 
advantageous to mycobacteriophages during lysis.  However, there are four phages (Che12, 
Myrna, Qyrzula, and Rosebush) that lack a LysB homolog or any protein with a similar predicted 
function near their lysis cassettes, indicating that LysB may not be essential for 
mycobacteriophage infection and lysis.  Therefore, we sought to test its essentiality and 
determine the role of LysB during infection by constructing a lysB deletion mutant and analyzing 
any resulting phenotypes for clues as to its function. 
3.6.1 Construction of a LysB deletion mutant phage 
To explore the role of LysB in mycobacteriophage lytic growth, we first asked whether it is 
essential for plaque formation by using the Bacteriophage Recombineering of Electroporated 
DNA (BRED) technology developed in our lab (Marinelli et al., 2008) to delete lysB (gene 32) 
from the mycobacteriophage Giles genome.  We decided to target Giles lysB because this phage 
has been successfully targeted by BRED recombineering in numerous instances, and notably, 
was previously used to show that the Giles lysA gene (gene 31) is essential for plaque formation 
(Marinelli et al., 2008).  In addition, we anticipated that it might be necessary to complement the 
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deletion with a lysB gene that is sufficiently different genetically from the one deleted by BRED, 
as to avoid recombination (i.e. D29 gene 12).  It should be noted, however, that the Giles LysB 
protein was cloned and purified in the same manner as D29 LysB and was also able to hydrolyze 
purified mAGP (data not shown). 
For the BRED recombineering, a 200 bp dsDNA substrate containing 100 bp flanking 
homology on either end was designed to introduce a 1,146 bp internal deletion in Giles lysB, 
fusing the 15 codons at the 5’ and 3’ ends of the gene (Figure 32 A).  The 200 bp dsDNA 
substrate was constructed by PCR; a 100 bp oligo with 50 bp homology flanking each side of the 
deletion was extended using 75 bp extender primers.  These primers had 25 bp homology to the 
100 bp oligo and a further 50 bp of homology to the sequence 5’ or 3’ to the oligo, totaling 200 
bp.  The decision to retain a short sequence at the beginning and end of the gene was made after 
discovering that the ORFs of lysA (gene 31) and lysB (gene 32) overlap by one nucleotide, with 
the A nucleotide functioning both in the TGA of lysA and the ATG of lysB. This was done in 
order to minimize effects on expression of adjacent genes as well as to avoid genetic polarity.   
After co-electroporation of the 200 bp deletion substrate and purified Giles genomic 
DNA into an M. smegmatis recombineering strain (i.e. containing a prior-induced pJV53 plasmid 
expressing Che9c gp60 and gp61) (van Kessel and Hatfull, 2007), plaques were recovered on a 
lawn of M. smegmatis mc2155:pKMC2 cells that were induced with acetamide to express D29 
LysB.  Not knowing if Giles lysB would be essential for plaque formation, we sought to plate the 
initial transformation on a putative complementing strain in the hopes of increasing the number 
of mixed plaques recovered.  Of 22 primary plaques screened by Deletion Amplification 
Detection Assay (DADA) PCR (Marinelli et al., 2008), two contained mixtures of wild-type and 
mutant phages (Figure 32 B).   
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In order to test for the presence of a viable Giles lysB mutant, one of these mixed 
plaques was picked into phage buffer and plated to recover ~600 isolated plaques on both a 
putative complementing strain (M. smegmatis mc2155:pKMC2) and a non-complementing 
control strain.  At this stage, propagation of the lysB mutant would only be possible if lysB was 
not essential for plaque formation (on the non-complementing strain) or if its function could be 
complemented by the D29 LysB protein expressed from pKMC2.  Secondary lysates from each 
plate representing all of the recovered particles were harvested and tested by PCR for the 
presence of the deletion mutant (data not shown).  The mutant genotype was present in 
approximately equivalent proportions in both the complementing and non-complementing 
strains.  Thirty individual plaques from a secondary plating of the lysates were each screened by 
PCR, and a homogenous mutant plaque was identified (Figure 32 C).  The Giles lysB mutant 
underwent several rounds of purification, and the correct, in-frame deletion was confirmed by 
DNA sequencing (data not shown).  As the Giles lysB mutant proved to be viable without 
complementation, future experiments were done using wildtype M. smegmatis.  This is in 
contrast to the Giles lysA mutant, which could only be propagated on M. smegmatis 
mc2155:pKMC4, a complementing strain expressing the Corndog LysA (gp69) (Marinelli et al., 
2008). 
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 Figure 32. Construction of a Giles lysB deletion 
 
 
 
Figure 32: 
A. A 200 bp dsDNA substrate was designed that has 100 bp homology flanking a 1,146 deletion 
in Giles gene 32.  The locations of primers F1, F2, and D1, used for PCR screening are shown. 
B.  Following co-electroporation of the 200 bp substrate and Giles genomic DNA, primary 
plaques were recovered and screened by PCR using primers D1 and F2, designed to 
preferentially amplify the deletion mutant.  A mixed plaque containing wildtype and mutant 
DNA is shown. 
C.  A mixed primary plaque was diluted and plated, and isolated secondary plaques screened 
using primers F1 and F2.  One homogenous wild-type Giles plaque (left) and one homogenous 
lysB deletion mutant plaque are shown (right). 
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3.7 CHARACTERIZATION OF GILES LYSB MUTANT 
Once the Giles lysB mutant was constructed and found to be viable, characterization of the 
mutant phenotype was necessary to discern the role of LysB in phage infection.  Since LysB was 
hypothesized to be involved in lysis, assays were chosen that examined this aspect of phage 
infection.  Plaque formation was the first phenotype assessed, since the ability to form plaques is 
entirely dependent on lysis.  Based on the plaque observations, other assays were conducted to 
determine if the mutant phenotype was the result of impaired ability to disrupt the cell wall, a 
delay in timing, or a decrease in the number of progeny phage produced. 
3.7.1 Loss of lysB in Giles directly results in a small plaque phenotype 
Since the Giles lysB mutant was capable of forming plaques at equivalent efficiencies on 
complementing and non-complementing strains, and the titers of wild-type and mutant phage 
lysates prepared on a wild-type M. smegmatis host under standard conditions are similar, we 
could conclude that Giles lysB is not essential for lytic growth (Figure 33).  However, we 
observed that the mutant forms somewhat smaller plaques on lawns of wild-type M. smegmatis 
when compared to the parental phage (Figure 33).  This phenotype is exaggerated when higher 
densities of plating cells are used (conditions that favor fewer bacterial doublings and thus fewer 
rounds of phage infection). Under such conditions (2 x 108 cfu/plate), the average number of 
particles in each plaque is ~100-fold reduced in the lysB mutant relative to wild-type Giles 
plaques (5 x 105 and 4 x 107 pfu/ml, respectively).   
Plating on a complementing strain (M. smegmatis mc2155:pKMC9) expressing D29 LysB 
from the pNIT-1 vector (Pandey et al., 2009) restored the plaque size to that of the wildtype 
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Giles (Figure 33), indicating that the small plaque phenotype is a direct result of the loss of Giles 
lysB.  To eliminate the possibility that this rescue was the result of a recombination event 
between the Giles genome and D29 lysB, several of the new plaques were picked and shown by 
PCR to contain only the mutant genotype (data not shown).  Therefore, unlike the lysA mutant, 
which absolutely requires complementation to form plaques (Marinelli et al., 2008), lysB is not 
essential for plaque formation, but given the smaller plaque size, lysB does affect phage lytic 
infection. 
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 Figure 33. Giles∆lysB has a small plaque phenotype that can be complemented by D29 LysB 
 
 
 
Figure 33:  M. smegmatis mc2155 containing either plasmid vector pNIT-1 or plasmid pKMC9 
carrying the D29 lysB gene was infected with wild-type or Giles lysB phages, as indicated.  The 
lysB mutant forms smaller plaques than its wild-type parent, but plaque size is restored by 
complementation with D29 lysB.  Scale bar indicates one cm. 
 190 
3.7.2 Lysis defects in the Giles lysB and lysA mutants 
In order to determine the specific effect of the lysB on phage lysis, we needed to test whether 
the small plaque phenotype is the result of a change in the pattern or the timing of lysis.  To do 
so we performed single-step infections wherein a sufficiently high multiplicity of infection 
(m.o.i.) was used to infect a culture of M. smegmatis, such that every cell would be infected 
simultaneously.  After infection, the progression of phage lysis was monitored by following the 
decrease in OD at 600 nm as cells lysed, or the permeabilization of the cell membrane was 
tracked by measuring the increase in extracellular ATP.  
After infection of wildtype M. smegmatis, the OD of wildtype Giles and the lysB and 
lysA mutants increased at the same rate as for the uninfected control culture for approximately 
3 hours.  Beginning at 3 hours post-infection, the OD of the wildtype-infected culture steadily 
declined before leveling after 5 hours, at which point all cells had been lysed (Figure 34 A).  
When infected with the Giles lysB mutant, the OD did not begin to decline until 3.5 hours post-
infection and was incomplete even 5.5 hours after infection, as indicated by the difference in OD 
between the Giles lysB- and wildtype-infected cells (Figure 34 A).  By comparison, cells 
infected with the Giles lysA mutant cease to grow after 3-3.5 hours—the onset of lysis in the 
wildtype lysB mutant—but show only a modest reduction in OD thereafter (Figure 34 A).  This 
agrees with the inability of the lysA mutant to form plaques and confirms the importance of 
having a functional lysin protein in order to effect lysis and phage release.  
The same timeline was mirrored in the ATP assay (Figure 34 B).  There is very little ATP 
release until three hours post-infection.  The concentration of ATP in the media sharply increases 
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in the wildtype Giles-infected culture and continues to steadily increase until 4.5-5 hours post-
infection, at which point the concentration levels off, presumably because all cells are lysed and 
thus there is no new ATP production (Figure 34 B).  The Giles lysB mutant is delayed in the 
onset of ATP release by about 30 minutes, and fails to achieve the wild-type level of 
extracellular ATP even 5.5 hours after infection.  Interestingly, the lysA mutant showed no 
defect in ATP release at all, and may even release more ATP than cells infected with wild-type 
Giles (Figure 34 B).  This is in obvious contrast to the failure of cells to lyse as observed in the 
OD assay (Figure 34 A).  However, this may reflect a key difference in the assays; the OD assay 
measures cell lysis, but the ATP assay measured the permeabilization of the membrane, which 
could still result in ATP release without cell lysis and the escape of progeny phages. 
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Figure 34. Giles lysA and lysB mutants show inefficient and incomplete lysis 
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Figure 34: 
A.  Lysis of phage-infected M. smegmatis mc2155 was monitored by measuring OD600 of 
cultures infected with wild-type Giles (red), a lysA mutant (green) or a lysB mutant (yellow) at 
different times after phage addition; uninfected cells are shown in blue.  Thicker lines correspond 
to trendlines.    
B.  M. smegmatis mc2155 cells were infected with Giles (red), a lysA mutant (green) or a lysB 
mutant (yellow), and ATP release measured at different times after infection; uninfected cells are 
shown in blue.  ATP was measured in a luciferase assay and reported as relative light units 
(RLU). 
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3.7.3 Production and distribution of new phage particles in Giles lysB and lysA 
mutants 
It could be argued that the smaller plaque size and less efficient progeny release are somehow the 
result of lower phage production within the cell prior to lysis.  We sought to test whether the 
lysB and lysA mutants produce the same yield of total phage particles as wildtype Giles, as 
well as to determine how those particles are distributed, that is, whether they are released into the 
supernatant or remain trapped in unlysed cells.  This was assayed by infecting cultures at a high 
m.o.i. and taking samples at 3, 4, and 5 hours post-infection.  At each time-point, cells were 
pelleted, and the supernatant was removed; phage were released from  any unlysed cells by 
sonication, and each fraction was titered.  The lysA and lysB mutants show no significant 
difference in the total yield of phage particles as compared to wildtype Giles (Figure 35 A).  
Immediately prior to the onset of lysis at 3 hours, the majority of new phages are in the cellular 
fraction for the wildtype and mutant Giles infections (Figure 35 B).  However, by 4 hours post-
infection, while >90% of wild-type particles are present in the culture supernatant, about 45% of 
the lysB particles remain associated with the unlysed cells.  After 5 hours nearly all phage 
particles have been released from both wildtype and lysB-infected cells.  In contrast and as 
expected, <10% of lysA phage particles are released into the supernatant even 5 hours after 
infection (Figure 35 B).  The disparity of particle distribution during lysis, and the lack of a 
significant difference in total phage yield, are consistent with the defects observed for the lysB 
resulting from a defect in host cell lysis. 
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 Figure 35. Phage particles are retained in unlysed cells in Giles lysA and lysB mutants 
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Figure 35: 
A.  M. smegmatis mc2155 cells were infected with wild-type Giles, the lysA mutant, or the 
lysB mutant, and the total number of progeny phage particles (pfu/ml) for each was determined. 
Wild-type Giles is shown in red, lysA in green, and the lysB mutant in yellow.   
B. The distribution (as percentage of total) of phage particles in the supernatant and cell pellet 
was determined.  For wild-type Giles, the supernatant is shown in dark grey, and the cell pellet in 
red; the lysA mutant supernatant is grey and the pellet is yellow; the lysB mutant supernatant 
is shown in light grey and the pellet in green. 
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3.8 CONCLUSIONS 
We have shown here that the mycobacteriophage D29 LysB protein—and by extension other 
mycobacteriophage LysB proteins—is a novel mycolylarabinogalactan esterase that efficiently 
completes the lysis of host mycobacterial cells.  Figure 36 shows a model of the mycobacterial 
cell wall indicating the role of the LysA and LysB proteins, as well as the reaction catalyzed by 
LysB.   
The efficient release of free mycolic acids from D29 LysB-treated cell walls, as observed 
by TLC, strongly suggests that mAGP is the substrate for the enzyme.  While there are other 
mycolic acid-containing constituents in the mycobacterial cell envelope, only the mycolic acids 
esterified to the arabinogalactan are linked to the cell wall, and extractable lipids—such as 
trehalose dimycolate (TDM; cord factor) and trehalose monomycolate (TMM)—are not major 
components of the mAGP preparations (Besra, 1998; Brennan and Nikaido, 1995).  Preliminary 
data suggest that D29 LysB can also hydrolyze TDM (A. Ojha, K. Payne and G. F. Hatfull, 
unpublished observations), but it seems unlikely that this has physiological relevance for lysis 
because TDM is not covalently attached to mycobacterial cells.  We propose that cleavage of the 
mycolic acids to sever the mycobacterial outer membrane from the peptidoglycan-
arabinogalactan layer is the primary role of LysB, which can be considered a mycolyl-
arabinogalactan esterase. 
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 Figure 36. A model for mycobacteriophage lysis of mycobacteria 
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Figure 36:  A.  Mycobacterial cell walls are unusual in that the cytoplasmic membrane (CM) is 
surrounded by a peptidoglycan layer (PG) to which a network of arabinogalactan (AG) is 
covalently attached.  A mycobacterial outer membrane consisting of mycolic acids (MA) and 
free lipids (FL) is covalently attached via an ester linkage of mycolic acids to arabinogalactan.  
We propose that LysA – assisted by holins encoded by at least some of mycobacteriophage – 
perform an essential step in lysis involving degradation of the peptidoglycan layer, and the lysis 
is completed through LysB-mediated cleavage of the outer membrane from arabinogalactan.   B.  
Diagram illustrating LysB cleavage of the ester bond linking mycolic acids and arabinogalactan. 
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While removal of LysB function in mycobacteriophage Giles results in an apparently 
mild plaque phenotype that can be rescued by expression of D29 LysB (Figure 33), other 
problems in lysis are made more apparent by measuring changes in optical density of the culture, 
ATP release, and phage particle distribution.  The phenotype observed in the Giles lysB mutant 
is consistent with a mild lysis defect, similar to that seen in the coliphage  Rz/Rz1 mutants 
(Zhang and Young, 1999), which are unable to efficiently achieve the final fusion of the E. coli 
membranes to induce lysis (Berry et al., 2008; Summer et al., 2007).  The unexpected ATP 
release by the Giles lysA mutant is in contrast to its lysis defect as seen in optical density 
measurements (Figure 34) and by the complete lack of plaque formation in the absence of 
complementation (Marinelli et al., 2008).  A simple explanation for this observation is that the 
peptidoglycan layer, which most probably remains intact during infection with the lysA mutant, 
provides no barrier to the release of hydrophilic ATP molecules, whereas both hydrophobic 
barriers—the cytoplasmic membrane and the mycobacterial outer membrane—must be 
compromised for complete ATP release.  Presumably, the cytoplasmic membrane is 
permeabilized through the action of a Giles holin, and the differences in ATP release observed 
between the lysA and lysB mutants are based on the presence or absence of an attached 
mycobacterial outer membrane. 
Phages infecting other Gram-positive bacteria typically complete lysis through simple 
endolysin-mediated degradation of the peptidoglycan layer, but the lipid-rich mycobacterial 
outer membrane presents a unique barrier.  The mycolyl-arabinogalactan linkage is not common 
among bacteria, since mycolic acids are found primarily in the Corynebacterineae suborder of 
the Actinomycetales, which includes Corynebacteria, Gordonia, Nocardia, Rhodoccocci and 
Mycobacteria.  Few phages infecting non-mycobacterial members of the Corynebacterineae have 
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been characterized, although these would be good candidates for also encoding 
mycolylarabinogalactan esterases.  However, neither phage P2101 of Corynebacterium 
glutamicum (Chen et al., 2008) nor BFK20 of Brevibacterium flavum (Bukovska et al., 2006) 
encode a LysB relative.  Unlike in Mycobacteria the mycolic acids of Corynebacteria, such as C. 
glutamicum, are not essential for growth (Portevin et al., 2004), and therefore may not pose a 
significant barrier to efficient lysis, thus rendering a LysB-like protein unnecessary, or may not 
provide enough selective pressure to maintain such a protein.  Alternatively, phages infecting 
these bacteria may address the mycolic acid barrier through another means, similar to the four 
mycobacteriophages that lack a LysB. 
Currently, the only known physiological circumstances in which free mycolic acids are 
released from mycobacterial cells is during maturation of M. tuberculosis biofilms (Ojha et al., 
2008), although the source of biofilm mycolic acids is predominantly from TDM (Ojha et al., 
2010).  While seven cutinase-like proteins (culps1-7; Rv1984c, Rv2301, Rv3451, Rv3452, 
Tv1758, Rv3802c, and Rv3724) encoded by M. tuberculosis have been expressed and 
characterized (Schue et al., 2010; West et al., 2009), they are not evidently related to LysB and 
have not yet been tested for mAGP hydrolysis.  Culp1 (Rv1984c) prefers medium-chain 
acylglycerols, while Culp4 (Rv3452) has phospholipase A2 activity (Schue et al., 2010) and only 
Culp6 (Rv3802c) has significant activity on longer carbon chain substrates (West et al., 2009).  It 
remains to be seen whether there are any host-encoded enzymes that share 
mycolylarabinogalactan esterase activity with LysB. 
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4.0  DISCUSSION 
At the end of a lytic infection, all bacteriophages need to release the newly made phage particles 
into the environment to find and infect new hosts.  All known dsDNA bacteriophages employ a 
minimum of two proteins to accomplish this: a holin and an endolysin (Young et al., 2000).  The 
holin regulates the timing of lysis and permeabilizes the cell membrane, resulting in a 
depolarization of the membrane potential.  The lysin is a peptidoglycan (PG) hydrolase, and it 
accesses its substrate either by passing through a holin lesion or by being secreted; in this case it 
is activated when a pinholin disrupts the membrane potential (Young, 2002).  Most lysins consist 
of two domains, an N-terminal PG hydrolytic domain and a C-terminal cell wall-binding domain 
(Lopez et al., 1997).  Each lysin possesses one or (rarely) two types of PG hydrolytic activity – 
amidase, glycosidase, or peptidase – and a binding domain that is highly specific to a component 
of the host’s cell wall. 
The holin-endolysin lysis system appears straightforward, but research continues to 
uncover new variations on the above basic mechanism.  Two types of holins have been identified 
thus far: classic holins, which create large lesions in the cell membrane, allowing lysins to pass 
directly through; and pinholins, which make small holes in the membrane and merely disrupt the 
membrane potential (Dewey et al., 2010).  In addition, the continual recombination of the lysins’ 
lytic and binding domains with those of other phage and host lysins is constantly generating 
unique lysins (Diaz et al., 1990; Lopez et al., 1997).  The resulting lysins are highly tailored to 
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their specific hosts, primarily due to the specificity of the cell wall-binding domain, but also due 
in part to selection for a lytic activity that is effective at degrading the host’s PG. 
In addition to this modular design, novel holin-independent methods of lysin transport 
across the host membrane have been discovered.  Signal-anchor-release (SAR) lysins are 
secreted into the periplasm via the host’s secretory pathway and are tethered to the cell 
membrane until depolarization – often caused by a pinholin – releases the lysins to act on the PG 
substrate (Xu et al., 2004).  Another method was very recently identified in the 
mycobacteriophage Ms6; an accessory lysis protein, gp1, acts as a chaperone to export the LysA 
across the membrane, where it is also activated by membrane depolarization (Catalao et al., 
2010). 
The most intriguing variations on the holin-endolysin theme involve accessory lysis 
proteins like gp1.  Often these proteins are encoded in alternate reading frames that overlap or 
are completely embedded within the reading frames of other lysis proteins (Sanger et al., 1982; 
Young, 1992).  Two accessory protein classes were originally identified in the lysis cassettes of 
enterophages such as : the anti-holin and the Rz/Rz1 proteins (Figure 10) (Hanych et al., 1993; 
Young, 1992).  The ratio of anti-holin to holin determines the triggering time of lysis, and these 
are often encoded within the holin gene and translated using a dual start motif (Barenboim et al., 
1999; Blasi and Young, 1996; Graschopf and Blasi, 1999). 
While the need for a means of regulating the timing of lysis is common to all phages, the 
specific type of accessory proteins serving this role are often dictated by the phage’s host.  The 
Rz/Rz1 proteins and their single-polypeptide functional analogs, the spanins, are encoded by 
phages infecting Gram-negative bacteria (Summer et al., 2007).  These proteins perform the final 
step in lysis by fusing the inner and outer membranes of the Gram-negative host bacterium 
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(Berry et al., 2008).  Lysis is still possible, albeit less efficient, in the absence of Rz/Rz1, but the 
evolutionary advantage of these proteins is evidenced by their widespread presence in the phages 
of Gram-negative species. 
In summary, the holin-lysin system is the most basic unit required for bacteriophage 
lysis.  However, phages have found ways to modify these two proteins and to incorporate 
additional proteins in an ongoing effort to optimize lysis of their specific hosts.  While the PG 
backbone of all bacteria is largely uniform, cell walls can vary greatly, from the dramatically 
different organizations of Gram-negative and Gram-positive bacteria (Figure 3) to the single 
substitution of a different amino acid in the PG peptide cross-link (Figure 2).  Evolutionary 
pressure to optimize lysis favors holins that time lysis for the most effective release of progeny 
and selects for lysins that can efficiently access and degrade the modified PG of their host.  As 
more barriers are introduced, phages must adapt further to effect lysis, as illustrated by the 
incorporation of Rz/Rz1 proteins to eliminate the barrier of the outer membrane in Gram-
negative bacteria. 
4.1 A COMPLEX BACTERIUM REQUIRES A COMPLEX LYSIS SYSTEM. 
While Mycobacteria have been classified as Gram-positive species, in some ways the cell wall 
organization is analogous to that of a Gram-negative bacterium (Minnikin et al., 1982).  Beyond 
the thick layer of PG is an asymmetrical lipid bilayer that can account for up to 60% of the cell 
envelope’s weight (Kremer and Besra, 2005).  Cryo-electron microscopy has shown this 
mycobacterial outer membrane to be only slightly larger than the cell membrane (Hoffmann et 
al., 2008; Zuber et al., 2008).   Its composition of mycolic acids and other extractable lipids 
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renders it highly hydrophobic and impermeable, which complicates chemotherapeutic treatments 
(Brennan and Nikaido, 1995).   The most significant difference between the mycobacterial outer 
membrane and that of Gram-negative species is that the membrane of mycobacteria is covalently 
tethered to the cell wall complex (Mahapatra et al., 2005b).  The mycolic acids that make up 
much of the membrane are esterified to the arabinogalactan chains, which are polysaccharides 
that substitute some of the MurNAc residues in the PG (McNeil et al., 1990).  The result of this 
complex structure is a cell wall with three barriers: the cell membrane, the PG complex, and the 
mycobacterial outer membrane. 
Mycobacteriophages have evolved mechanisms to address these barriers.  Indeed, they 
are not only a barrier to progeny phage egress, but also to phage infection; mycobacteriophages 
must get their genomic DNA through these layers and into the cell.  Research from our lab 
(Marinelli, 2008; Pedulla et al., 2003; Piuri and Hatfull, 2006) has revealed several features of 
the mycobacteriophage tape measure proteins that may aid in the injection of DNA into the cell 
during infection.  Regions of many of the tape measure proteins are predicted to be hydrophobic, 
which may facilitate its insertion into the lipophilic membranes of mycobacteria, and other 
observations have noted possible changes in the nature of the bacterial cell surface upon 
expression of the Barnyard tape measure protein (Marinelli, 2008).  Even more interesting, 
several PG hydrolytic motifs have been identified in the tape measure proteins (Marinelli, 2008; 
Piuri and Hatfull, 2006).  Motif 1 shows similarity to Rpf lysozymes (Pedulla et al., 2003), and 
the Giles and Barnyard Rpf Motifs have been demonstrated to have hydrolytic activity when 
expressed into the E. coli periplasm (Marinelli, 2008).  PG hydrolytic activity has also been 
demonstrated for Motif 3-containing tape measure proteins via zymography (Piuri and Hatfull, 
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2006).  Intriguingly, the Rpf motif in the tape measure proteins of Cluster D phages shows high 
sequence similarity to the lytic domain of one of the LysA proteins. 
My research has  focused on  the same obstacles presented by  the mycobacterial 
cell wall, but from the opposite end of the phage  infection cycle.   I have characterized 
the  diverse  LysA  proteins,  which,  while  sharing  many  of  the  same  PG  hydrolytic 
activities as other phage lysins, are unique in terms of their modular organizations and 
the presence of several domains of completely unknown function.  I have also examined 
the  novel  mycobacteriophage  accessory  lysis  protein,  LysB,  and  identified  its  most 
probable  natural  substrate  in  the  mycobacterial  cell  wall  and  its  role  in 
mycobacteriophage infection. 
4.1.1 The Diversity of LysA Proteins 
Bioinformatic analyses of more than 60 mycobacteriophage LysAs (Hatfull et al., 2010) revealed 
that, similar to all other endolysins, the LysA proteins are modular, containing PG hydrolytic 
domains and predicted cell wall-binding domains.  However, these analyses also revealed an 
amazing degree of diversity and recombination within these proteins.  The variety of domains 
found in LysAs is unusually high relative to the lysins of other phages; this family of proteins 
contains 13 shared domains that are combined in various ways to form 19 unique organizations.  
Six different PG hydrolytic domains (Ami1, Ami2, GH19, GH25, M23, and TG) were identified, 
as well as three C-terminal domains (C1-3), but there were also four N-terminal domains (N1-4) 
and three domain-sized regions of unknown function.  This unusual diversity of domains may 
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reflect the large number of sequenced mycobacteriophages, relative to phages of other bacteria, 
and possibly the variable sites of their origin; the mycobacteriophages were isolated from soil 
samples taken from around the world (Hatfull et al., 2006). 
The LysA proteins have also diverged from the standard two-domain lysin structure and 
predominantly consist of three-domain architectures, in which the predicted lytic domain is in the 
center, most often preceded by one of the unknown N-terminal domains.  The second most-
commonly observed organization is a two-domain structure, which lacks any of the predicted 
lytic domains, containing only one of the four unknown N-terminal domains and one of three C-
terminal domains.  In fact, only one LysA, Barnyard gp39, showed an organization similar to 
other phage lysins with an N-terminal amidase domain and a C-terminal domain with LGFP 
binding motifs.  To date, only a few lysins of other phages have been identified that have three 
domains, and in all cases, the third domain is an extra lytic domain at the N-terminus (Navarre et 
al., 1999; O'Flaherty et al., 2005; Oshida et al., 1995; Pritchard et al., 2004).  The two-lytic 
domain organization is seen in a few LysAs (e.g. Che9d gp35, Giles gp31, Halo gp27, and 
Wildcat gp49); however, the three-domain architecture with the unknown N-terminal domain 
seems to be a hallmark of the mycobacteriophage LysAs.  The reason for this is unknown, but 
the most frequently identified LysA organizations contain both an N-terminal domain and a 
central PG hydrolytic domain, so the combination of the two may be important for function.  
However, the existence of two-domain LysAs with no predicted PG hydrolytic activity suggests 
that the unknown N-terminal domains may have lytic activity. 
The majority of the PG hydrolytic activities identified in the LysAs (amidase, 
muramidase, and peptidase) have also been observed in other phage lysins, although there may 
be some modifications to accommodate the slight differences in mycobacterial PG (Figure 5).   
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There were, however, some interesting observations related to the origins of the different 
domains.  The amidase domains were divided into two groups, Ami1 and Ami2, based on a 
complete lack of sequence similarity between the two; the Ami1 domain shows weak 
resemblance to Corynebacterium and Propionibacterium amidases, while the Ami2 domain is 
similar to mycobacterial proteins.  This suggests two separate acquisition events in the past, 
similar to what has been proposed for the acquisition of the GH19 family chitinase genes in 
purple bacteria; based on a phylogenetic analysis, the GH19 genes in purple bacteria form two 
clusters that are independently traced back to ancestral plant GH19 chitinases (Udaya Prakash et 
al., 2010).  Regardless of the dissimilarities in sequence, both groups appear to have all of the 
conserved catalytic residues, and preliminary zymography studies have shown PG hydrolytic 
activity by Bxz1 gp236 (Ami2), Che8 gp32 (Ami1), and Corndog gp69 (Ami2) (Appendix A.1).  
Two other PG hydrolytic domains, the glycoside hydrolase family 25 (GH25) and M23 family 
metallopeptidase (M23), have been identified in both phage and host PG hydrolytic proteins.   
Alignments for each of these domains show a conservation of the catalytic and other important 
residues.  However, experimental evidence for their PG hydrolytic ability has not yet been 
obtained. 
Transglycosylase (TG) activity is rarely seen in phage lysins outside of the  R lysin and 
a few other Gram-negative lysins (Bienkowska-Szewczyk et al., 1981; Briers et al., 2007).  This 
makes Hammer gp13 rather unique in its possession of a TG domain in place of the GH19 
domain found in other Cluster A phages.  Transglycosylases are muramidases, but are distinct in 
that they cleave the glycosidic bond between MurNAc and GlcNAc to form a 1,6-anhydro-
MurNAc residue (Figure 6).  Conversely, lysozome-type muramidases hydrolyze the same bond 
but produce MurNAc residues with a reducing end.  TG motifs, also referred to as Rpf motifs, 
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due to the similarity in sequence to resuscitation-promoting factors (Skeiky and Sadoff, 2006), 
are often found in the phage tape measure proteins (Marinelli, 2008; Moak and Molineux, 2000; 
Pedulla et al., 2003; Piuri and Hatfull, 2006).  Hammer gp13 is the first mycobacteriophage 
LysA identified as having a TG domain.  Mycobacteriophage Hammer is a member of the larger 
Cluster A, whose lysins consist of N1, N4, GH19, and C1 domains.  The TG domain of Hammer 
gp13 shows 71% sequence similarity with regions of the tape measure proteins of Cluster D 
phages.  This level of similarity argues for a recombination event between proteins with two 
different functions from mycobacteriophages in two different clusters. 
The N-terminal domains of LysA proteins appear to be completely novel and are thus far 
unique to phages infecting mycobacteria.  The four domains are found in different combinations 
with other domains, either with glycosidases (N1 and N4) or amidases (N2 and N3); peptidases 
are always found N-terminal to another activity, so they are not associated with any N-terminal 
domains.  In Chapter 3, I speculated on many possible functions for the N-terminal domains; 
here, I will focus on those possibilities with the most experimental support. 
There are very few two-domain LysAs, and the majority of these consist of an N1 or N4 
domain with a C1 or C3 domain, or with an unmatching C-terminal region as seen in Brujita 
gp29.   The absence of an identifiable PG hydrolase domain in these LysAs suggests that the N1 
or N4 domains may in fact be novel PG hydrolases.  Indeed, the Cluster D and Sub-cluster H1 
LysAs, as well as Brujita gp29, all possess PG-binding motifs; the sole exception is L5 gp10 
(Cluster A), which has an N4-C1 organization and is the only N4 LysA that lacks a PG 
hydrolytic domain.  The presence of a PG-binding motif implies that the activity of the LysA is 
targeted to the PG.  Indeed, some form of lytic activity has been observed for three of the LysAs 
possessing N4 domains: D29 gp10 (N4-GH19-C1), Kostya gp33 (N4-GH25-C1), and L5 gp10 
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(N4-C1).  Upon endogenous expression of these LysAs in M. smegmatis (Appendix A.3), L5 
gp10 showed the most activity, efficiently lysing all cells, followed by the slightly less effective 
D29 gp10 and the moderately lytic Kostya gp33.  However, endogenous expression of Plot gp36 
(N1-C3) and Brujita gp29 (N4-PGBD, unmatched) did not result in lysis.  D29 gp10 has shown 
some PG hydrolytic activity on zymograms (Appendix A.1), but this could be attributable to the 
GH19 domain.  An in vitro assay for PG hydrolysis by purified L5 gp10, Plot gp36, and Brujita 
gp29 would be very informative, and to date, similar studies with several LysAs have used 
zymography for this purpose (Appendix A.1).  However, a negative result would be 
uninformative, since this could result from the dissimilarities between the types of PG used in the 
assay (Micrococcus luteus and, to a lesser extent, Bacillus subtilis), the uncertainty of a 
successful renaturation, or to the fact that conditions for optimal hydrolysis are unknown. 
The N2 and N3 domains are always followed by an amidase domain, making it unlikely 
that the N2 or N3 domains themselves possess PG hydrolytic activity.  A putative role may have 
been identified for the N3 and possibly the N2 domain in the recent characterization of the 
accessory lysis protein gp1 of mycobacteriophage Ms6 (Catalao et al., 2010).  It was found that 
gp1 acts as a chaperone that binds to the Ms6 gp2 LysA and aids in its export into the periplasm 
through the sec system.  The LysA appears to become active upon membrane depolarization, 
which is similar to the SAR lysins, except that in this case, an accessory protein, rather than a 
signal peptide, mediates translocation (Xu et al., 2004).  Catalao et al. (2010) have also found 
that the N-terminal 60 amino acids are necessary and sufficient for export.  The Ms6 gp2 LysA is 
highly similar to the Fruitloop gp29 LysA (with a N3-A1-C2 orgamization), and homologs of 
Ms6 gp1 are seen in the lysis cassettes of other Cluster F1 phages, all of which encode LysAs 
containing both N2 and N3 domains.  These observations suggest the N2 and N3 domains may 
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have a role in the export of the LysA by binding gp1-like chaperones.  Experimental evidence 
may further support the idea of a non-PG hydrolytic function for N3 and possibly N2; 
zymography with purified Corndog gp69 (N3-Ami2-C2) revealed highly active degradation 
products that were discovered to have lost most of the N3 domain (Appendix A.1).  Similar 
fragments were found in zymograms with Bxz1 gp236 (N2-Ami2-C1), but the loss of the N2 
domain in this case has not been verified. 
There is significantly less diversity in the C-terminal domains of the LysAs, but this is 
not unexpected.  C1, C2, and C3 dominate the organizations found, although these groups are 
very broad; the C1 domains from two different LysA proteins could be completely unrelated as 
membership in a particular group only requires identity to at least one other member of the 
group, similar to the relationships observed in the numerous members of some phamilies (Hatfull 
et al., 2008).   The decreased variety of C-terminal domains is likley a result of evolution 
directed to bind a select set of cell wall components.  These domains must bind structures that 
are not only specific to their host, but also that cannot easily be altered in any way that would 
disrupt binding or remove the substrate altogether.  Because of this, lysins have evolved to target 
cell wall components that are essential for the organism’s growth; for example, many lysins of 
Gram-positive phages target the polysaccharide-based teichoic acids (Garcia et al., 1988; 
Giudicelli and Tomasz, 1984; Usobiaga et al., 1996).  Further, some Streptococcus phage lysins 
have evolved to bind only to choline-containing teichoic acids, which restricts their range to 
specific Streptococcus species (Hermoso et al., 2003).  While several LysAs contain a more 
widely recognized PG-binding motif in the C3 domain, the motifs identified in the C1 and C2 
domains could represent novel binding motifs that are specific to essential mycobacterial cell 
wall components.  Two likely candidates for binding substrates are the arabinogalacatan and the 
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lipoarabinomannan, two polysaccharides that are attached to the PG and cell membrane, 
respectively (Brennan and Nikaido, 1995). 
4.1.2 The Novelty of the LysB Proteins and Comparison to Other Host-Specific Lysis 
Proteins 
As discussed above, a more complex barrier to progeny phage release may necessitate additional 
lysis proteins.  The identification of lysB as a second putative lysis protein by Garcia et al. 
(2002) was originally based solely on its consistent location downstream of lysA and the 
prevalence of homologs in the majority of mycobacteriophage genomes.  A later study identified 
the Gly-X-Ser-X-Gly motif characteristic of lipolytic enzymes and showed enzymatic activity on 
lipase and esterase substrates (Gil et al., 2008).  However, this artificial activity did not explain 
LysB’s presence in the lysis cassette or identify its natural substrate.  Still, both a substrate and 
role for LysB could be hypothesized merely by looking at the mycobacterial cell wall.  A LysA 
is identifiable in all genomes, and a holin protein can be predicted in many, but these proteins 
only compromise the cell membrane and PG complex, leaving the lipid-rich mycobacterial outer 
membrane largely intact.  This outer membrane is reminiscent of that in Gram-negative bacteria, 
and the phages infecting these species are known to encode proteins – Rz/Rz1 or spanins – that 
remove this barrier by fusing it with the inner membrane (Berry et al., 2008; Summer et al., 
2007).  It would be reasonable to predict that an analogous system should exist in 
mycobacteriophage to address the mycobacterial outer membrane. 
Thus, the predicted role of LysB is to remove this final barrier to lysis, similar to the role 
of Rz/Rz1 proteins, and this has been verified experimentally.  LysB has been shown to be a 
serine esterase capable of hydrolyzing purified M. smegmatis cell wall to release mycolic acids, 
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which constitute much of the outer membrane.  The removal of this barrier greatly increases the 
efficiency of lysis, as is demonstrated by the impaired lysis and phage release observed in a 
GileslysB mutant.  However, as with the Rz/Rz1 proteins (Berry et al., 2008), LysB is not 
essential for plaque formation but merely enhances it.  This is logical, as the outer membrane is 
connected to the PG complex through the mycolylarabinogalactan, and so as LysAs degrade the 
PG, they are also weakening the attachment of the outer membrane to the cell wall and 
compromising the entire structure. 
The evolutionary advantage likely granted by LysB has resulted in its inclusion in the 
lysis cassette of 56 of the 60 published mycobacteriophage genomes; however, its absence in the 
remaining four (Che12, Myrna, Qyrzula, and Rosebush) is curious.  It is possible that these 
phages have simply not needed the additional help, perhaps due to the lack of competition by 
other phages that would select for such an advantage in quick progeny release.  Alternatively, 
these phages may infect a different host in which mycolic acids are either not present or not 
essential for growth, such as in Corynebacterium (Portevin et al., 2004).  No LysB-homologs 
have been found in the few phages characterized as infecting non-Mycobacterium bacteria that 
possess mycolic acids (Bukovska et al., 2006; Chen et al., 2008).  It is unclear whether these 
phages encode other proteins with analogous functions; no other predicted lipolytic enzymes 
have been identified.  The circumstances by which these mycobacteriophages came to be without 
a LysB may differ.  The area surrounding the lysis cassette of Che12 is syntenic with other 
Cluster A phages except for the absence of LysB, and there is no alternate protein in its place, 
suggesting that Che12 may simply have lost its lysB gene.  Rosebush and Qyrzula both possess 
an additional gene downstream of lysA that is not present in fellow Cluster B phages, all of 
which encode a LysB.  This small additional protein (178 aa) is predicted to have two 
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transmembrane domains, similar to class II holins (Wang et al., 2000); no putative holins are 
found in the lysis cassettes of the other Cluster B phages, which is in itself, a perplexing 
observation.  Lastly, in Myrna, there are two proteins, gp244 and gp245, immediately 
downstream of the LysA gene with no similarity to other mycobacteriophage proteins.  However, 
gp244 appears to share some similarity with unclassified regions in several bacterial PG 
hydrolases, so it is a good candidate for another lysis protein, perhaps replacing the role of LysB. 
We have observed that most mycobacteriophage lysis cassettes contain at least three 
proteins: a LysA endolysin, a putative holin, and a LysB protein, which has an important role in 
removing the final barrier to lysis.  However, there are many other predicted ORFs surrounding 
lysA and lysB that may play a role in mycobacteriophage lysis.  Most recently, Ms6 gp1 was 
identified as a chaperone for the Ms6 LysA protein (Catalao et al., 2010).  Although gp1 
homologs have only been identified in some phages of Sub-Cluster F1, small ORFs are found 
upstream of many lysA genes in other mycobacteriophages, while others have intergenic regions 
upstream of the lysA that may contain promoters or unrecognized ORFs.  Most 
mycobacteriophage lysis cassettes contain a LysA followed by a LysB and putative holin, all of 
which are adjacent, but several have two or three small genes intervening between the lysA and 
lysB genes, the majority of which are unique to mycobacteriophage and have no currently 
assigned function.  The variety and complexity of the mycobacteriophage lysis cassettes suggest 
that we have only just begun to understand the strategies that these phages have evolved to solve 
the problem of progeny phage release in Mycobacterium species. 
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4.2 A FUTURE FOR MYCOBACTERIOPHAGE LYSINS IN RESEARCH AND 
THERAPY? 
The research on mycobacteriophage lysins reaches beyond the objective of increasing 
understanding of mycobacteriophage lysis mechanisms.  There are several potential applications 
for mycobacteriophage lysins, both as tools for research and as therapeutics. 
4.2.1 Applications of Mycobacteriophage Lysins in Research 
Much of the recent work from our lab has taken advantage of mycobacteriophages and the 
genetic tools they provide to augment current research and clinical methods.  Several recent 
examples include the design of a mycobacterial recombineering system using gp60 and gp61 
from mycobacteriophage Che9c (van Kessel and Hatfull, 2007), the adaptation of that system to 
engineer mutations and deletions in mycobacteriophages (Marinelli et al., 2008), and the creation 
of a fluorescently labeled mycobacteriophage for detection of M. tuberculosis in clinical samples 
and for the assessment of antibiotic sensitivities (Piuri et al., 2009).  The mycobacteriophage 
lysins have the potential to aid in cell wall studies by selectively hydrolyzing certain fragments.  
For example, mycolic acids are currently removed from purified mAGP by harsh alkaline 
hydrolysis with tetrabutyl ammonium hydroxide overnight at 100oC (Parish and Stoker, 1998); 
LysB is capable of hydrolyzing mycolic acids at a much faster rate at room temperature in a 
basic buffer.  LysA proteins can also be employed to selectively hydrolyze portions of the PG to 
isolate specific fractions for further study.  Purified mAGP – or AGP if the mycolic acids are 
removed by LysB – could be incubated with an amidase LysA such as Bxz1 gp236 or Corndog 
gp69, both of which have demonstrated PG hydrolytic activity (Appendix A.1), in order to 
 216 
separate the glycan strands from the peptide cross-links, which could then be isolated and 
analyzed separately. 
Another interesting application may be derived from the recently observed, and as yet not 
understood, ability of L5 gp10 to rapidly lyse M. smegmatis cells when expressed endogenously.  
Currently L5 gp10 is on the pLAM12-derived plasmid pKMC11 under the control of an 
acetamidase promoter, which is well-repressed in the absence of acetamide in M. smegmatis.  
However, when induced with 0.2% acetamide, a log-phase culture begins to lyse after 2 hours 
and is nearly completely lysed within 1-2 hours of induction (Appendix A.3), similar to the lysis 
observed during a phage infection.  Interestingly, this occurs in the absence of a holin, or any 
other apparent mechanism for transport across the cytoplasmic membrane.  Currently 
mycobacteria can be sonicated or put through a French pressure cell press in order to rupture the 
cells and gain access to intracellular materials, but these methods can be inadequate in breaking 
the strong cell walls or separating clumped bacteria.  Mycobacteria with L5 gp10 on a plasmid or 
integrated into the genome can be efficiently lysed on command by the addition of 0.2% 
acetamide.  In fact, while most proteins cloned into pLAM12 require induction in succinate 
media to prevent repression of the acetamide promoter by the ADC present in normal 
mycobacterial media, induced L5 gp10 is capable of lysing the culture even in the presence of 
ADC (data not shown).  However, since the mechanism of lysis by L5 gp10 and any other effects 
on the cell are not yet fully understood, this method should be used with caution, although this is 
another interesting potential future area of investigation. 
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4.2.2 Mycobacteriophage Lysins as Anti-mycobacterial Agents 
Tuberculosis (TB), caused by M. tuberculosis, is the number one cause of death due to an 
infectious agent; more than 1.3 million deaths were reported in 2008 (W.H.O., 2009).  The 
bacterium is present in more than one-third of the world’s population, although only 5-10% of 
those who are infected with M. tuberculosis develop active TB, while the remaining 90-95% 
maintain an asymptomatic latent infection (W.H.O., 2010).  However, these numbers do not 
account for people co-infected with human immunodeficiency virus (HIV).  TB is the leading 
cause of death among HIV-positive individuals, whose immune systems weaken until the 
bacterium can no longer be suppressed (W.H.O., 2010).  Currently the World Health 
Organization (WHO) is conducting a program focused in Sub-Saharan Africa called The Global 
Plan to Stop TB, in an effort to reduce the occurrence of TB and curb the development of drug-
resistant M. tuberculosis (W.H.O., 2009).   The strategy centers on providing all populations with 
access to quality health care and TB treatments, as well as promoting research into new 
diagnostic methods, drugs, and vaccines. 
TB is primarily a pulmonary disease; aerosolized M. tuberculosis particles are inhaled 
and multiply, eventually activating the immune system, which sends macrophages to the site of 
infection (Tripathi et al., 2005).  Many bacteria are eliminated by the macrophages, but others 
survive phagocytosis and replicate within the macrophages.  As cells die, more macrophages 
aggregate around the site to suppress the infection.  This results in the formation of a granuloma, 
a collection of macrophages and other immune cells that mediate containment of the 
mycobacteria (Saunders and Cooper, 2000).  The mycobacteria may ultimately form a caseating 
granuloma in which they lie dormant within necrotic tissue in the center of the granuloma.  This 
is the basis for a latent infection and the reason that 6 to 9 months of antibiotic therapy is needed 
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to eradicate these hard to reach dormant or persister cells (Connolly et al., 2007).  The 
granulomas are not absolute in their containment of the bacterium, and as a result, bacteria-laced 
caseous material can be expelled from the lungs during coughing (Ducati et al., 2006), thereby 
disseminating M. tuberculosis bacteria to new hosts.  This can be especially problematic in 
crowded populations (Tripathi et al., 2005). 
Current methods for the control of TB focus on vaccination and chemotherapeutic 
treatment.  The Bacilli Calmette-Guerin (BCG) vaccine is currently used, but its efficacy at 
preventing pulmonary TB varies, especially in adults (Tripathi et al., 2005).  Much research is 
currently being conducted to improve the BCG vaccine and develop new vaccines (Skeiky and 
Sadoff, 2006).  Currently, most TB infections are treated with antibiotics, primarily rifampicin 
and isoniazid.  Rifampicin interacts with the  subunit of the prokaryotic RNA polymerase, and 
isoniazid inhibits mycolic acid synthesis, leading to rapid lysis of mycobacteria (Di Perri and 
Bonora, 2004).  These are considered first-line drugs, and resistance to both defines multidrug-
resistant TB (MDR-TB) (Telenti and Iseman, 2000).  Resistance requires extending treatment or 
proceeding to second- and third-line drugs, which are increasingly toxic to humans.  A few years 
ago, the Centers for Disease Control defined a new group, the extensively drug-resistant TB 
(XDR-TB), which are resistant to isoniazid, rifampicin, and at least three of the six classes of 
second-line drugs (CDC, 2009). 
The spread of antibiotic resistance, the general phenotypic resistance of latent M. 
tuberculosis, and the insufficiency of current vaccines make the need for novel treatment options 
for TB all the more pressing.  Given the success of lysins in treating other diseases in animal 
models of infection (Borysowski et al., 2006; Fischetti, 2008; Hermoso et al., 2007), 
mycobacteriophage lysins should also be investigated as possible therapeutic agents.  While new 
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chemotherapeutics and drug cocktails are being developed, the threat of antibiotic resistance is 
ever-present, and, as noted in Chapter 1, lysins have many advantages over antibiotics.  Foremost 
of these advantages is the inability of bacteria to develop resistance to lysins.  While antibiotics 
bind to a single protein that is capable of mutation to prevent the binding, lysins target a complex 
structure – the cell wall – that is the result of over 20 enzymes, and thus far no attempts to 
generate resistance have been successful (Loeffler et al., 2001) making mutation to prevent its 
degradation by lysins nearly impossible.  However, not all resistance to antimicrobial treatments 
is due to genetic mutations; phenotypic changes in bacteria, such as the formation of a biofilm or 
entry into a non-replicating state, also increase resistance to treatment by antibiotics and likely 
lysins as well (Russell, 2001).    
In addition, lysins are a more focused tool than some antibiotics.  That is, although they 
target the PG found in all bacteria, lysins show a high degree of specificity, a result of their cell 
wall-binding domains that bind unique molecules on the cell surface.  In contrast, the spectrum 
of antibiotics varies; while some are targeted – isoniazid, for example, is very specific to 
mycobacteria, since it targets InhA, an enzyme in the biosynthesis pathway of mycolic acids 
(Quemard et al., 1995) – others function more broadly.  Rifampicin, for example, is most often 
used to treat Mycobacterium infections, but it also affects other Gram-positive bacteria like 
Staphylococcus aureus (Wehrli, 1983).  Moreover, use of antibiotics, as with many small 
compounds, poses the risk of drug interactions, allergic responses, and non-specific interactions.  
For example, many people are allergic to penicillin (Solensky, 2003), and the antibiotic 
chloramphenicol targets the 50S ribosomal subunit to inhibit protein synthesis in Gram-negative 
and Gram-positive bacteria (Weber and DeMoss, 1969), but it can also inhibit protein synthesis 
in human mitochondria (Yunis et al., 1970).   As substantially larger proteins that target 
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structures not found in eukaryotes, the risk of side effects for lysins is considerably lower, and 
indeed few adverse effects have been observed (Fischetti, 2008). 
Additionally, the effectiveness of lysins is less influenced by the growth stage of the 
bacteria.  Many antibiotics, especially those targeting cell wall synthesis, require the bacteria to 
be actively replicating to be effective, since stationary phase cells are not dividing and therefore 
are not synthesizing new cell wall material (Gilbert et al., 1990).  Lysins do not require active 
cell growth to hydrolyze the PG, although alterations in the PG in different growth phases, such 
as increased cross-linking, can affect the activity of a lysin (Vollmer et al., 2008a). 
Finally, more phage genomes are constantly being sequenced, ever expanding the genetic 
repertoire from which one can find new lytic genes, including traditional endolysins, new lysins 
such as LysB, and other antimicrobial proteins.  Due to the modular nature of endolysins, an 
endless number of chimeric proteins can also be engineered in order to create a lysin with the 
optimal level of activity and specificity.  These artificially-generated anti-bacterial proteins could 
also be altered to contain signal peptides or localization sequences and targeting domains, or to 
have different biophysical properties such as an altered overall charge or hydrophobicity.   Small 
molecule compounds are less malleable, with more limitations on the possible alterations in 
structure. 
Despite the advantages of lysins discussed above, many of which could apply to 
mycobacteriophage lysins, there are still factors that must be considered for every potential lysin-
based therapeutic, such as the possibility of the protein eliciting an immune response, being 
inactivated in vivo, or releasing toxic cell wall or cytosolic compounds upon cell lysis.  
Moreover, there are several additional considerations particular to treatment of TB, and in these 
circumstances, antibiotics have several key advantages over lysins.   Previous lysin studies have 
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focused on treating diseases with bacteria that are relatively exposed and thus accessible to lysins 
– either on mucosal surfaces (Fischetti, 2003) or in septic models (Rashel et al., 2007).  
However, much of the M. tuberculosis bacteria reside in masses of necrotic tissue encased by 
macrophages, i.e. granulomas.  This is not as much of a problem for antibiotics, but it will likely 
present a barrier to larger proteins. 
Not only have lysin therapies focused on extracellular bacteria, but additionally, so far 
only Gram-positive pathogens have been successfully treated (Borysowski et al., 2006; Hermoso 
et al., 2007; Loessner, 2005).  While technically Mycobacterium species are Gram-positive 
bacteria that lack a traditional outer membrane and contain a relatively thick layer of PG, they 
also have a unique outer membrane structure that, in some ways, is analogous to the outer 
membrane of Gram-negative species.  For a small molecule compound with the proper 
physiochemical properties, diffusing past these barriers and into the cell is not a problem.  The 
mycobacterial outer membrane is highly impermeable and hydrophobic, but the anti-
mycobacterial antibiotics rifampicin and isoniazid are both moderately lipophilic and thus 
capable of passing into the cell (Tripathi et al., 2005).  Having evolved to lyse the cell from 
within during phage progeny release, the substrates of both LysA and LysB are on the opposite 
side of the mycobacterial outer membrane, and the passage of large proteins through a densely 
packed lipid membrane is problematic. 
Thus the immediate problem with any treatment of TB using mycobacteriophage lysins is 
access, both to the cell through the granuloma and then to the substrate underneath the 
membrane.  However, the latter problem may already be solved – by the mycobacteriophage tape 
measure protein.  Phages need to effectively inject their DNA into the cell, which requires the 
insertion of the phage tail through the cell envelope, even one as complex as that of 
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Mycobacterium.  An analysis of the mycobacteriophage tape measure proteins revealed several 
features consistent with this objective (Marinelli, 2008; Pedulla et al., 2003; Piuri and Hatfull, 
2006).  Despite their enormous diversity, mycobacteriophage tape measure proteins have a 
characteristic amino acid composition, which in some ways (e.g. a high Ala-Gly content) 
resembles that of eukaryotic viral proteins involved in membrane fusion and penetration (Del 
Angel et al., 2002).  Tape measures are also predicted to possess largely -helical secondary 
structures, and many are predicted to contain transmembrane domains, which would better 
enable passage through the outer membrane (Marinelli, 2008).  Additionally, there are several 
tape measure-associated PG hydrolytic motifs, some of which have demonstrated hydrolytic 
activity (Marinelli, 2008; Piuri and Hatfull, 2006).  Of special interest is the Rpf Motif (Pedulla 
et al., 2003), which is similar to resuscitation promoting factors, signaling proteins that have 
been shown to stimulate the growth of dormant bacteria, likely through cleavage of inert PG on 
the surface of non-growing cells and/or at the septum (Kana and Mizrahi, 2010; Keep et al., 
2006; Kell and Young, 2000).  The presence of either this motif or Motif 3, a putative peptidase, 
appears to enhance the infection of stationary phase cells (Marinelli, 2008; Piuri and Hatfull, 
2006), which may be due to localized PG hydrolysis and/or to a stimulatory effect on cell 
growth. 
Exogenous applications of several purified LysAs and the D29 LysB to a freshly 
inoculated culture of M. smegmatis did result in some inhibition of growth, especially by the 
LysB (Appendix A.3), although whether this was due to a bactericidal or bacteriostatic 
mechanism is unknown.  However, direct addition of purified LysA or LysB protein to grown 
cultures of M. smegmatis showed no effect (data not shown).  If the reason for this lack of lysis is 
an inability to access the substrates, mycobacteriophage tape measure proteins may be able to 
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remedy this situation.  While the tape measure proteins can have their own PG hydrolytic 
activity, naturally it is not sufficient to lyse the cell, since lysis prior to phage replication would 
not be evolutionarily advantageous.  However, they are theoretically capable of penetrating the 
outer membrane to reach the PG.  Therefore, adding purified tape measure protein in addition to 
LysA and/or LysB protein could create an effective cocktail that can lyse mycobacterial cells 
exogenously.  Another possibility is the engineering of recombinant lysins that possess specific 
regions of the tape measure protein important for passing through the outer membrane that would 
then deliver catalytically active domains from LysA and/or LysB proteins to their respective 
substrates.  There is also the potential for synergistic killing of mycobacteria by combining lysin 
treatment with antibiotics.  In this scenario, including the Rpf motif of the tape measure (or other 
motifs that function similarly) could prove beneficial.  Dormant M. tuberculosis are more 
resistant to antibiotics, especially those that rely on active cell growth.  These motifs could serve 
to stimulate growth of the cells, while exogenously-applied lysins could make the cell more 
permeable to all compounds, thus enhancing the effects of antibiotic treatments. 
While this theoretical therapeutic strategy addresses the problem of allowing lysins 
access to their substrates on the other side of the outer membrane, it still offers no solution for 
the problem of getting through the granuloma to the true persister cells.  Therefore, 
mycobacteriophage lysins may not be capable of directly treating tuberculosis.  However, M. 
tuberculosis is transmitted by coughing or sneezing, which expels aerosolized caseous material 
containing the bacteria.  Along with its ability to cause a latent infection, the ease of 
dissemination of M. tuberculosis – especially in densely populated cities – is one of the reasons 
that it is so difficult to eradicate.  It is estimated that, if not treated, an individual with active TB 
can infect 10-15 people each year (WHO, 2010).  Preventing the transmission of M. tuberculosis 
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is one step of the epidemic that mycobacteriophage lysins could address; by administering lysins 
directly into the lungs of infected individuals, exposed mycobacteria that might have been spread 
to others could be killed.  Naturally, such an approach would face different obstacles such as the 
mucosal barriers and secreted proteases in the lungs (Sheehan et al., 2006).  While this would not 
cure the individual of TB and may not fully prevent transmission, a significant reduction in risk 
of transmission, especially in cities or health care settings, could go far in fighting TB. 
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5.0  MATERIALS AND METHODS 
5.1 BACTERIAL STRAINS AND MEDIA 
5.1.1 Mycobacterium smegmatis 
M. smegmatis mc2155, a high efficiency transformation strain (Snapper et al., 1990) was grown 
in 7H9 broth (Difco) supplemented with 10% albumin dextrose complex (ADC), 0.2% glycerol 
and 0.05% Tween-80 and on 7H10 agar (Difco) supplemented with 10% ADC and 0.5% 
glycerol.  Unless stated otherwise, the antibiotics carbenicillin (CB, 50 μg/ml) and 
cyclohexamide (CHX, 10 μg/ml) were included.  When required, kanamycin (KAN) was added 
to a concentration of 20 μg/ml.  For phage infections, 1 mM CaCl2 was added and Tween-80 was 
omitted.  During inductions using pLAM12-derived plasmids, ADC was replaced with 0.2% 
succinate and acetamide was added to a final concentration of 0.2% for induced samples.  
Growth inhibition assays used biofilm minimal media (see 5.9.6).  Strains were stored in 20% 
glycerol at -80oC. 
5.1.2 Escherichia coli 
E. coli strains were grown in Luria broth (LB) or on LB agar (Difco) supplemented as needed 
with CB (50 μg/ml) and KAN (20 μg/ml).  High transformation efficiency GC5 (Gene Choice, 
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Inc.) or NEB5alpha (New England Biolabs) competent cells were used to transform ligation 
reactions, and plasmids were propagated in these cells or DH5 (Sambrook and Maniatis, 1989). 
BL21(DE3) cells (Novagen) were used for protein over-expression from pET21a-derived 
plasmids.  Strains were stored in 20% glycerol at -80oC. 
5.2 GENERAL CLONING AND DNA MANIPULATIONS 
5.2.1 Plasmids 
Table 4. Plasmids cloned by others 
Cb, carbenicillin 
Kan, kanamycin 
OriE, E. coli origin of replication 
OriM, Mycobacterium origin of replication 
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Table 5. Plasmids cloned by KP 
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(Table 6 Continued) 
 
Cb, carbenicillin 
Kan, kanamycin 
OriE, E. coli origin of replication 
OriM, Mycobacterium origin of replication 
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5.2.2 Primers and Oligonucleotides 
Table 6. Cloning primers 
 
 
FCP, forward cloning primer 
RCP, reverse cloning primer 
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(Table 7 Continued) 
 
 
FCP, forward cloning primer 
RCP, reverse cloning primer 
FSDMP, forward site-directed mutagenesis primer 
RSDMP, reverse site-directed mutagenesis primer 
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(Table 7 Continued) 
 
 
FCP, forward cloning primer 
RCP, reverse cloning primer 
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Table 7. Sequencing and verification primers 
 
FSP, forward sequencing primer 
RSP, reverse sequencing primer 
 233 
 
Table 8. Recombineering primers 
 
DADA, deletion amplification detection assay primer 
DO, deletion oligo 
FDP, forward diagnostic primer 
RDP, reverse diagnostic primer 
FEP, forward extender primer 
REP, reverse extender primer 
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5.2.3 General Cloning Procedures 
Cloning of plasmids used DNA inserts generated by PCR of genomic DNA or a parental insert.  
PCR reactions were cleaned and concentrated using the Qiaquick PCR purification kit or Qiagen 
gel extraction kit.  DNA inserts and vector were digested with restriction enzymes (NEB) in 20-
30 μl volumes and incubated at the required temperature for approximately 3 hr.  Restriction 
enzymes were heat-killed and 1 μl of calf intestinal phosphatase (NEB) added to the vector and 
incubated at 37oC for 1 hr to remove the 5’ phosphate and prevent re-ligation of any partially-
digested vector.  Digestion products were gel-purified with the Qiagen kit and quantified using 
an ND-1000 Spectrophotometer nanodrop. 
5.2.3.1 Ligation and Transformation 
Ligations were performed with Fast-link DNA ligase (Epicentre) in 15 μl reactions containing 1 
μl ligase, 1.5 μl ligation buffer and 1.5 μl ATP that were incubated at room temperature for 1 hr, 
followed by heat-killing by incubation at 75oC for 20 min.  Ligation reactions were transformed 
into GC5 or NEB5 high transformation efficiency chemically-competent cells, or in some 
instances XL-1 Blue electrocompetent E. coli cells.  Cells were thawed on ice and 5 μl of ligation 
reaction were added to 50 μl of cells and incubated on ice for 20 min.   
Transformation into E. coli  
Chemically-competent E. coli were transformed by heat-shocking for 30 sec at 42oC.  
Transformation into electrocompetent E. coli was done using an electroporator set to 2.5 kV, 25 
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uF, and 200 .  Following transformation, 450 μl of TSB was added and cells were incubated at 
37oC for 30-60 min.  Recovered transformations were then plated on selective media. 
Transformation into M. smegmatis 
Electrocompetent M. smegmatis mc2155 cells were made as previously described (Bibb and 
Hatfull, 2002).  Briefly, cells were grown to an OD600 between 0.8 – 1.0 and then rested on ice 
for 30 min to 2 hr.  Cells were then washed repeatedly with ice-cold 10% glycerol in shrinking 
volumes down to between 1/25 – 1/50 of the original culture volume.  Cells were aliquoted, 
frozen on dry ice, and stored at -80oC. 
5.2.3.2 Sequencing 
Sequencing was done through GeneWiz, Inc. using approximately 500-800 ng of plasmid DNA 
and 8 pmol of a primer that was 100-200 bp upstream or downstream of the region to be 
sequenced. 
5.2.4 PCR 
5.2.4.1 Primer Design 
Cloning primers were designed to be between 25 – 35 nt in length with a melting temperature 
around 62oC.  Each has 18-25 bp homology flanking the PCR target and, if required, a restriction 
enzyme sequence preceded by 8 nucleotides intended to aid in restriction endonuclease digestion 
by enzymes requiring a significant number of nucleotides to either side of the cleavage site.  The 
8 nucleotides were modified to obtain the desired melting temperature.   Sequencing primers 
were designed to have sequence homology along the full length and were 23 – 30 nt in length 
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with melting temperatures around 62oC.  Specific primers for recombineering or Deletion 
Amplification Detection Assay (DADA) PCR are described below.  Primers and other 
oligonucleotides were purchased from Integrated DNA Technologies (IDT) and resuspended 
with dH2O to a concentration of 100 μM (stock solution) and diluted with dH2O to 10 μM 
(working solution) unless otherwise specified.  All were stored at -20oC.   
5.2.4.2 Standard and Diagnostic PCR 
PCR for the generation of cloning inserts and for the detection of a DNA fragment used the same 
protocol.  PCR reactions were performed using 1U of Pfu polymerase (Stratagene) with 1X Pfu 
Buffer, 5% DMSO, 0.2 mM dNTPs, 0.5 μM primers, and varying concentrations of DNA 
template.  The thermocycler conditions were 94oC for 5 min, 25x (94oC for 30 sec, varying 
annealing temperature for 30 sec, 72oC for 1 min/kb of desired product), 72oC for 7 min, and 
cooling at 4oC. 
5.2.4.3 Colony and Plaque PCR 
Colony PCR was performed as stated for the standard PCR except that the template was obtained 
by picking a single colony into 100 μl of dH2O and boiling for 5 min, and 5 μl was used in the 
reaction.  Plaque PCR was similarly performed except that the plaque was picked into 100 μl 
phage buffer and did not require boiling. 
5.2.4.4 DADA-PCR 
Deletion Amplification Detection Assay (DADA) PCR (Marinelli et al., 2008) used primers with 
homology to the region adjacent to the deletion, but the final 3’ base matched the sequence of the 
deletion mutant and not the wildtype, thus preferentially amplifying the mutant.  DADA-PCR 
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was performed as described for standard PCR except for the use of 1 μl of Platinum Taq High-
Fidelity DNA polymerase and the addition of 2 mM MgSO4. 
5.2.4.5 Site-directed mutagenesis 
The QuikChange XL site-directed mutagenesis kit (Stratagene) was used according to 
manufacturer’s instructions.  Briefly, the plasmid target was amplified via PCR with Pfu Turbo 
using PAGE-purified primers containing the mutation.  The PCR reaction was digested with Dpn 
I to degrade template plasmid and then transformed into GC5 E. coli cells. 
5.3 PROTEIN EXPRESSION AND PURIFICATION 
Escherichia coli BL21(DE3) cells carrying the different lysA or lysB genes cloned into pET21a 
were grown to OD600 between 0.4 and 0.6 at 37oC in LB containing carbenicillin  (50 μg/ml), 
followed by induction with 1 mM IPTG for 4 h at 30oC.  Cells were pelleted and resuspended in 
10 ml TWEB (50 mM Tris-HCl pH 8.0, 300 mM NaCl) per 500 ml original culture volume and 
then frozen at -80oC.  Pellets were thawed, sonicated 6x for 30s bursts on ice, and pelleted by 
centrifugation at 12,500 rpm for 25 min at 4oC.  The clarified lysate was added to 3 bed-volumes 
(BV) per original 500 ml culture of TALON Co2+ resin (Clonetech) pre-equilibrated with TWEB 
and rocked at 4oC for 1 h.  The resin was washed sequentially by rocking for 10 min at 4oC with 
10 BV each of TWEB (2x), TWEB with 10 mM imidazole (1x), and TWEB with 20 mM 
imidazole (2x).  The resin was allowed to settle in the column and bound protein was eluted with 
five BV of 120 mM imidazole in TWEB.  Samples of each elution were analyzed on an SDS 
PAGE gel and factions containing a significant amount of protein were concentrated using 
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Vivaspin concentration columns (molecular weight cut-off 10 kDa; Sartorius) followed by 
dialysis against storage buffer (50 mM Tris pH 8.0, 50 mM NaCl, 50% glycerol) and stored at -
20°C.  Concentrations were determined using the ND-1000 Spectrophotometer nanodrop and 
adjusted based on the extinction coefficient of each protein sequence as calculated by ProtParam 
(ExPasy). 
5.4 PHAGE MANIPULATIONS 
5.4.1 Lysate production and titering 
Serially-diluted phage was added to 300 μl of a saturated culture of M. smegmatis mc2155 that 
contained 1 mM CaCl2 and no Tween.  Cells were infected at room temperature standing for 30 
minutes for adsorption and then added to 1.2 ml 7H9/ADC/CaCl2 and 1.5 ml MBTA and poured 
as top agar lawn onto a 7H10 plate.  After incubation at 37oC, plates with a web-like pattern of 
infection were flooded with 5 ml of phage buffer and placed at 37oC for 30 min.  The lysate was 
removed and cellular and other debris pelleted by centrifugation at 5000 rpm for 5 min.  The 
remaining lysate was filtered (0.22 μm filters), titered, and stored at 4oC. 
The titer of the lysate or other samples was determined by spotting serially diluted 
samples on M. smegmatis lawns.  A top agar lawn was created by adding 300 μl of a saturated 
culture of M. smegmatis mc2155 to 1.5 ml 7H9/ADC/CaCl2 and 1.5 ml MBTA and pouring the 
mixture onto a 7H10 plate with appropriate antibiotics.  Phage solutions were serially diluted 
with phage buffer and 5 or 10 μl amounts were spotted onto the M. smegmatis lawn.  The plates 
were incubated face-up at 37oC. 
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5.4.2 Single-step infections 
The intent of the single-step infection for analysis of lysis defects required the simultaneous 
infection of all cells in a culture to create a synchronized infection.  A calculated m.o.i. (usually 
10) was added to a culture of log-phage M. smegmatis mc2155 cells (OD600 between 0.3 – 0.8) 
and allowed to adsorb at room temperature for 30 min.  If necessary, viable phages remaining in 
the media were inactivated by the addition of 10 mM virucide (ferrous ammonium sulfate) for 5 
min at room temperature (McNerney et al., 1998), followed by gently pelleting the cells at 5000 
rpm for 5 min and resuspending in fresh media.  Infected cultures were then incubated shaking at 
37oC while measurements were taken. 
5.4.3 DNA Isolation 
Phage genomic DNA was isolated as previously described (Sarkis and Hatfull, 1998).  Briefly, 
high-titer dialyzed phage was extracted with equal volumes of buffer-equilibrated phenol to 
remove protein.  The aqueous phase was removed and repeatedly extracted with the phenol while 
the phenolic phases were back-extracted with TE (Tris-EDTA) buffer to increase the yield.  
Once the interface containing the protein was no longer visible, the final extraction used 
phenol:chloroform:isoamyl alcohol (25:24:1) followed by an additional extraction with 
chloroform.  The DNA was ethanol-precipitated with 95% ethanol and pelleted at 13,500 x g for 
30 min.  After a final wash with 70% ethanol, the pellet was air-dried and then resuspended in 
TE. 
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5.5 BACTERIOPHAGE RECOMBINEERING 
5.5.1 Deletion Mutant Construction 
The phage deletion mutant was constructed as described previously (Marinelli et al., 2008).  The 
200 bp dsDNA substrate was generated using a PAGE-purified 100 nt deletion oligo (IDT DNA) 
with 50 bp of homology upstream and downstream of the deletion site, which was then expanded 
by PCR using two PAGE-purified 75 nt extender primers.  Each extender primer was designed 
with 25 nt of homology to either end of the 100 nt deletion oligo and a further 50 nt homology 
upstream or downstream of the deletion oligo region.  The 200 bp deletion substrate was verified 
on an agarose gel and cleaned with the QIAquick PCR purification kit (Qiagen). 
5.5.2 Competent cell preparation 
Electrocompetent recombineering cells were made with M. smegmatis mc2155:pJV53 cells.  The 
cells were grown in an inducing media (7H9, 0.2% succinate, Kan, and Tween) to an OD600  
between 0.4 – 0.6 and then induced with 0.2% acetamide for 3 hr with shaking at 37oC.  After 
induction, the competent cells were prepared as described above (1.2.3.2). 
5.5.3 Transformation and isolation of mutant phage 
Purified phage DNA (350 ng) was co-electroporated with 200 ng of the 200 bp substrate into 
induced electrocompetent M. smegmatis mc2155 pJV53 cells, recovered at 37°C for 2 hr in 7H9 
with ADC and Tween and plated on top agar lawns with M. smegmatis mc2155.  Individual 
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recovered plaques were picked into 100 μl phage buffer and analyzed by DADA-PCR (Marinelli 
et al., 2008) using 1 μl sample.  Primary plaques containing both wild-type and mutant alleles 
were diluted and plated with 300 μl of M. smegmatis mc2155 cells.  To test for viability of the 
mutant, lysates from plates containing approximately 600 plaques were harvested and tested by 
diagnostic PCR.  Individual plaques from the secondary plating were picked and also tested with 
diagnostic PCR.  A mutant derivative was plaque purified and the deletion confirmed by DNA 
sequencing (GENEWIZ). 
5.6 IN VITRO ASSAYS 
5.6.1 Zymography 
Zymograms were performed as described previously (Piuri and Hatfull, 2006) by incorporation 
of 0.2% lyophilized Micrococcus luteus cells as a source of peptidoglycan into the 
polyacrylamide gel matrix.  After separation at 200V, the gel was rinsed with dH2O for 15 min 
and then renatured overnight at 37°C in renaturation buffer (25 mM Tris pH 7.5, 1% Triton X-
100 and 0.1 mM ZnSO4), stained with 0.5% methylene blue with 0.01% KOH and destained 
with dH2O. 
5.6.2 p-Nitrophenol Ester Assay 
Enzymatic assays for lipolytic activity were adapted from those described previously (Gilham 
and Lehner, 2005).  pNPX substrates were purchased from Sigma and Spectrum (X represents 
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the carbon chain length: A, acetate (1 carbon); R, propionate (3); B, butyrate (4); V, valerate (5); 
O, octoanate (8); C, caprate (10); L, laurate (12); M, myristate (14); P, palmitate (16).  The 
compounds were diluted or dissolved into pure dichloromethane at a final concentration of 250 
mM or 100 mM based on solubility requirements and stored at -20oC.  Immediately prior to the 
assay, pNPX solutions were diluted into 2X pNP buffer; at higher volumes or concentrations, the 
dichloromethane interacted with the Triton X-100 in pNP buffer to form a white precipitate that 
disappeared upon further dilutions.  1 ml of pNPX substrates (1 mM) (Sigma) in 1X PNP buffer 
was incubated with 1 μg of D29 LysB, D29 LysB S82A, lipase (Pseudomonas fluorescens, 
Sigma), or 5 μl of a mock purified sample (derived from E. coli BL21(DE3) cells containing 
pET21a) in pNP assay buffer at room temperature for 30 min.  Release of p-nitrophenol was 
determined by measuring absorbance at 420 nm (A420) using a Beckman Coulter DU 530 
Spectrophotometer.   
A standard curve was generated by measuring the A420 of different concentrations of p-
nitrophenol (1, 5, 10, 25, 50, 75, 100, 250 uM) and determining that 140.8 x Abs420 = 1 uM of 
pNP.  The reaction rate (product formed over time) was calculated as uM min-1.  Enzyme activity 
(U) was calculated by multiplying the reaction rate by the volume of the reaction to obtain 
umoles min-1.  Lastly, the specific activity was calculated as the moles of product formed per mg 
of enzyme, or umoles min-1 mg-1. 
5.6.3 mAGP Hydrolysis 
5.6.3.1 Purification of mAGP 
Mycolylarabinogalactan–peptidoglycan was isolated from M. smegmatis as described previously 
(Besra, 1998).  Briefly, M. smegmatis cells were grown, collected and washed three times in 
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phosphate buffered saline (PBS; pH 7.4), and resuspended in PBS + 2% Triton X-100 (PBSX).  
Cells were disrupted by extensive sonication, centrifuged to collect the insoluble cell wall 
fraction, resuspended in PBSX and agitated overnight at 4°C.  After centrifugation the pellet was 
resuspended in PBS + 2% SDS and incubated at 100°C for 60 min; this was done three times. 
After three rounds of extraction, the pellet was washed once each with H2O, 80% acetone in 
H2O, and acetone.  Following evaporation of the acetone, the mAGP-enriched cell wall material 
(mAGP) was resuspended in PBS + 0.1% Triton X-100 (final concentration 10 mg ml-1) and 
frozen aliquots stored at -80°C. 
5.6.3.2 Chemical and Enzymatic Hydrolysis of mAGP 
For a control sample, mAGP material was chemically hydrolyzed by addition of an equal volume 
of 15% tetrabutyl ammonium hydroxide (TBAH) to 1 mg mAGP resuspended in PBS + 0.1% 
Triton X-100 and incubated at 100°C overnight.  Enzymatic assays were performed by 
incubation of 1 mg mAGP in 100 μl with varying concentrations of protein at 37°C. TBAH- and 
enzyme-treated samples were prepared for analysis by thin-layer chromatography (TLC) by 
addition of an equal volume of dichloromethane and incubation for 15 min at room temperature.  
The lipid-rich lower dichloromethane layer was removed, extracted once with 0.25 M HCl and 
once with water, and lipids collected by evaporation. 
5.6.3.3 Thin Layer Chromatography 
Dried reaction products were resuspended in dichloromethane, spotted onto silica-aluminium 
TLC plates, and separated once by chromatography in chloroform/methanol (97:3); lipids were 
identified by spraying with 5% molybdophosphoric acid (in ethanol) and charring for 15 min at 
110°C. 
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Methyl-esterification of lipids in order to identify specific types of mycolic acids was 
performed by resuspension of enzyme reaction products in 15% TBAH, addition of an equal 
volume of dicholoromethane and 1/10 volume iodomethane.  Reactions were incubated with 
shaking at room temperature for 15 min and the lower dichloromethane layer recovered and 
extracted with HCl and water as described above.  Lipids were separated by six developments 
with 95:5 petroleum ether/ethyl ether and recognized with 5% molybdophosphoric acid and 
charring as above. 
5.7 IN VIVO ASSAYS 
5.7.1 OD Assay 
Mycobacterium smegmatis cells grown in 7H9 supplemented with ADC, carbenicillin, 
cyclohexamide and calcium were grown to log-phase, as indicated by an OD600 0.3–1.0.  Single-
step infections were set up with a starting culture OD600 of 0. 3 and m.o.i. of 10, and no virucide 
was used.  1 ml samples were removed at different times and the OD600 was measured using a 
Beckman Coulter DU 530 Spectrophotometer.  
5.7.2 ATP Release Assay 
Mycobacterium smegmatis cells were grown to log-phase as described above.  Single-step 
infections were set up with a starting culture OD600 of 0.03 and m.o.i. of 10, and no virucide was 
used. 100 μl samples were periodically taken from the infected culture.  ATP release was 
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measured by addition of 100 ml of ENLITEN rLuciferase/Luciferin reagent (Promega), and 
luminescence recorded for a 10 s interval in a Monolight 2010 luminometer.  The results were 
reported as the fold-difference in ATP-release compared to an uninfected control culture. 
5.7.3 Total Phage and Distribution Assay 
To determine the number of phage released into the supernatant or retained in unlysed cells, M. 
smegmatis cells were grown as above and diluted to an OD600 of 0.25.  These cells were infected 
at a m.o.i. of 0.1 with adsorption for 30 min followed by inactivation of any viable phage in the 
media using virucide and then incubation with shaking at 37°C.  1 ml of samples was removed at 
different times and separated by centrifugation at 5000 rpm for 5 min into supernatant and pellet 
fractions. The pellet was resuspended in 1 ml phage buffer and sonicated.  Both pellet and 
supernatant were serially diluted in phage buffer and 5 μl samples were spotted onto top agar 
lawns containing M. smegmatis in 0.35% MBTA with 1 mM CaCl2 on 7H10 plates and 
incubated at 37oC. 
5.7.4 Growth Inhibition Assay 
The assay for growth inhibition in detergent-free media is adapted from the biofilm assays (Ojha 
et al., 2005) that use minimal media.  Media is dispensed into small petri dishes or multiple-well 
plates and inoculated 1:1000 with M. smegmatis.  An amount of purified lysin or control is added 
to the media and the plate is incubated without motion at 30oC and monitored for 5-8 days.  If 
endogenous expression is being tested, the media was supplemented with succinate instead of 
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glucose and acetamide was added to a final concentration of 0.2% to induce expression.  Images 
were taken with a Canon Powershot A530. 
5.8 BIOINFORMATIC ANALYSIS 
5.8.1 Programs 
5.8.1.1 Sequence Comparisons 
BLASTp and PSI-BLAST:  alignment of two or more protein sequences; Position-
Specific-Iterated (PSI) Blast allows the construction of a position-specific scoring matrix 
that can be used in successive alignments. (Altschul et al., 1997; Schaffer et al., 2001) 
ClustalW:  multiple sequence alignments of proteins, default settings used (Thompson et 
al., 1994) 
NJPlot:  phylogenetic tree drawing program (Perriere and Gouy, 1996) 
PHYML 3.0:  generation of maximum likelihood phylogenetic trees based on ClustalW 
multiple alignments with bootstrap and SH tests (Felsenstein, 1993; Guindon and 
Gascuel, 2003) 
5.8.1.2 Protein Analysis and Pattern Recognition 
MEME (v. 4.4.0):  Multiple Em for Motif Elicitation, pattern discovery based on  
alignment of multiple protein sequences (Bailey et al., 2006) 
ProtParam (ExPASy):  calculation of general protein properties including molecular 
weight based on primary amino acid sequences (Gasteiger et al., 2005) 
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SignalP 3.0 Server:  prediction of signal peptides based on primary amino acid 
sequences (Bendtsen et al., 2004) 
TMHMM Sever (v. 2.0):  prediction of transmembrane helices based on primary amino 
acid sequences(Krogh et al., 2001) 
5.8.1.3 Others 
CLC Bio Workbench (v. 4.1.2):  organization of sequences, cloning and primer design, 
ClustalW and other alignment programs, maximum likelihood phylogeny (neighbor 
joining), pairwise comparisons 
MyDomains (Prosite):  image creator for protein domain maps 
5.8.2 Databases 
5.8.2.1 Annotated and Classified Protein Sequences 
InterPro:  database of predictive protein signatures for classification and automatic  
annotation of proteins (Hunter et al., 2009) 
GenBank:  NIH gene and protein sequence database (Benson et al., 2009) 
Pfam:  database of annotated protein families (Finn et al., 2010) 
5.8.2.2 Enzymes 
BRENDA:  general enzyme database (Chang et al., 2009)  
CAZy:  Carbohydrate-Active enZYmes database (Henrissat and Davies, 1997) 
MEROPS:  peptidase database (Rawlings et al., 2010) 
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5.9 REAGENTS AND BUFFERS 
5.9.1 Protein purification buffers 
TEWB (Tris Elution Wash Buffer): 
50 mM Tris Hcl, 300 mM NaCl, pH 8.0  
(optionally added 10-120 mM imidazole from 1 M imidazole stock) 
Filter, store at room temperature or 4oC 
 
Dialysis/storage buffer: 
50 mM Tris HCl, pH 8.0, 50 mM NaCl, 50% glycerol 
(optionally added: 0.1 M EDTA, 0.1 mM DTT) 
Store at 4oC or -20oC 
5.9.2 SDS-PAGE  
Separating gel (10%, 10 mL for two small gels):  5 mL dH2O, 2.5 mL acrylamide:bis- 
acrylamide (29:1), 2.5 mL 4X separating buffer, 50 μl 10% ammonium persulfate (APS),  
10 μl tetramethylethylenediamine (TEMED) 
Make fresh 
 
Stacking gel (4.5%, 5 mL for two small gels):  3 mL dH2O, 1.25 mL 4X stacking  
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buffer, 0.625 mL acrylamide:bis-acrylamide (29:1), 25 μl 10% APS, 5 μl TEMED 
Make fresh 
 
4X Separating Buffer: 
1.5M Tris HCl pH 8.8, 0.4% (w/v) SDS 
Filter, store at room temperature 
 
4X Stacking Buffer: 
0.5 M Tris HCl pH 6.8, 0.4% (w/v) SDS 
Filter, store at room temperature 
 
4X Sample Buffer (40 mL): 
62.5 mM Tris HCl pH 6.8, 40% glycerol, 2% (w/v) SDS, 5% 2-mercaptoethanol, 0.2%  
(w/v) bromophenol blue 
Filter, store at room temperature 
 
Protein Gel Running Buffer: 
25 mM Tris base, 192 mM glycine, 0.035% (w/v) SDS, pH 8.3 
Store at room temperature 
 
Commassie Blue Stain: 
1.25 g Coomassie blue, 225 ml methanol, 45 ml acetic acid, dH2O to 500 ml 
Store at room temperature 
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5.9.3 Zymograms 
Zymogram Separating gel (10%, 10 mL for two small gels):  5 mL dH2O, 2.5 mL 
acrylamide:bis-acrylamide (29:1), 2.5 mL 4X Zymogram separating buffer, 0.01 g 
peptidoglycan or 0.02 g lyophilized cells, 50 μl 10% ammonium persulfate (APS), 10 μl 
tetramethylethylenediamine (TEMED) 
Make fresh. 
 
Zymogram Stacking gel (4.5%, 5 mL for two small gels):  3 mL dH2O, 1.25 mL 4X 
Zymogram stacking buffer, 0.625 mL acrylamide:bis-acrylamide (29:1), 25 μl 10% APS, 
5 μl TEMED 
Make fresh 
 
4X Zymogram Separating Buffer: 
1.5M Tris HCl pH 8.8, 0.04% (w/v) SDS 
Filter, store at room temperature 
 
4X Zymogram Stacking Buffer: 
0.5 M Tris HCl pH 6.8, 0.04% (w/v) SDS 
Filter, store at room temperature 
 
2X Sample Buffer (20 mL): 
125 mM Tris, pH 6.8, 4% SDS, 40% glycerol, 10% -ME, 0.01% bromophenol blue 
Filter, store at room temperature 
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 Renaturing Solution: 
25 mM Tris HCl, 1% Triton X-100, pH as needed 
(optionally added: 0.1 mM DTT, various cations) 
Make fresh 
 
Methylene Blue Staining Stain: 
0.25% methylene blue, 0.01% KOH 
Make fresh 
 
 
5.9.4 p-Nitrophenol Ester Assay 
pNPX Stock Solutions 
Substrates were dissolved to a final concentration of 250 mM or 100 mM in 
dichloromethane 
Store at -20oC, dilute fresh at room temperature for assay 
 
pNP Assay Buffer: 
20 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% Triton X-100 
Filter, store at room temperature 
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5.9.5 mAGP hydrolysis and Thin Layer Chromatography 
mAGP hydrolysis buffer: 
PBS pH 7.4, 0.1% Triton X-100 
Store at room temperature 
 
Chloroform : Methanol: 
97 ml chloroform, 3 ml methanol 
Make fresh 
 
Petroleum Ether : Ethyl Ether: 
95 ml petroleum ether, 5 ml ethyl ether 
Make fresh 
 
Molybdophosphoric acid spray: 
1 g molybdophosphoric acid, 20 ml 100% ethanol 
Store at room temperature 
 
5.9.6 Others 
Phage buffer: 
10 mM Tris-HCl pH 7.5,10 mM MgSO4, 68.5 mM NaCl, 1 mM CaCl2 
Filter, store at room temperature 
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 Virucide: 
10 mM ferrous ammonium sulfate in dH2O 
Make fresh 
 
Biofilm Base Minimal Media 
In 900 ml dH2O, add 13.6 g KH2PO4, 2.0 g (NH4)2SO4, adjust the pH to 7.2 with KPH 
pellets, add 0.5 mg FeSO47H2O, 0.5 g casamino acid 
Autoclave 20 min at 121 oC, store at room temperature 
 
Reconstituted Biofilm Minimal Media 
Prior to assay, reconstitute 100 ml of media: 94 ml of base media, 5 ml 40% glucose, 1 
ml CaCl2, 100 ul MgSO4 (if inducing, replace 5 ml 40% glucose with 1 ml 20% succinate 
and 4 ml dH2O and add 1 ml/100 ml 20% acetamide to induce; add 40 ul/100 ml of Kan 
if necessary) 
Use fresh, usually at 30oC 
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APPENDIX 
DEMONSTRATED LYTIC ACTIVITY & GROWTH INHIBITION OF M. SMEGMATIS 
BY MYCOBACTERIOPHAGE LYSINS 
The body of this dissertation has focused on the process of bacteriophage lysis, the mechanisms 
of cell wall degradation and host-specific substrate binding, and the complex evolution between 
phage and host.  However, much current lysin research focuses on the therapeutic potential of 
lysins in preventing and treating disease (Borysowski et al., 2006; Fischetti, 2008; Loessner, 
2005).  Extensive research has demonstrated the ability of lysins to kill the host of their phage 
with incredible speed and specificity, both in vitro and more recently in vivo using animal 
models.  In particular, lysins have proven efficacious against Streptococcus pneumoniae and 
other pathogenic streptococci, Listeria monocytogenes, Bacillus anthracis, and Staphylococcus 
aureus (Cheng et al., 2005; Djurkovic et al., 2005; Donovan et al., 2006b; Entenza et al., 2005; 
Rashel et al., 2007; Schuch et al., 2002; Turner et al., 2007).   
Development of new therapeutic agents is a long-term goal of research on 
mycobacteriophage lysins as well.  Accordingly, several individual LysA proteins were cloned 
and purified for empirical study.  The ability of these proteins to hydrolyze cell walls was tested 
using zymography (Leclerc and Asselin, 1989), and the effects of both LysA and LysB on the 
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growth of mycobacteria was studied with exogenous application of purified protein and 
endogenous expression within M. smegmatis.  The preliminary results of these experiments are 
described below. 
A.1 IN VITRO HYDROLYTIC ACTIVITY OF LYSA PROTEINS 
Five LysA proteins were cloned into the pET21a vector for IPTG-induced expression with a C-
terminal His tag.  These were Bxz1 gp236, Che8 gp32, Corndog gp69, D29 gp10, and L5 gp10 
(Figure 37).  Three of these LysAs were used because they had already been cloned for 
expression prior to my arrival.  Corndog gp69 was chosen based on its domain organization: an 
N3 domain (Bxz1 gp236 and Che8 gp32 have N2; D29 gp10 has N4); a central Ami2 domain 
similar to Bxz1 gp236 and having the same predicted activity as the Ami1 of Che8 gp32; and a 
C2 domain similar to Che8 gp32 but distinct from the C1 domains in Bxz1 gp236 and D29 gp10.  
L5 gp10 was later added because it is similar to D29 gp10, yet lacks a GH19 domain (Figure 37).  
It was thought that by comparing activities and domains through recombination the functions of 
the distinct domains could be interpreted.  However, the in vitro analysis of these proteins has 
not yet proceeded beyond an examination of their general ability to hydrolyze cell wall material 
using zymography. 
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 Figure 37. Domain organization of LysAs cloned and purified for empirical study 
 
 
 
Figure 37:  Five purified LysA proteins were used for studies of lytic activity.  Not all identified 
domains are represented; this set contains the N-terminal domains N2, N3, and N4 (pink and red 
shades); the lytic domains Ami1, Ami2, and GH19 (greens and yellow, respectively); and the C-
terminal domains C1 and C2 (purple shades). 
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A.1.1 Zymography of LysA proteins with Micrococcus luteus peptidoglycan 
Initial experiments used lyophilized Micrococcus luteus cells, which are a standard substrate for 
zymography for peptidoglycan (PG) hydrolytic activity (Leclerc and Asselin, 1989; Piuri and 
Hatfull, 2006).  The LysAs Bxz1 gp236, Che8 gp32, and Corndog gp69 showed high activity on 
the M. luteus zymogram (Figure 38).  However, there was little activity seen from D29 gp10 (not 
shown), and no activity by D29 gp12, the LysB protein (not shown).  Knowing that LysB 
proteins target the mycolyl-arabinogalactan ester bond – a substrate unique to mycobacteria and 
related genera – it is logical that no activity would be seen on the M. luteus zymogram.  The 
addition of Zn2SO4 to the renaturation buffer did not appear to have a significant effect, which 
seemed odd considering Bxz1 gp236, Che8 gp32, and Corndog gp69 are all predicted Zn2+ 
amidases.  The controls used were ovalbumin (non-hydrolytic) and lysozyme (hydrolytic), 
although the quantity of lysozyme used made the clearing difficult to discern (Figure 38, red 
arrows). 
Several interesting phenomena were observed in these zymograms, in that numerous 
other bands were visible in addition to the primary band corresponding to the protein (Figure 38).  
It is possible that these were contamination, but the bands between the proteins were not 
consistent, and they were not observed on zymograms with mock purifications of induced cells 
containing the empty pET21a vector (not shown).   
First, several bands (Figure 38, green arrows) traveled more slowly than the larger band 
or clearing that corresponds in size to the LysA.  Che8 gp32 especially had numerous bands of 
high molecular weight as seen at the top of the SDS PAGE gel, and there was activity in the 
zymogram corresponding to these bands.  The other bands seen for Corndog gp69 could also 
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correspond to dimers or other complexes, and at least one showed activity on the zymogram.  
This is not entirely unprecedented among lysins; PlyC forms a multimeric holoenzyme based on 
two lysis proteins that assemble in an 8:1 ratio (Nelson et al., 2006).  This has not been recorded 
for any other lysin, nor are the genes encoding other lysins similar in organization to that of 
PlyC; however, while the lysA genes do not resemble PlyC, this does not preclude the possibility 
of multimers.   
Second, numerous other bands were seen below the expected protein sizes, several of 
which seemed to correspond to smaller clearings on the zymogram (Figure 38, brackets).  These 
were hypothesized to be degradation fragments that retained activity; the modular nature of 
LysAs presumes short linker sequences between the domains, which are more susceptible to 
cleavage.  When comparing the amount of protein as seen on the SDS PAGE gel to the size of 
the clearing on the zymogram, several of these fragments had incredible hydrolytic activity given 
the amount.  The best example of this was seen with Corndog gp69 (Figure 39).  Two very small 
fragments around that were barely visible on SDS PAGE around 30 kDa showed levels of 
activity similar to the full-sized Corndog gp69 protein (Figure 39 A).  The larger of these bands 
was purified and sequenced by Edman degradation to determine the amino acid sequence at the 
N-terminus (Konigsberg, 1967).  The N-terminal sequence corresponded to amino acids 153-160 
of Corndog gp69 (Figure 39 B), which results in a 28 kDa, 253 aa polypeptide that has lost 
nearly its entire N-terminal, or N3, domain.  This indicates that, in these in vitro circumstances 
using M. luteus PG substrate, the N3 domain is dispensable for hydrolytic activity and may in 
fact inhibit activity.   
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 Figure 38. SDS PAGE and corresponding zymogram of three LysA proteins 
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Figure 38:  The upper gel is a standard SDS PAGE and shows all protein present in each 
sample, while the lower gel is a zymogram that has been inverted so that the clearings appear as 
dark bands.  Clearings in the zymogram indicate hydrolytic activity, and the size of the bands is 
correlated to those in the SDS PAGE gel.  It should be noted that, due to the addition of an 
enzymatic substrate, protein separation is altered in the zymogram compared to the SDS PAGE 
gel, as shown by the ladder sizes.  The red arrow indicates the lysozyme positive control.  Green 
arrows highlight protein larger than the expected protein size showing hydrolytic activity.  
Brackets highlight smaller protein fragments showing activity in the zymogram.  The table lists 
the sizes of the various proteins. 
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Figure 39. Identification of Corndog gp69 fragment with increased lytic activity 
 
 
 
Figure 39:  A. Left, SDS PAGE with increasing amounts of Corndog gp69 sample illustrating 
the minute amount of protein (red asterisk) corresponding to one of the bands of high activity 
seen in the zymogram on the right (red box).  B. Highly concentrated sample of Corndog gp69 
from which a sample was taken (red asterisk) and submitted to Edman degradation.  The control 
sequencing of the large band matched the N-terminal sequence of Corndog gp69 (blue brackets), 
while the smaller fragment corresponded to a sequence 153 aa C-terminal to the start of Corndog 
gp69 (orange brackets). 
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A.1.2 Zymography of LysA proteins with B. subtilis and M. smegmatis 
Considering the high specificity of lysins, there was some concern that the differences between 
mycobacterial PG and that of M. luteus may inhibit the activity of the LysAs.  Specifically, the 
type A2 M. luteus PG has an interpeptide bridge in its PG cross-links, and the type Al of 
mycobacteria has direct m-DAP-D-Ala cross-links (Figure 5).   Later experiments tried Bacillus 
cells or purified PG, which also have A1 PG but are less amenable to zymography.  M. 
smegmatis PG was more difficult to use as a substrate due to the small amount available, its 
uneven distribution throughout the gel, and problems retaining the methylene blue dye.  
However, preliminary results were obtained with both of these substrates alongside M. luteus 
zymograms acting as a control.   
D29 gp10 and L5 gp10 were also used in these studies.  Both proved difficult to purify; 
additional bands were occasionally seen in SDS PAGE gels, and the proteins had a consistent 
tendency to precipitate during concentration and dialysis or upon addition to other solutions, 
including buffers used for assays.  Despite these difficulties, adequate amounts of protein were 
purified to use in zymography and other studies. The following results are the accumulation of 
data from three separate zymography studies, although only one example is shown. 
All five LysA proteins were separated on both an SDS PAGE gel and zymograms 
containing M. luteus, B. subtilis, or M. smegmatis PG.  After renaturation overnight the gels were 
stained with methylene blue and destained to observe any clearings formed by hydrolysis by the 
proteins.  B. subtilis did not stain as well as M. luteus, and the M. smegmatis zymograms did not 
retain the stain well nor have strong contrast between the stain and any clearings (Figure 40).  
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Lysozyme was added as a positive control, and D29 gp12 (LysB) was used as a possible negative 
control.   
Interestingly, as shown on the SDS PAGE gel, Che8 gp32 again did not separate but 
remained at the top of the separating gel (Figure 40 A).  In addition, L5 gp10 appeared as two 
bands (Figure 40 A); these bands are approximately the correct size, but in alternate purifications 
a single band has been observed.   
Clearings were distinctly visible on the M. luteus zymogram by Bxz1 gp236, Che8 gp32, 
and Corndog gp69 (Figure 40 B).  In this instance, a Bxz1 gp236 degradation product of around 
30 kDa – which is a plausible size if Bxz1 gp236 were to lose a large portion of its N2 domain – 
was seen to have strong activity.  Also, the aggregate of Che8 gp32 at the top of the gel again 
showed activity (Figure 40 B).  Faint activity was also shown by D29 gp10 (Figure 40 B, red 
arrow), but there was no activity from either L5 gp10 or D29 gp12.  A small band around 48 kDa 
appeared in all lanes except Corndog gp69 and lysozyme (Figure 40 B); this may be a 
contaminant.  
Activity by the first three LysAs was also apparent on the B. subtilis zymogram (Figure 
40 C).  Interestingly, there did not appear to be an active degradation product for Bxz1 gp236; 
this could indicate a lack of degradation during the separation through B. subtilis PG or, more 
intriguingly, the possibility that the N2 domain is required for activity on A1-type PG.  Again, 
weak activity was shown by D29 gp10 (Figure 40, red arrow), although activity was stronger on 
other zymograms  (not shown).  Oddly, there were bands in the lanes of both L5 gp10 and D29 
gp12.  The clearing for L5 gp10 was at approximately the correct location for a protein of 32 
kDa (Figure 40 C, yellow arrow); based on size alone, the band seen for D29 gp12 (Figure 40 C, 
green arrowhead) was not likely to be the 29 kDa LysB protein.  Weak activity by L5 gp10 was 
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also seen in a second B. subtilis zymogram (not shown) but was indeterminant in a third one 
(data not shown). 
The M. smegmatis zymogram was difficult to discern due to the granular nature of the 
substrate and a gradient of staining that rendered the left half of the gel largely unreadable 
(Figure 40 D).  Difficult to see in this image were a smear of potential clearing in the lane of 
Che8 gp32 and a possible clearing in the lane of Corndog gp69, although better activity was seen 
by Bxz1 gp236 and Corndog gp29 in a later zymogram (not shown).  There did appear to be 
clearings present in the lanes of L5 gp10 (Figure 40 D, yellow arrow) and D29 gp10 (Figure 40 
D, red arrow).  The band for L5 gp10 seemed to be a little smaller in comparison to the ladder 
and to the protein seen in the SDS PAGE gel (Figure 40 A).  Still, protein separation varies in 
each zymogram, so it is plausible that this band was the L5 gp10 protein seen in the SDS PAGE.  
Since the dyeing properties of B. subtilis and M. smegmatis zymograms are uncharacterized, it is 
also possible that clearings on these gels were due to the protein excluding the dye; however, this 
was not a concern for M. luteus zymograms. 
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 Figure 40. Zymography with M. luteus, B. subtilis, and M. smegmatis substrates 
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Figure 40:  Several zymograms with different embedded substrates were run simultaneously.  
The zymogram images have been inverted so that the clearings appear as dark bands.  A.  SDS 
PAGE gel of the protein loaded, shown twice so that it can be aligned above both B and C.  B.  
M. luteus zymogram. C.  B. subtilis zymogram.  D.  M. smegmatis zymogram.  The red arrows 
point to clearings by D29 gp10, the yellow arrows point to possible clearings by L5 gp10, and 
the green arrowhead points to an unknown band in the lane of D29 gp12.  The table indicates the 
protein sizes in kDa, and ladders are found to the side of every zymogram. 
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A.1.3 Conclusions 
Several purified LysAs were shown to have PG hydrolytic activity on zymograms containing M. 
luteus cells and, to varying extents, on zymograms with B. subtilis PG or M. smegmatis PG.  The 
three LysAs with predicted amidase activity, Bxz1 gp236, Che8 gp32, and Corndog gp69, all 
showed strong activity on M. luteus and B. subtilis substrates, and possible activity on the M. 
smegmatis zymogram.  D29 gp10, a predicted GH19 lysozyme, showed weak activity on the M. 
luteus and B. subtilis substrates, but appeared more active on the M. smegmatis zymogram.  L5 
gp10 did not show any activity on M. luteus, but may have been active on B. subtilis and M. 
smegmatis zymograms.   
The results of these zymogram experiments may provide some clues to the functions of 
the N-terminal domains. When the N3 domain was lost from Corndog gp69, there was an 
increase in Corndog gp69’s hydrolytic ability on M. luteus PG (Figure 39).  A similar 
circumstance may also have occurred with Bxz1 gp236, where a smaller fragment showed 
greatly increased activity on a later M. luteus zymogram (Figure 38 B); however, in this instance 
we cannot be confident that it was the N2 domain lost, since we did not perform Edman 
degradation to identify the N-terminal sequence.  Nonetheless, this smaller band of activity was 
not seen on the B. subtilis zymogram that was run simultaneously (Figure 40 C).  This raises the 
possibility that the portion of Bxz1 gp236 that was lost is important in the hydrolysis of B. 
subtilis substrate, which varies in PG structure from M. luteus.  Therefore, the function of the N2 
and N3 domains may not be conducive to in vitro hydrolysis of M. luteus PG, but at the same 
time may not inhibit or could even enhance activity on B. subtilis PG, which is highly similar in 
composition to that of mycobacteria.  The majority of Bxz1 gp236 and Corndog gp69 was still in 
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the full-length form, which argues against proteolytic processing to create a truncated protein, 
unless this is executed by a protease not present in E. coli. These zymograms do not provide any 
overt evidence that the N2 or N3 domains alone have PG hydrolytic activity; however, the 
smaller hydrolytic bands have not been sequenced and could be fragments of the N-terminal 
domain.  The increase in activity seen upon the loss of the N3 domain of Corndog gp69 and the 
presumed loss of the N2 domain of Bxz1 gp236 is consistent with a role in protein export as was 
observed for the N-terminus of the homologous Ms6 LysA (Catalao).  It is reasonable that the 
loss of a N-terminal domain that has no function in PG hydrolysis could result in an increase in 
PG hydrolytic ability  
Considering the similarity between D29 gp10 and L5 gp10, these results may support a 
hydrolytic role for the N4 domain that is specific to A1-type PG.  The GH19 lysozyme domain 
in D29 gp10 alone would be expected to have activity on most PG types, and indeed there was 
some activity by D29 gp10 seen on all zymograms (Figure 40 B-D).  L5 gp10, on the other hand, 
lacks this domain (Figure 37) and showed no activity on M. luteus (FIG B).  However, L5 gp10 
may have been active on the A1-type PG that is shared between B. subtilis and M. smegmatis 
(Figure 40 C, D).  This could mean that the N4 domain is an uncharacterized PG hydrolase, 
which would then identify D29 gp10 and other N4-containing LysAs (Table 1) as having two 
catalytic domains.  Meanwhile, the N4 activity of L5 gp10 alone may be sufficient for the lysis 
of mycobacteria by phage L5, although this introduces the question of why the two-domain 
architecture is so common if the single N4 domain can fulfill the role of endolysin.  Mutagenesis 
studies to elucidate the mechanism of lysis by L5 gp10 have been started. 
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A.2 INHIBITION OF MYCOBACTERIAL GROWTH BY EXOGENOUS 
APPLICATION OF LYSINS 
The ability of lysins of Gram-positive-infecting phage to rapidly lyse their hosts when externally 
applied is well documented (Borysowski et al., 2006; Hermoso et al., 2007).  This is attributed to 
the exposure of the PG to the external environment (Figure 3 B).  In contrast, it has been 
significantly more difficult to effect lysis of Gram-negative cells in the same manner due to the 
presence of the outer membrane, a hydrophobic permeability barrier that prevents access to the 
underlying PG (Figure 3 A).  The mycobacterial cell wall shares characteristics of both Gram-
negative and Gram-positive cell walls: it has a thick layer of PG, but this is surrounded by a 
hydrophobic bilayer of mycolic acids and other lipid derivatives (Figure 4 A) similar to the outer 
membrane.  This waxy coating presents a formidable barrier to any enzyme trying to access the 
PG, as well as any molecule trying to gain entry to mycobacteria in general, such as antibiotics 
(Brennan and Nikaido, 1995; Karakousis et al., 2004; McNeil and Brennan, 1991).  However, 
unique to mycobacteriophage is the second lysin, LysB, which targets the mycolic acid ester 
bond.  Not only is this bond found in the mycolyl-arabinogalactan, but also many of the 
glycolipids in the mycobacterial outer membrane contain sugars esterified to mycolic acids, most 
notably trehalose dimycolate (TDM, or cord factor).  They are also important in the formation of 
biofilms, which are surface-bound communities of bacteria within a secreted extracellular matrix 
made of polysaccharides, lipids, protein, or DNA (Hall-Stoodley and Stoodley, 2005).  It has 
recently been shown that M. smegmatis encodes a cutinase-like serine esterase that acts similarly 
to LysB to liberate the mycolate from TDM (Ojha et al., 2010).  Mycobacterial biofilms are 
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composed primarily of free mycolic acids, and the hydrolysis of mycolic acids from TDM by this 
esterase is implicated in biofilm maturation in M. smegmatis and likely M.tuberculosis (Ojha et 
al., 2010).  Mycobacteria within the biofilm are drug-tolerant persisters (Ojha et al., 2008), and 
such formations may contribute to the difficulty in treating M. tuberculosis infections, which 
require 6-9 months of antibiotic treatment (Connolly et al., 2007). 
A.2.1 Addition of purified LysA and LysB to M. smegmatis 
The complex mycobacterial cell wall augmented by the formation of lipid-based biofilm 
formation presents a formidable barrier to exogenous lysis by mycobacteriophage lysins.  Still, 
while there is little hope of LysA proteins reaching the PG, there is some evidence for LysB 
activity on TDM (Ojha et al., 2010), and the external lipid-rich cell wall structures are more 
likely to contain substrates for LysB.  As a note, the addition of lysins to shaking cultures of M. 
smegmatis had no visible effect on growth (data not shown), so these experiments were 
conducted in detergent-free standing cultures similar to the assays for biofilm formation.  It was 
not investigated at this time whether the lysins had a bactericidal or bacteriostatic effect on M. 
smegmatis, and so all observations are in terms of “growth inhibition.”  Tested substances 
included lysins, other enzymes such as lysozyme and lipase, non-enzymatic proteins like bovine 
serum albumin (BSA), and enzyme storage buffer.  Growth was monitored for 5-8 days, and 
pictures were taken with a hand-held digital camera.  In addition to overall growth, formation of 
a mature biofilm (similar to negative control) was also examined. 
Figure 41 shows 5 day-old cultures to which 1, 10, or 100 µg/ml each of D29 gp10 
(D29A, Figure 41 A), D29 gp12 (D29B, Figure 41 B), or the D29 gp12 Ser82Ala mutant (S82A, 
Figure 41 C).  In addition to a negative control, one well had 50 µl of the protein storage buffer 
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added, and a second had 100 ug/ml of BSA (Figure 41 D).  D29A had very little effect on growth 
at a concentration of 1 µg/ml, but appeared to inhibit biofilm maturation at 10 µg/ml and 
inhibited the formation of a full film at 100 µg/ml (Figure 41 A).  D29B had an even stronger 
effect, inhibiting maturation at only 1 µg/ml, significantly inhibiting growth at 10 µg/ml, and 
almost completely preventing growth at 100 µg/ml (Figure 41 B).  The D29B active site mutant, 
S82A, had no obvious effect at 1 µg/ml, but seemed to impact maturation of the biofilm at higher 
concentrations (Figure 41 C).  This could indicate that enzymatic activity is not absolutely 
necessary; perhaps the binding of the substrate may be sufficient for some inhibition of 
stationary growth.  All negative controls appeared normal (Figure 41 D). 
It is possible that the proteins were being degraded by extracellular proteases or 
eliminated in some other way.  To examine this, a controlled amount of sample was carefully 
taken from the media beneath the growth at the interface every day for 7 days.  These were 
separated on an SDS PAGE gel (Figure 42).  The results showed no degradation of D29B over 
the entire time.  However, the bands for D29A, S82A, and BSA all decreased, especially after 
day 4.  It is therefore possible that the difference in the levels of inhibition was due not to the 
proteins’ activity, but to whether they remained intact throughout the experiment.  Considerable 
changes in protein expression occur over the course of biofilm growth and maturation (Ojha et 
al., 2005; Zambrano and Kolter, 2005); some protein may have been produced and secreted 
starting around day 4 or 5 that can degrade the lysins and BSA.  The sustained presence of D29B 
could be due to a resistance to degradation, or to the failure of the culture to reach the point in 
time where the degradative protein is expressed. 
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 Figure 41. Growth inhibition by D29 LysA, LysB, and LysB S82A mutant 
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Figure 41:  Biofilm pictures were taken after 5 days of growth at 30oC.  Increasing amounts of 
each protein were added, including 1 µg/ml, 10 µg/ml, and 100 µg/ml.  The negative control has 
nothing added, the storage buffer control was a solution of 50 mM Tris pH 8.0, 50 mM NaCl, 
50% glycerol, and the BSA was a non-reactive protein. 
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 Figure 42. Lysin protein present in growth media over time 
Figure 42:  Samples from the growth media with 100 µg/ml of each protein added were taken 
daily for 6 days.  The debris was pelleted and an equal amount was loaded and separated on an 
SDS PAGE gel and stained with Coomassie blue dye.   A ladder in kDa is in the center of each 
pair of gels. 
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A.2.2 Inhibitory activity of lysin combinations 
We predicted that D29A and gp12 might work synergistically to lyse bacteria since they are from 
the same mycobacteriophage.  We tested varying combinations of D29A and D29B in the growth 
inhibition assay.  Having observed the strength of the response in previous assays, the base 
amounts for D29A and D29B were 5 µg/ml and 1 µg/ml, respectively.  These amounts showed 
an inhibitory effect on M. smegmatis but were not so great as to mask any increases in efficacy 
(e.g. 10 µg/ml of D29B was sufficient to prevent most but not all growth; Figure 41 B).  The 
growth was assessed after 5 days. 
The addition of increasing amounts of D29A to 1 µg/ml D29B showed varying increases 
in growth inhibition (Figure 42 A, B).  A significant increase in inhibition and prevention of 
biofilm maturation was seen at 10 µg/ml of D29A, but the inhibition seemed to decrease from 
this peak when the concentration was increased to 25 µg/ml and 50 µg/ml (Figure 42 A).  
Additionally, 5 µg/ml of D29B was tested with 5 or 10 ug/ml of D29A (Figure 42 B).  Compared 
to 5 µg/ml of D29A alone, addition of 5 µg/ml of D29B showed a great increase in inhibition, 
and this was even higher when 10 µg/ml of D29A was added to 5 µg/ml D29B.  Unfortunately a 
control with only 5 µg/ml of D29B was not prepared, so it is difficult to say with certainty that 
the effect was truly synergistic.  In sum, there is potentially a synergistic interaction between 
D29A and D29B in growth inhibition of M. smegmatis, but it should be explored further. 
Another interaction that was tested is the combination of D29B with the active site 
mutant D29B S82A.  Increasing amounts of S82A were added to cultures with 10 µg/ml D29B 
and assessed after 7 days of growth (Figure 42 C).  Interestingly, S82A amounts of 25 µg/ml or 
more limited D29B’s inhibition of M. smegmatis growth.  When 100 µg/ml of S82A was added 
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with 10 µg/ml D29B, there was cell growth across the entire well (Figure 42 C).  However, there 
was still no maturation of the biofilm, which seems to happen in any situation where a lysin is 
added.  From these results, it appears that the addition of S82A interferes with the effect of D29B 
on the growth inhibition.  Indeed, S82A alone slightly inhibited growth, although there were still 
some signs of biofilm maturation (Figure 41 C).  S82A may have a sort of “dominant negative” 
effect in its ability to decrease the effectiveness of D29B. 
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 Figure 43. The effect of combinations of lysins on growth of M. smegmatis 
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Figure 43:  Biofilm pictures were taken after 7 days of growth at 30oC.  A. and B. Combinations 
of D29B and D29A.  The amount of D29B precedes that of D29A (e.g. D29B µg/ml : D29A 
µg/ml).  C. Increasing amounts of the D29B mutant S82A was added to cultures with 10 µg/ml 
of D29B.  The amount of D29B precedes that of S82A (e.g. D29B µg/ml : S82A µg/ml). 
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A.2.3 Lytic activity of lysins on Propionibacterium acnes 
The lytic activity of exogenously-applied lysins was also tested on Propionibacterium acnes, 
another member of the order Actinomycetales that is a Gram-positive bacteria but lacks 
mycolylarabinogalactan or the complex hydrophobic outer membrane of mycobacteria 
(Kamisango et al., 1982).  Purified lysins were added to cultures of P. acnes, and after 30-60 min 
clumping and lysis were visible.  The OD600 of the cultures decreased over time (data not 
shown), and samples with the most rapid decrease in OD corresponded to the more extreme lytic 
activity seen below.  Samples of the cultures were mounted on a slide and observed using bright-
field microscopy (Figure 44).  The strongest lytic activity was observed with Bxz1 gp236 (Figure 
44 B), followed by D29 gp10 (Figure 44 E).  Significant lysis was seen with Che8 gp32 (Figure 
44 C), although it required more time to lyse the culture.  Corndog gp69 (Figure 44 D) and the 
control lysozyme (Figure 44 G) showed a little activity; the cultures slowly lysed, but it was not 
very apparent under the microscope.  Surprisingly, the D29 gp12 LysB also caused the culture to 
slowly lyse, although it was also not evident when a sample was examined with the microscope 
(Figure 44 F).  Nonetheless, the strong activity of Bxz1 gp236 and D29 gp10 demonstrates that 
these LysAs can effect lysis of bacteria when applied exogenously. 
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 Figure 44. Addition of lysins to Propionibacterium acnes 
Figure 44:  Purified lysins were added exogenously to cultures of P. acnes and, after 30-60 min 
of incubation at room temperature, samples were mounted on a slide and examined using bright-
field microscopy.  A. Negative control; B. Bxz1 gp236; C. Che8 gp32; D. Corndog gp69; E. D29 
gp10; F. D29 gp12; G. lysozyme. 
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A.2.4 Conclusions 
The external application of purified lysins to M. smegmatis does not have the dramatic effect that 
other lysins have shown on Gram-positive bacteria.  This is not surprising considering the 
exceptionally effective barrier of lipids mycobacteria have assembled around the cell, which can 
elaborate into a complex biofilm under the right conditions (Zambrano and Kolter, 2005).  In 
spite of this, exogenously-applied LysA and LysB proteins did appear to inhibit the growth and 
biofilm formation by M. smegmatis in detergent-free cultures.  D29B was especially effective 
(Figure 41 B), although this may be influenced by the stability of the protein or its rate of action 
(Figure 42).  Surprisingly, the S82A active site mutant of D29B also inhibited biofilm maturation 
to some extent (Figure 41 C).  The potency of D29B and the effect of S82A may be tied to the 
composition of mycobacterial cell walls and the extracellular matrix (Brennan, 2003; Ojha et al., 
2008; Ortalo-Magne et al., 1996).  Numerous glycolipids, including TDM, are in the 
mycobacterial outer membrane, and the biofilm matrix is comprised of free mycolic acids that 
have been released from TDM by a mycobacterial esterase.  It has been shown that D29B is also 
able to hydrolyze TDM to release mycolic acids (Ojha et al., 2010), and so the LysB may 
interfere with the formation of biofilms by binding substrates, unregulated hydrolysis, or some 
other mechanism.  Interference by binding the substrates or products may explain why the S82A 
mutant is able to affect the maturation of the biofilm but does not appear to inhibit growth 
significantly (Figure 41 C).  Competition for substrates may also explain why S82A is able to 
decrease the inhibitory effects of D29B (Figure 43 C).  However, the difference in the extent of 
inhibition between S82A and D29B shows that the inhibition of growth by D29B is connected to 
its enzymatic activity. 
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The mechanism of inhibition by LysA proteins is unclear, since it is highly unlikely that 
they have access to the PG from outside of the cells.  It would be interesting if the inhibitory 
activity was associated with specific N-terminal domains or other activities, but that possibility 
was not addressed in these studies.  There may also have been some synergy in growth inhibition 
when D29A and D29B were added simultaneously to a culture, but the majority of the activity 
still appears to be the result of D29B (Figure 32 A).  However, the degradation of D29A in the 
growth media may complicate these results (Figure 42). 
The activity of the lysins on P. acnes demonstrates their ability to effect lysis 
exogenously.  It is somewhat surprising to see such strong activity by Bxz1 gp236 and D29 
gp10, since lysins are thought to be highly specific to their phage’s host, but P. acnes is 
significantly different; it lacks arabinogalactan and mycolic acids, and does not have type A1 
PG (Kamisango et al., 1982).  Intriguingly, the only domain Bxz1 gp236 and D29 gp10 share is 
C1 (Figure 37), which is presumed to be involved in cell wall binding.  Che8 gp32 and Corndog 
gp69 both have C2 domains and both show less effective lysis of P. acnes.  Therefore, the C1 
domain may represent a less-specific cell wall binding domain that confers a broader specificity 
on some LysAs. 
These results warrant further assessment of the activity of purified lysins on 
mycobacteria.  Studies involving alternate lysins need to be conducted, and it would be very 
interesting to identify any synergistic activity when combining lysins with antibiotics such as 
isoniazid and rifampicin.  Many of these experiments should also be conducted with M. 
tuberculosis; in fact, several of the experiments discussed in this appendix were also attempted 
with M. tuberculosis, but either failed due to technical difficulties or were not completed as of 
this writing. 
 283 
A.3 ENDOGENOUS EXPRESSION OF LYSINS IN M. SMEGMATIS 
Outside of the context of phage infection, lysin research is primarily concerned with exogenous 
application and resulting lysis (Borysowski et al., 2006; Fischetti, 2008; Hermoso et al., 2007; 
Loessner, 2005).  The canonical holin-endolysin system emphasizes the requirement of a holin 
for the hydrolytic activity of a lysin (Young, 2002), whether by allowing it access to the PG or 
activation by depolarization of the membrane.  Studies expressing lysins within cells have 
required a means of permeabilizing the membrane, usually with chloroform, in order to effect 
lysis (Ames et al., 1984).  Therefore, lysins are not expected to have significant activity when 
expressed from within cells in the absence of a holin or a compound serving an analogous 
function. 
Lysins are known to be essential for plaque formation (Young, 1992), and so as a proof 
of principle experiment for mycobacteriophage recombineering, Marinelli et al. (2008) created a 
deletion mutant of Giles lysA.  The resulting mutant phage was unable to form plaques unless 
infecting a complementing strain, one that was expressing an alternate LysA.  This requirement 
proved the essentiality of LysA in mycobacteriophage Giles, and the same method demonstrated 
that LysB was not essential, since it could plaque without complementation (Chapter 3).  The 
complementing strain was M. smegmatis mc2155:pKMC4, which expresses Corndog gp69 under 
an acetamidase promoter (Marinelli et al., 2008).  However, the first attempt to complement the 
GileslysA mutant used pKMC1 instead, which expressed the D29 gp10 LysA.  When plated on 
inducing media (plates including acetamide), no growth was seen.  This bactericidal phenotype 
from pKMC1 expression was intriguing, especially when pKMC4 expression had no effect on 
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growth.  We decided to examine the effects of endogenous expression of other 
mycobacteriophage lysins on mycobacterial growth. 
A.3.1 Cloning and expression of a diverse set of LysA proteins into pLAM12 
In addition to Bxz1 gp236, Che8 gp32, Corndog gp69, and D29 gp10, 8 additional LysA proteins 
were cloned to create a set of 12 LysAs that included at least one representative of each domain 
(Figure 45), excluding the transglycosylase domain of Hammer gp13.  All were cloned into the 
acetamide-inducible pLAM12 vector and transformed into M. smegmatis mc2155.   
We attempted to assess the expression of the protein upon induction and the distribution 
(pellet or supernatant) by separating induced and uninduced culture samples on SDS PAGE gels 
(Figure 46).  Larger amounts of sample were loaded for D29 gp10, Kostya gp33, and L5 gp10 
because of the decreased density in culture (see A.3.3).  Expression of protein was visible for 
almost all LysAs.  Several showed low or uncertain expression (Figure 46, question marks).  The 
presence of protein was difficult to verify with L5 gp10, although based on later results it is 
assumed that protein was expressed.  For all of the LysAs, the majority of the protein was 
consistently found in the pellet; this could reflect binding of the PG, which would be associated 
with the rest of the cell wall in the pellet.  There does not appear to be any association of protein 
in the supernatant with a specific C-terminal domain, nor with any other domains.  The LysAs 
with the strongest expression included Brujita gp29, Bxz1 gp236, and Rosebush gp46 (Figure 
46). 
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 Figure 45. Cloned LysAs for expression in M. smegmatis 
Figure 45:  The above 12 LysAs were cloned into the acetamide-inducible pLAM12 vector.  
They were chosen to represent the diversity of domains, with each domain represented at least 
once and all three unmatching regions present (C-terminus of Barnyard gp39, C-terminus of 
Brujita gp29, and N-terminus of Bxz2 gp11).  Molecular weights are listed to the right of the 
LysA name, and an amino acid length ruler is below. 
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 Figure 46. Expression profiles of lysins induced in M. smegmatis 
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Figure 46:  The above samples are from the cultures used in the ATP assay described in A.3.2.  
One milliliter samples were taken from induced and uninduced cultures with pLAM12 vector 
control, one of 12 LysAs, or one LysB (D29 gp10).  These were sonicated, centrifuged at 14,000 
rpm to produce pellet and supernatant fractions, and separated on SDS PAGE gels.  Red asterisks 
mark identifiable expressed protein.  Red question marks indicate instances of uncertain protein 
expression. 
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A.3.2 ATP release from M. smegmatis endogenously expressing lysins 
Upon reaching log-phase growth, all 12 LysAs and the D29 LysB cultures were split, and half 
were induced with 0.2% acetamide.  Induced and uninduced cultures were sampled hourly for 7 
hours, and the release of ATP was measured using a luminometer and luciferase reagents (see 
Chapter 3).  The fold-difference in ATP release between induced and uninduced strains was 
plotted over time (Figure 47).  The results showed an increase in ATP release by three LysAs: 
D29 gp10, Kostya gp33, and L5 gp10.  There was also a vast difference in the degree of release 
between these three LysAs; D29 gp10 was about 2-fold greater than Kostya gp33, but L5 gp10 
released nearly 3-fold more ATP than D29 gp10 and 4.5-fold more than Kostya gp33. 
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 Figure 47. ATP release upon induction of lysin expression 
 
 
 
Figure 47:  Cultures of M. smegmatis mc2155 carrying pLAM12-based plasmids with different 
lysins were split and half were induced with 0.2% acetamide.  ATP release was measured for 7 
hours and the fold-difference between induced and uninduced ATP release calculated for each 
lysin and plotted versus the time. 
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A.3.3 Visible lysis and growth inhibition of lysin-expressing strains 
The induced cultures from A.3.2 were allowed to grow overnight at 37oC, and the turbidity was 
examined the next day.  Most cultures did not vary significantly in cell density from the negative 
control (pLAM12 empty vector), but significant differences were observed for D29 gp10, Kostya 
gp33, and L5 gp10 (Figure 48).  Kostya gp33 had a noticeable decrease in turbidity compared to 
pLAM12; however, the cultures expressing D29 gp10 and L5 gp12 were completely lysed 
(Figure 48).   
To analyze the effects of lysin induction on M. smegmatis growth on solid media, 
cultures were plated on media with or without 0.2% acetamide.  Plates were placed at 37oC 
overnight and colony size was assessed.  Four outcomes were observed when comparing induced 
to uninduced colonies:  no change in colony size, a moderate decrease in colony size, a large 
reduction in size (pinprick colonies), and no growth.  The negative control strain carrying 
pLAM12 showed no difference in colony size (Figure 49 A), as did Barnyard gp39, Bxz2 gp11, 
and Giles gp31.  This could be due to the poor expression seen when inducing Barnyard gp39 
and Giles gp31 (Figure 46), but Bxz2 gp11 showed good protein expression (Figure 46).  Brujita 
gp29, Che8 gp32, Corndog gp69, Plot gp36, and Rosebush gp46 had only a moderate reduction 
in size (Figure 49 B).  Bxz1 gp236, D29 gp12, and Kostya gp33 had tiny colonies (Figure 49 C). 
Only D29 gp10 and L5 gp12 showed no growth (not shown). 
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 Figure 48. Turbidity of induced and uninduced M. smegmatis cultures expressing lysin 
Figure 48:  Induced and uninduced M. smegmatis cultures used for the ATP assay were allowed 
to grow overnight at 37oC, and the turbidity was compared the following day.  pLAM12 is the 
vector negative control.  U is uninduced; I is induced. 
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 Figure 49. Effect of endogenous lysin expression on M. smegmatis growth on solid media 
 
 
 
Figure 49: The colony size of M. smegmatis containing acetamide-inducible lysins was 
compared between uninduced and induced.  Representative plates are shown for three of the four 
phenotypes scored for growth based on colony size.  A. No significant difference in size between 
uninduced and induced.  The empty vector pLAM12 plates are shown and represent results for 
Barnyard gp39, Bxz2 gp11, and Giles gp11.  B. Moderate reduction in colony size when lysin 
expression was induced.  Colonies for Plot gp36 are shown and represent the results for Brujita 
gp29, Che8 gp32, Corndog gp69, and Rosebush gp46.  C. Induction that produced pinprick-sized 
colonies.  Kostya gp33 represents the results for Bxz1 gp236 and D29 gp12 (LysB).  D. Closeup 
of colonies for induced pLAM12 and Kostya gp33.  The fourth phenotype – no visible growth – 
was observed for D29 gp10 and L5 gp10 and is not shown here. 
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A.3.4 Conclusions 
It is not difficult to imagine that endogenous expression of toxic proteins such as lysins in M. 
smegmatis could have an impact on growth; however, it is surprising to see actual lysis of M. 
smegmatis by D29 gp10, L5 gp10, and to a lesser extent, Kostya gp33, considering these proteins 
were expressed in the absence of a holin.  These three LysAs share N4 and C1 domains (Figure 
37).  D29 gp10 and Kostya gp33 are predicted to have different lysozyme activities – GH19 and 
GH25, respectively – but L5 gp10 is comprised solely of an N4 and C1 domain, with no visible 
lytic domain (see Chapter 2).  The C1 domains were found in many of the non-active LysAs 
(Figure 37) and so are unlikely to be responsible for the lytic activity.  The strong bactericidal 
effect of endogenous L5 gp10 expression strongly supports a lytic activity for N4.  However, this 
raises two questions: if the N4 domain is so lethal, why do D29 gp10 and Kostya gp33 contain 
other PG hydrolytic activities? And what is the substrate of N4?   
Somewhat complicating the attribution of the lytic activity to N4 is Brujita gp29, which 
also has an N4 domain and no other predicted activity (Figure 37), similar in organization to L5 
gp10 except for differing C-termini.  It may be that both the N4 and C1 domains are required, 
since Brujita differs in its C-terminus (Figure 37).  Brujita gp29 had strong protein expression 
(Figure 46) but shows no lysis as measured by ATP release (Figure 47) or a decrease in turbidity 
(not shown).  In comparison with N4 of L5 gp10, the N4 of D29 gp10 is 81.0% similar, of 
Kostya gp33 is 14.4% similar, and Brujita gp29 is 29.9% similar; thus, decreasing similarity to 
the N4 of L5 gp10 does not appear to be the reason for a lack of lysis by Brujita gp29.  
All known dsDNA phage lysins are PG hydrolases (Hermoso et al., 2007), and only a few 
examples of non-PG hydrolytic lysis systems have been characterized (Chapter 1).  The latter 
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consist of single proteins that bind to enzymes involved in the biosynthesis of PG (Bernhardt et 
al., 2002), and so the focus is still on compromising the PG of the host to induce lysis.  It would 
be easy to hypothesize that the N4 domain represents a new PG hydrolytic activity, but its holin-
independent lysis brings this into question.  Many of the targeted PG bonds are not made until 
the PG precursors have been assembled outside the cell membrane (Vollmer and Holtje, 2001), 
so either N4 has a different target that is accessible inside the cell or it is capable of accessing the 
PG without a holin.  It remains to be determined by what mechanism L5 gp10 lyses M. 
smegmatis.  Future studies may employ random mutagenesis to identify important residues, 
possible generation of resistant host mutants to identify important lysin-host interactions, and 
chemical analysis of lysis products by mass-spectroscopy or NMR to determine the molecular 
target.  In addition, L5 gp10 and all lysins studied should be examined for activity on M. 
tuberculosis. 
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